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1. Introduction 1 
1. Introduction 
1.1. Innate immunity 
The innate immune system provides a first line of defense against invading pathogens. 
It includes physical barriers like the skin and other epithelial surfaces, humoral barriers 
like the complement system, and cellular barriers1. Innate immune cells include 
dendritic cells, monocytes, macrophages, granulocytes, and natural killer (NK) cells2. 
The innate immune system relies on a defined set of receptors and targets whole 
classes of pathogens in a nonspecific manner3. Cells and proteins of the innate 
immune system are constantly circulating in the body ready to immediately fight 
microbes at the site of infection. Activation of the innate immune system results in the 
elimination of pathogens and induction of the adaptive immune response which is 
mediated by the secretion of cytokines and upregulation of the expression of 
costimulatory molecules on antigen presenting cells (APC)3. 
The adaptive immune system is only found in vertebrates and, in contrast to the innate 
immune system, relies on highly specific antigen receptors which are expressed on 
B and T lymphocytes1. The adaptive immune response is usually inactive. A critical 
step for the induction of adaptive immunity is the interaction between activated APC 
and T lymphocytes. Upon activation, the adaptive immune system selectively expands 
antigen-specific B and T cells expressing unique antigen receptors3. This results in the 
specific elimination of pathogens or pathogen-infected cells and the development of an 
immunological memory which enables a more rapid response to specific pathogens 
upon further exposures3. 
 
1.1.1. Pattern recognition receptors 
The innate immune system discriminates between self and nonself based on the 
recognition of invariant features of microorganisms4. Host recognition of these 
pathogen-associated molecular patterns (PAMPs) relies on germ-line encoded 
receptors called pattern recognition receptors (PRRs). PRRs do not only respond to 
molecules of microbial origin, but also sense host-derived molecules which are 
potentially dangerous, like for example nuclear proteins or nucleic acids which have 
been released from necrotic cells. These molecules are collectively termed damage (or 
danger)-associated molecular patterns (DAMPs). The class of PRRs which was first 
identified and is the best characterized is the class of Toll-like receptors (TLRs)5,6. Toll-
like receptors are membrane-bound receptors which initiate immune responses upon 
the recognition of extracellular and endosomal PAMPs and DAMPs, like bacterial cell 
wall proteins or nucleic acids of microbial, but also of self origin. The second group of 
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PRRs is the group of C-type lectin receptors (CLRs). Like TLRs, most CLRs are 
transmembrane proteins. CLRs recognize carbohydrate structures and play a central 
role in innate immunity to fungal pathogens7. More recently, cytosolic PRRs have been 
discovered8,9. Cytosolic PRRs have evolved to sense nucleic acids of microbial and 
also host origin in the cytoplasm. The family of cytosolic PRRs comprises retinoic acid-
inducible gene-I (RIG-I)-like receptors (RLRs) and cytosolic DNA sensors. RLRs sense 
cytoplasmic RNA and mediate antiviral responses, whereas cytosolic DNA sensors 
recognize cytoplasmic DNA upon viral or bacterial infections10. The activation of TLRs, 
CLRs, RLRs, and cytosolic DNA sensors induces the transcription of genes involved in 
inflammatory responses including proinflammatory cytokines and type I interferon 
(IFN)10. 
The last group of PRRs which has been described so far is the group of nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs). The cytosolic NLRs 
sense PAMPs and DAMPs in the cytoplasm leading to the formation of multiprotein 
complexes called inflammasomes which consist of NLRs, apoptosis-associated speck-
like protein containing a caspase recruitment domain (ASC), and caspase-111. 
Caspase-1 is activated upon inflammasome formation and facilitates the maturation 
and secretion of the proinflammatory cytokines interleukin-1β (IL-1β) and IL-1811. 
 
1.1.2. Toll-like receptors 
The Toll receptor was first identified to promote dorsoventral polarity in the 
development of the fruit fly Drosophila melanogaster12. A mutation in the toll gene 
resulted in abnormal embryonic development. Later, the group of Jules Hoffmann 
showed that the Toll receptor contributes to the host defense against fungal infections 
in Drosophila melanogaster5. The first human homolog of the Drosophila Toll protein, 
hToll, was described in 1997 by Ruslan Medzhitov and Charles Janeway6. This protein 
was identified as TLR4, the signaling receptor for lipopolysaccharide (LPS), by the 
group of Bruce Beutler who, together with Jules Hoffmann, was awarded with the 
Nobel Prize in Physiology or Medicine in 2011 "for their discoveries concerning the 
activation of innate immunity"13,14. Soon, further Toll homologs, collectively termed Toll-
like receptors (TLRs), and their respective ligands were discovered14. 
 
TLRs are type I transmembrane proteins which consist of three different domains, an 
ectodomain, one transmembrane domain, and a cytoplasmic Toll-interleukin-1 receptor 
(TIR) domain. The N-terminal ectodomain consists of leucine-rich repeats (LRRs), 
which mediate ligand recognition, and the C-terminal cytoplasmic TIR domain mediates 
downstream signal transduction15. So far, 10 human and 12 murine TLRs have been 
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identified16. TLRs 1-9 are conserved in humans and mice. TLR10 has only been found 
in humans and TLRs 11, 12, and 13 are only expressed in mice (Table 1). 
 
Table 1: Localization, species, and ligands of TLRs. 
TLR Localization Species Physiological ligands Synthetic ligands 
TLR1/
TLR2 
Plasma 
membrane 
Human and 
mouse 
Triacetylated lipopeptides Pam3CSK4 
TLR2 Plasma 
membrane 
Human and 
mouse 
Lipoproteins, peptidoglycan, 
lipoarabinomannan, LTA 
Not defined 
TLR2/
TLR6 
Plasma 
membrane 
Human and 
mouse 
Diacetylated lipopeptides, 
LTA, zymosan 
Malp2, FSL-1 
TLR3 Endolysosome Human and 
mouse 
dsRNA Poly(I:C) 
TLR4 Plasma 
membrane and 
endolysosome 
Human and 
mouse 
LPS, RSV fusion protein, 
MMTV envelope protein, 
mannan, glycosylinositol-
phospholipids 
Lipid A derivates 
TLR5 Plasma 
membrane 
Human and 
mouse 
Flagellin Not defined 
TLR7 Endolysosome Human and 
mouse 
ssRNA Poly(U), 
imidazoquinolines: 
imiquimod, 
resiquimod (R848) 
TLR8 Endolysosome Human and 
mouse 
ssRNA Poly(U), R848 (only 
in humans) 
TLR9 Endolysosome Human and 
mouse 
DNA, hemozoin CpG oligo-
nucleotides 
TLR10 Not defined Human Not defined Not defined 
TLR11 Endolysosome Mouse Profilin, flagellin Not defined 
TLR12 Endolysosome Mouse Profilin Not defined 
TLR13 Endolysosome Mouse Bacterial 23S rRNA Not defined 
LTA, lipoteichoic acid; Malp2, macrophage-activating lipopeptide 2; dsRNA, double-stranded 
RNA; Poly(I:C), polyinosinic-polycytidylic acid; LPS, lipopolysaccharide; RSV, respiratory 
syncytial virus; MMTV, mouse mammary tumor virus; ssRNA, single-stranded RNA; Poly(U), 
polyuridylic acid; rRNA, ribosomal RNA. 
 
TLRs 1, 2, 4, 5, and 6 are primarily localized at the cell surface (Figure 1). They 
recognize microbial components such as lipopeptides, lipoproteins, lipopolysaccharide 
(LPS), and flagellin13,17-20. TLRs 3, 7, 8, 9, and 13 are mainly expressed intracellularly 
and have been described to recognize nucleic acids (Table 1)21-25. Most TLRs form 
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homodimers26-30. TLR2 heterodimerizes with TLR1 and TLR6 which extends its 
repertoire of ligands31-33. TLR11 can form heterodimers with TLR1234. 
 
 
Figure 1: Toll-like receptors are localized at the cell surface or intracellularly. TLRs 1/2, 
2/6, 4, and 5 are located at the plasma membrane. TLR1/2 and 2/6 recognize bacterial cell wall 
components, TLR4 recognizes LPS, and TLR5 recognizes flagellin. TLRs 3, 7/8, and 9 are 
located in the endolysosome and recognize nucleic acids. TLR3 senses double-stranded RNA, 
TLR7/8 sense single-stranded RNA, and TLR9 senses double-stranded DNA. Upon activation 
TLRs recruit specific adaptor proteins which lead to the production of proinflammatory cytokines 
and type I IFN. 
 
Upon ligand recognition, TLRs recruit distinct TIR-domain-containing adaptor proteins 
including myeloid differentiation primary response gene 88 (MyD88), TIR domain-
containing adaptor inducing IFNβ (TRIF, also known as TICAM1), TIR domain-
containing adaptor protein (TIRAP, also known as MAL), and TRIF-related adaptor 
molecule (TRAM, also known as TICAM2) (Figure 1)35. The recruited adaptor 
molecules activate distinct signaling cascades which initiate proinflammatory cytokine 
and type I IFN responses (Figure 2). Signaling of cell surface TLR1/TLR2, TLR2/TLR6, 
and TLR5 mainly induces proinflammatory cytokine responses. In contrast, intracellular 
TLRs can induce proinflammatory cytokines as well as type I IFN15. TLR2 can also 
induce the production of type I IFN in response to vaccinia virus or mouse 
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cytomegalovirus upon internalization36. TLR4 forms a complex with myeloid 
differentiation factor 2 (MD-2). The TLR4-MD-2 complex initially signals from the cell 
surface upon delivery of LPS by the LPS-binding protein (LBP) and cluster of 
differentiation 14 (CD14) and is subsequently internalized into the endosomal 
compartment where it initiates an IFNβ response37. 
All TLRs, except TLR3, recruit MyD88. Upon TLR activation, MyD88 recruits IL-1 
receptor-associated kinase 4 (IRAK4), IRAK1, IRAK2, and tumor necrosis factor 
receptor-associated factor 6 (TRAF6). The E3 ligase TRAF6 catalyzes the synthesis of 
K63-linked polyubiquitin chains which bind to TAK1-binding protein 2 (TAB2) and 
TAB3. TAB2 and TAB3 are components of the transforming growth factor β-activated 
kinase 1 (TAK1) complex and activate TAK1. The TAK1 complex simultaneously 
activates mitogen-activated protein kinases (MAPKs) and the IκB kinase (IKK) 
complex. The IKK complex consists of NF-κB essential modulator (NEMO), IKKα, and 
IKKβ and catalyzes the phosphorylation of IκB proteins. Degradation of IκB proteins 
facilitates translocation of the p50 and p65 subunits of NF-κB into the nucleus. 
Activation of the transcription factors nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and activator protein 1 (AP-1), which is activated by MAPKs, 
induces the production of proinflammatory cytokines like tumor necrosis factor (TNF), 
interleukin 6 (IL-6), and IL-1215.  
Recruitment of MyD88 by endosomal TLRs 7 and 9 can additionally lead to the 
activation of interferon regulatory factor 7 (IRF7) which triggers the production of type I 
IFN, a pathway that is especially important in plasmacytoid dendritic cells (pDC). Upon 
activation of TLR7 and TLR9, MyD88 leads to the recruitment of IRAK4 and TRAF6. 
This results in the activation of NF-κB, but also leads to IRAK1- and IKKα-dependent 
phosphorylation of IRF7 via TRAF3 activation. IRF7 initiates the production of type I 
IFN in the nucleus.  
The adaptor molecule TRIF is used by TLR3 and the internalized TLR4-MD-2-LPS 
complex38. TRIF recruits TRAF6, TRAF3 and TNF receptor type 1-associated Death 
domain protein (TRADD) which interacts with Pellino-1 and receptor-interacting 
protein 1 (RIP1). RIP1 and TRAF6 activate the TAK1 complex which leads to the 
activation of MAPKs and NF-κB. Activation of TRAF3 additionally leads to the 
phosphorylation and activation of IRF3 via the TANK-binding kinase 1 (TBK1) and 
IKKε. Translocation of activated IRF3 leads to the production of type I IFN, mainly 
IFNβ15. 
TIRAP has been described as a sorting adaptor which links TLRs 2 and 4 on the 
plasma membrane to MyD8815. Recent evidence suggests that TIRAP also functions 
as a sorting adaptor for endosomal TLRs which signal via MyD8839. TRAM seems to 
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function exclusively in the TLR4 pathway and has been described as a sorting adaptor 
for the recruitment of TRIF to TLR415,35. 
 
 
Figure 2: Schematic overview of TLR signaling. The adaptor protein MyD88 is used by all 
TLRs, except TLR3. MyD88 initiates signaling cascades which lead to the production of 
proinflammatory cytokines via the transcription factors AP-1 and NF-κB. Recruitment of MyD88 
by TLR7 and 9 additionally activates the production of type I IFN via IRF7. TLR3 and the TLR4-
MD-2-LPS complex use the adaptor molecule TRIF which initiates the production of pro-
inflammatory cytokines and activates a type I IFN response via IRF3. 
 
1.1.3. UNC93B regulates trafficking and signaling of intracellular TLRs 
Nucleic acid-sensing intracellular TLRs reside in the endoplasmic reticulum (ER)40. 
Upon activation, TLRs 3, 7, and 9 rapidly relocalize to the endolysosomal compartment 
where they recognize and bind double-stranded RNA (dsRNA), single-stranded RNA 
(ssRNA), or double-stranded DNA (dsDNA), respectively, and initiate downstream 
1. Introduction 7 
signal transduction41. Recent evidence suggests that RNA-DNA hybrids, which are 
essential intracellular replication intermediates generated during infection, are also 
recognized by TLR9 in dendritic cells42. The intracellular localization of nucleic acid-
sensing TLRs is highly important to prevent autoimmunity caused by improper 
recognition of self nucleic acids43,44. It was shown that redirection of TLR9 to the cell 
surface by an exchange of its transmembrane and cytosolic domain with that of TLR4 
facilitates the recognition of host genomic DNA by TLR943. Similarly, the introduction of 
point mutations in the transmembrane domain of TLR9 (TLR9TM-MUT) led to localization 
of TLR9TM-MUT to the plasma membrane where it recognized host genomic DNA and 
mice expressing TLR9TM-MUT developed systemic lethal inflammation44. Overexpression 
of TLR7 caused a fatal acute inflammatory pathology in mice45-47. Distinct motifs, which 
mediate the intracellular localization of nucleic-acid sensing TLRs, have been identified 
in the cytoplasmic linker region of TLR3 and the transmembrane regions of TLR7 and 
TLR948-51. 
 
In a forward genetic screen using N-ethyl-N-nitrosourea (ENU) mutagenesis, mice with 
defects in signaling of intracellular TLRs 3, 7, and 9 and class I and II major 
histocompatibility complex (MHC)-restricted antigen presentation were identified52. 
Macrophages derived from these mice did not respond to stimulation of intracellular 
TLRs with Poly(I:C) (TLR3), resiquimod (TLR7), and CpG DNA (TLR9) and were 
termed “triple defect” (3d) mice. 3d mice are highly susceptible to infections with mouse 
cytomegalovirus (MCMV), Listeria monocytogenes, and Staphylococcus aureus. The 
cause for the 3d phenotype was mapped to one single histidine-to-arginine (H412R) 
point mutation in the Unc93b gene52. UNC93B (UNC-93 homolog B1 (Caenorhabditis 
elegans)) is a 598-amino-acid glycoprotein that localizes to the ER and is predicted to 
have twelve transmembrane domains with an N- and C-terminus facing the cytoplasm 
(Figure 3). Deficiency of UNC93B has been linked to herpes simplex virus-1 
encephalitis (HSE) in children53. The H412R substitution is predicted to be located 
within the ninth transmembrane domain of UNC93B (Figure 3). 
Wild type and mutant (H412R) UNC93B have similar half-lives (~4 h), but exhibit 
different migration patterns upon SDS-polyacrylamide gel electrophoresis (PAGE)54. 
Polyclonal antibodies raised against C-terminal or N-terminal peptides of UNC93B 
recognize wild type as well as mutant UNC93B54. In contrast to wild type UNC93B, 
which shows a diffuse band pattern, a more distinct band pattern is observed for 
mutant UNC93B. It has been shown that wild type, but not mutant, UNC93B interacts 
with the transmembrane domains of TLRs 3, 7, 9, and 1354. Chimeric TLR3 and TLR9 
constructs in which the transmembrane domains of TLR3 or TLR9 were replaced with 
1. Introduction 8 
the transmembrane domain of TLR4, were unable to interact with UNC93B, whereas 
chimeric TLR4 constructs containing the transmembrane domains of either TLR3 or 
TLR9 co-precipitated with UNC93B54.  
 
                               
 
Figure 3: Predicted topology of UNC93B. UNC93B is an ER protein and is predicted to have 
twelve transmembrane domains with an N- and C-terminus facing the cytoplasm. The histidine-
to-arginine (H412R) point mutation causing the 3d phenotype in mice is located in the ninth 
transmembrane domain of UNC93B. Predicted N-linked glycosylation sites are indicated (*). 
 
UNC93B delivers intracellular TLRs from the ER to the endolysosomal compartment 
where they can bind their ligands and initiate downstream signal transduction 
(Figure 4)55. In cells derived from 3d mice, neither UNC93B nor TLR7 and 9 are able to 
leave the ER and therefore fail to respond to specific stimulation. In accordance with 
this observation, it has been shown that a portion of wild type UNC93B gained 
Endoglycosidase H (Endo H)-resistance in multiple cell types, whereas mutant 
(H412R) UNC93B failed to acquire Endo H resistant glycans, indicating that wild type 
UNC93B traffics through the Golgi apparatus56. N-linked glycosylation of wild type 
UNC93B was demonstrated using an UNC93B mutant in which an asparagine residue 
within a consensus N-linked glycosylation site was substituted (N251A)56. UNC93B 
was also linked to functioning of TLRs 11, 12, and 1325,57-59. Trafficking and signaling of 
cell surface TLRs is not affected by mutation of UNC93B52,55.  
 
UNC93B has been reported to mediate differential trafficking of endosomal TLRs56,60,61. 
TLR9 competes with TLR7 for UNC93B-dependent delivery to the endolysosome60. 
Trafficking of TLR9, but not TLR7, seems to be dependent on the N-terminal region of 
UNC93B56,60. UNC93B preferentially associates with TLR9. Mutation of aspartic acid at 
position 34 in UNC93B (D34A) biases the UNC93B-TLR association towards TLR7 and 
also TLR13 in dendritic cells (DC)60. Mice harboring the D34A mutation develop a 
spontaneous TLR7-dependent autoimmunity61. This study emphasizes the importance 
of UNC93B in the regulation of intracellular TLRs. At the ER, UNC93B facilitates 
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loading of TLR9 into coat protein complex II (COPII) vesicles and traffics in a complex 
with TLR9 through the Golgi apparatus56,62. In the same way, UNC93B mediates 
delivery of TLR3, TLR7, TLR11, and TLR13 to the endolysosome56. Acidic amino acids 
in the juxtamembrane region of nucleic acid-sensing TLRs seem to play an important 
role for their interaction with UNC93B as well as trafficking and signaling of these 
receptors63. TLR9 was initially thought to directly traffic from the ER via the Golgi 
apparatus to the endolysosomal compartment. However, recently small amounts of 
TLR9 were detected on the cell surface of human embryonic kidney (HEK) 293T cells 
transfected with TLR9 and UNC93B and immune cells such as splenic DC, B cells, and 
neutrophils which suggests that TLR9 traffics via the cell surface56,64-66. Internalization 
of UNC93B-TLR9 complexes from the cell surface to the endolysosome has been 
reported to be mediated by UNC93B-dependent recruitment of the adaptor protein 2 
(AP-2) at the cell surface (Figure 5)56. In contrast, TLR7 does not travel via the cell 
surface and requires AP-4 for endosomal delivery after leaving the Golgi apparatus. 
Intracellular TLRs 3, 11, 12, and 13 seem to use the same route as TLR756. 
 
 
Figure 4: UNC93B mediates endosomal trafficking of intracellular TLRs. UNC93B interacts 
with the transmembrane domains of intracellular TLRs 3, 7, and 9 and delivers them from the 
ER to the endolysosome where TLRs initiate the production of proinflammatory cytokines and 
type I IFN upon ligand binding. Introduction of a single point mutation (H412R) in UNC93B 
disrupts binding between UNC93B and intracellular TLRs and both proteins fail to leave the ER. 
 
Besides UNC93B, the ER chaperone proteins gp96 (also known as glucose-regulated 
protein of 94 kDa GRP94) and protein associated with TLR4 (PRAT4A) have been 
shown to mediate trafficking of intracellular TLRs. Heat shock protein gp96 is 
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necessary for the function of TLRs 1, 2, 4, 5, 7, and 967. PRAT4A is required for 
trafficking of TLRs 1, 2, and 4 to the cell surface and trafficking of TLRs 7 and 9, but 
not TLR3, to the endolysosome68. gp96 and PRAT4A have been shown to work 
together and ensure proper folding of TLRs in the ER69.  
 
 
Figure 5: Proinflammatory cytokine and type I IFN responses upon stimulation of TLR9 
and TLR7 are initiated from different endolysosomal compartments. In order to reach the 
endolysosomal compartment, TLR9 uses the secretory pathway and traffics together with 
UNC93B via the cell surface. At the cell surface, UNC93B recruits AP-2 which mediates 
endocytosis and endosomal delivery of the UNC93B-TLR9 complex. In the endolysosome, 
TLR9 binds to dsDNA and is proteolytically cleaved which facilitates the induction of a 
proinflammatory cytokine response via NF-κB. Upon AP-3-mediated delivery of TLR9 from the 
endolysosomal to the lysosomal compartment, it induces the production of type I IFN via the 
activation of IRF7. TLR7 in complex with UNC93B directly traffics from the ER to the 
endolysosome. This process is dependent on AP-4 and facilitates binding of TLR7 to ssRNA in 
the endolysosome. 
 
Furthermore, the hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) 
has been identified as a regulator for trafficking of TLRs 7 and 9 in a genome-wide 
RNA interference (RNAi) screen70. HRS is a component of the endosomal sorting 
complex required for transport (ESCRT) pathway which mediates lysosomal 
degradation of receptors upon their internalization from the cell surface. However, 
TLRs 7 and 9 seem to use a noncanonical ESCRT pathway for sorting and recycling 
rather than degradation. Ubiquitination of TLR9, and presumably TLR7, in a post-ER 
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compartment facilitates their recognition by HRS and delivery of these TLRs to the 
endolysosomal compartment70. 
 
In the endolysosome, the ectodomain of TLR9 is proteolytically cleaved to generate a 
functional receptor71,72. Proteolytic processing of the TLR9 ectodomain is a multistep 
event. The first cleavage step, which results in removal of the majority of the 
ectodomain, is mediated by asparagine endopeptidases or cathepsins. It is followed by 
a second trimming step which is completely cathepsin-dependent73. Cleavage of TLR9 
has been shown in macrophages, B cells, conventional dendritic cells (cDC), and 
pDC71,72,74. Although proteolytic processing is not necessary for ligand binding, only 
processed TLR9 can recruit the adaptor protein MyD88. Binding of MyD88 to TLR9 is 
induced by a conformational change of the cytosolic TIR domains of preassembled 
TLR9 homodimers72,75. TLR3 and TLR7 are processed similarly to TLR973,76,77. Besides 
intracellular localization of nucleic acid-sensing TLRs, the requirement for proteolytic 
processing provides an additional mechanism of protection against recognition of self 
nucleic acids. This seems especially important for TLR9 since it traffics via the cell 
surface on its way to the endolysosome78. Whether the N-terminal cleavage fragments 
of processed TLRs play a role in ligand binding and signaling is not clear. Two studies 
showed that deficiency of TLR9 can be rescued by expression of the C-terminal TLR9 
cleavage fragment alone, suggesting that the N-terminal cleavage fragment of TLR9 is 
not required for TLR9 signaling71,79. On the other hand it was reported that a mutation 
in the N-terminus of TLR9 results in a signaling defect without affecting receptor 
dimerization or cleavage of TLR980. Furthermore, it was shown that the N-terminal 
cleavage fragment of TLR9 remains associated with the truncated receptor and that it 
is required for signaling in response to DNA in bone marrow-derived (BM)-DC64. 
Structural analysis of TLR3 revealed binding sites for Poly(I:C) in N- as well as 
C-terminal regions of the TLR3 ectodomain81. Additionally, N- and C-terminal cleavage 
fragments of TLR3 have recently been reported to remain associated after proteolytic 
processing82.  
 
Upon ligand binding, TLRs 7 and 9 initiate the production of proinflammatory cytokines 
and type I IFN. The transcription of these two different classes of genes originates from 
two different types of endolysosomal compartments83. Activation of TLR9 with synthetic 
CpG oligonucleotides (ODN) results in the activation of different signaling pathways 
dependent on the type of CpG ODN84-87. Three different classes of CpG ODN have 
been identified: type A, type B, and type C CpG ODN. All of them contain immune 
stimulatory CpG motifs and have a phosphorothioate-stabilized backbone. Type A CpG 
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ODN are characterized by a phosphodiester central CpG-containing palindromic motif 
and a phosphorothioate 3`poly-G string. Type B CpG has a complete phosphorothioate 
backbone with at least one CpG dinucleotide. CpG C combines features of type A and 
type B CpG ODN. It has a full phosphorothioate backbone with a CpG-containing 
palindromic motif. CpG A aggregates in large multimeric complexes and strongly 
induces type I IFN. In contrast, CpG B remains monomeric and leads to the production 
of proinflammatory cytokines like TNF, IL-6, and IL1278. The ability of CpG A and 
CpG B to activate different immune pathways is caused by differential trafficking of 
these ODN to endosomal compartments83. In pDC, CpG A primarily traffics to early 
endosomes where it activates IRF7 and the production of type I IFN, whereas CpG B 
preferentially traffics to late endosomes where it activates NF-κB and the production of 
proinflammatory cytokines. Why these different types of CpG ODN end up in different 
endosomal compartments is not fully understood. If CpG B is complexed with cationic 
lipids, like the transfection reagent DOTAP, the localization of CpG B in pDC is altered 
to the early endosome which results in the activation of a type I IFN response83. 
Additionally, CpG A complexed with DOTAP can also induce the expression of type I 
IFN in cDC and macrophages indicating that functionally distinct signaling 
compartments exist not only in pDC, but also in cDC and macrophages. 
The adaptor protein 3 (AP-3) has been shown to facilitate trafficking of TLR9, and 
probably TLR7, from the endosome to lysosome-related organelles (LRO) in pDC, a 
mechanism which is crucial for the TLR9-dependent type I IFN response (Figure 5)88,89. 
AP-3 directly interacts with TLR9 and mediates trafficking of the UNC93B-TLR9 
complex from vesicle-associated membrane protein 3 (VAMP3)-positive endosomes to 
the lysosomal-associated membrane protein 2 (LAMP2)-positive LRO compartment88. 
AP-3-deficient mice did not produce type I IFN upon stimulation with ligands for TLR7 
and TLR9, whereas the proinflammatory cytokine response was intact88. However, a 
second study reported that in addition to the lack of a type I IFN response, pDC derived 
from mutant mice also failed to produce proinflammatory cytokines in response to 
stimulation of TLRs 7 and 9 which would suggest a more general role of AP-3 for TLR 
trafficking89. 
 
1.1.4. Recognition of the murine herpesviruses mouse cytomegalovirus and 
murine herpesvirus 68 by TLRs 
TLRs play an important role in the recognition of herpesviruses like mouse 
cytomegalovirus (MCMV) and murine herpesvirus 68 (MHV-68)90. Cell surface TLR2 
and intracellular TLRs 3, 7, and 9 are involved in the recognition of the betaherpesvirus 
MCMV. TLR2 is important for the natural killer (NK) cell-mediated control of MCMV 
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in vivo91. It was shown that TLR2-deficient mice had elevated levels of MCMV in the 
spleen and liver after intraperitoneal infection. In inflammatory monocytes, TLR2 
induces a type I IFN response upon recognition of MCMV36. Activation of the TLR2-
dependent production of type I IFN requires receptor internalization and seems to be 
unique to inflammatory monocytes. In pDC, TLR9 is crucial for the induction of type I 
IFN and also mediates IL-12 responses and NK cell activation upon MCMV infection92. 
Intracellular TLRs 3 and 9 are essential for the recognition of MCMV in vivo93. Mice 
expressing a mutated, non-functional version of TLR9 (TLR9CpG1) and mice deficient for 
TLR3 have been reported to be hypersusceptible to MCMV infection and to show 
impaired serum levels of type I IFN and IL-12p40 as well as impaired NK cell 
activation93. These effects were more pronounced in TLR9CpG1 mice compared to 
TLR3-deficient mice. Furthermore, intraperitoneal infection with MCMV was lethal for 
TLR9CpG1 mice, whereas TLR3-deficient mice showed no significant difference in 
survival rates compared to control animals, although they showed more signs of 
sickness than control animals93. This demonstrates that TLR9 is more important, but 
that TLR9 and TLR3 are both essential, for the innate immune response against 
MCMV infection. TLR7 also plays a role for the innate immune response upon MCMV 
infection94. In pDC, the type I IFN, IL-12, and TNF responses were impaired in pDC 
from TLR9-deficient, but not in pDC from TLR7-deficient mice. However, only in pDC 
from mice lacking TLR7 and TLR9, the type I IFN, IL-12, and TNF responses were 
completely abolished, indicating overlapping functions for TLR7 and TLR9 for the 
innate immune response against MCMV infection. Furthermore, mice deficient of TLR7 
and TLR9 were more susceptible to MCMV infection in vivo than mice only lacking 
TLR9 upon intraperitoneal infection94.  
Cell surface TLR2 and intracellular TLR9 are involved in the recognition of the 
gammaherpesvirus MHV-68. An NF-κB reporter was activated by recognition of 
MHV-68 by murine TLR2 in transfected HEK 293T cells and IL-6 and type I IFN 
responses upon MHV-68 infection were reduced in TLR2-deficient mouse embryonic 
fibroblasts (MEF) and in TLR2-deficient mice in vivo compared to wild type controls95. 
TLR9 contributes to antiviral immunity against MHV-68 in dendritic cells96. Upon 
MHV-68 infection, TLR9-deficient dendritic cells secreted reduced levels of IL-12, IL-6, 
and IFNα compared to wild type cells and intraperitoneal infection of mice lacking TLR9 
resulted in increased viral loads compared to wild type controls96. 
 
1.1.5. Cytosolic sensing of nucleic acids 
During infections, pathogenic nucleic acids can access the cytoplasm of infected cells. 
Especially upon viral replication, RNA is generated in the cytosol. Cytosolic DNA does 
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not only occur during viral infections, but also upon infections with intracellular bacteria. 
Cytosolic nucleic acids are sensed by cytosolic PRRs in a TLR-independent manner. A 
variety of cytosolic PRRs detecting RNA or DNA in the cytoplasm has been discovered 
in the last few years (Figure 6)16. 
 
 
Figure 6: Overview of cytosolic sensing of nucleic acids. Cytosolic dsRNA is sensed by 
RIG-I and MDA5, which are regulated by LGP2, and induces the expression of proinflammatory 
cytokines and type I IFN via NF-κB or IRF3 and IRF7, respectively. Cytosolic DNA is sensed by 
RNA Pol III, AIM2, DDX41, MRE11, DAI, IFI16, cGAS, DNA-PK, LRRFIP1, DHX9, and DHX36. 
RNA Pol III converts dsDNA into dsRNA which is recognized by RIG-I. The cytosolic DNA 
sensor AIM2 as well as RIG-I induce the formation of inflammasomes. DDX41, MRE11, DAI, 
IFI16, cGAS, and DNA-PK activate the production of type I IFN via STING, TBK1, and IRF3 
upon sensing of cytosolic DNA. LRRFIP1 activates β-catenin which induces an IRF3-mediated 
type I IFN response and DHX9 and DHX36 activate the NF-κB- and IRF7-mediated production 
of proinflammatory cytokines and type I IFN via MyD88. The ER-anchored exonuclease Trex1 
digests cytosolic DNA and thereby negatively regulates STING-dependent cytosolic DNA 
responses. 
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Cytosolic RNA is detected by retinoic acid-inducible gene-I (RIG-I)-like receptors 
(RLRs). So far, three RLR family members have been identified, RIG-I, melanoma 
differentiation-associated gene-5 (MDA5), and laboratory of genetics and physiology 2 
(LGP2)8,97. RLRs sense cytosolic dsRNA, a replication intermediate of RNA viruses. 
RLR signaling depends on the mitochondrial antiviral signaling protein (MAVS, also 
known as IPS-1 or CARDIF) which is located at the outer membrane of mitochondria 
and leads to activation of the transcription factors NF-κB, IRF3, and IRF7 and 
ultimately results in the production of proinflammatory cytokines and type I IFN98.  
RLRs are members of the DExD/H-box helicase superfamily. RIG-I and MDA5, but not 
LGP2, contain two caspase recruitment domains (CARD). The helicase domain 
mediates interaction with dsRNA and the CARD domains are required for downstream 
signal transduction. The role of LGP2 for cytosolic DNA sensing is not completely 
understood. It seems to have a regulatory effect on RIG-I and MDA599. 
RIG-I specifically recognizes short RNA with blunt-ended base pairing and an 
uncapped 5`triphosphate end100. RIG-I preferentially recognizes short RNA molecules, 
whereas MDA5 preferentially recognizes long dsRNA101. It has also been shown that 
RIG-I recognizes dsRNA intermediates which have been transcribed from cytosolic 
B-form DNA by RNA polymerase III (Pol III)102,103.  
Whether viral RNA is recognized by TLRs or RLRs seems to be cell type dependent. It 
was shown that RIG-I and MDA5 are critical for the induction of a type I IFN response 
against RNA viruses in fibroblasts, macrophages, and cDC, whereas the TLR system 
was dispensable104,105. In contrast, intracellular TLRs were crucial for a type I IFN 
response against the RNA virus Newcastle disease virus (NDV) in pDC, while the 
production of type I IFN in pDC derived from RIG-I-deficient mice was not impaired104. 
This suggests that RLRs are the major sensors for viral RNA in fibroblasts, 
macrophages, and cDC, whereas in pDC TLRs play a more important role, although 
expression of RIG-I and MDA5 in pDC has been reported106. 
 
In contrast to the response to cytosolic RNA, which has been extensively studied for 
some time, the response to DNA has only recently come into focus when TBK1 and 
IRF3 were linked to the TLR- and RLR-independent recognition of cytosolic DNA107,108. 
The first direct cytosolic DNA sensor which was identified upstream of TBK1 and IRF3 
was the DNA-dependent activator of IFN-regulatory factors (DAI, also known as 
ZBP1)109. DAI was shown to bind to dsDNA which enhances its association with IRF3 
and TBK1. Knockdown of DAI in murine fibroblasts reduced their ability to induce an 
IFNβ response upon stimulation with cytosolic DNA109. However, a subsequent study 
showed that DAI is not essential for type I IFN responses to cytosolic DNA110. Recently, 
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DAI was reported to stimulate necrosis in MCMV-infected fibroblasts which activates an 
antiviral immune response111. 
The ER protein stimulator of interferon genes (STING, also known as MPYS, MITA, 
ERIS, or TMEM173) plays a crucial role for the TBK1/IRF3-mediated type I IFN 
response to cytosolic DNA112-115. STING has four N-terminal transmembrane domains, 
which mediate localization of STING to the ER membrane, and a large C-terminal 
cytoplasmic domain. It was shown that upon activation with dsDNA, the C-terminal 
domain of STING assembles with IRF3 and TBK1. This leads to TBK1-dependent 
phosphorylation of IRF3 and subsequent type I IFN production116. Upon activation, 
STING translocates with TBK1 from the ER to as yet undefined perinuclear vesicles in 
the cytosol117.  
Recently, the cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) 
synthase (cGAS) was identified as a STING-dependent cytosolic DNA sensor118,119. 
Upon binding of DNA in the cytoplasm, cGAS facilitates the synthesis of cGAMP from 
adenosine triphosphate (ATP) and guanosine triphosphate (GTP). cGAMP acts as a 
second messenger and binds to STING. STING recruits TBK1, which phosphorylates 
IRF3 and leads to the production of type I IFN116. It has been shown that cGAMP 
spreads to neighboring cells via gap junctions where it can activate antiviral STING-
dependent signaling120. This way, cells can rapidly initiate antiviral responses prior to 
the spread of the virus. However, the rapid spread and high amplification of innate 
immune signaling can also promote adverse effects. Excessive activation of STING in 
vivo has been linked to autoimmune diseases121,122. For this reason, STING-dependent 
signaling is usually tightly regulated. After activation, STING co-localizes with markers 
for autophagy and becomes phosphorylated116,123. A recent study suggests that after 
autophagy-dependent STING-mediated delivery of TBK1 to endolysosomal compart-
ments and activation of IRF3, STING is subsequently phosphorylated by the 
autophagy-associated kinase UNC-51-like kinase 1 (ULK1) on a serine residue in the 
C-terminus (S366) of STING, which suppresses IRF3 phosphorylation and 
translocation124. Thereby, ULK1 negatively regulates STING-dependent signaling. 
ULK1 activity is usually suppressed by adenosine monophosphate-activated protein 
kinase (AMPK)-mediated phosphorylation. DNA stimulation leads to disassociation of 
ULK1 from its repressor AMPK, which is dependent on cyclic dinucleotides. Thus, 
although cyclic dinucleotides initially activate STING, they subsequently trigger 
negative regulation of STING to prevent persistent activation of immune responses. 
Besides ULK1, the autophagy-related gene 9a (Atg9a) and the three prime repair 
exonuclease 1 (Trex1) have been identified as negative regulators of STING 
signaling122,123. 
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In addition to DAI, RNA Pol III, and cGAS, the human PYHIN proteins absent in 
melanoma 2 (AIM2) and IFNγ-inducible protein 16 (IFI16) have been identified as 
cytosolic DNA sensors125-129. PYHIN proteins have an N-terminal pyrin domain, which 
mediates protein-protein interactions and one or two C-terminal HIN domains which 
mediate DNA binding. AIM2 localizes to the cytoplasm and induces the assembly of a 
multimeric inflammasome complex with ASC and caspase 1 which activates the 
secretion of IL-1β in response to dsDNA125-128. The generation of AIM2-deficient mice 
revealed that AIM2 is essential for inflammasome activation upon infections with the 
bacterial pathogen Francisella tularensis, vaccinia virus, and MCMV130. Human IFI16 
bind to dsDNA and induces a STING-dependent type I IFN response129. IFI16 has also 
been shown to induce inflammasome formation and the production of IL-1β upon 
nuclear sensing of DNA in Kaposi`s sarcoma-associated herpesvirus (KSHV) infected 
epithelial cells131. The murine homolog to IFI16 is the PYHIN protein p204. p204 has 
been shown to be crucial for DNA-induced IFNβ responses in murine macrophages129. 
The RNA helicases RIG-I, MDA5, and LGP2 of the DExD/H-box helicase family have 
been implicated as RNA sensors8. The DNA helicase DDX41, which is also a part of 
the DExD/H-box helicase family, has been shown to interact with dsDNA and to be 
essential for the STING- and TBK1-dependent induction of type I IFN132. Interestingly, 
in addition to its role as a cytosolic DNA sensor, DDX41 was recently reported to 
directly bind cyclic dinucleotides (CDNs) like STING. Knockdown of DDX41 resulted in 
defective activation of STING, TBK1, and IRF3 in response to cyclic dinucleotides133. 
This indicates a possible role for DDX41 as an essential signaling molecule for STING-
dependent responses to CDNs. 
Furthermore, the DExD/H-box helicases DHX9 and DHX36, as well as the leucine-rich 
repeat flightless-interacting protein 1 (LRRFIP1), and DNA-dependent protein kinase 
(DNA-PK) and meiotic recombination 11 (MRE11), which are both involved in the DNA 
damage response, have also been implicated in sensing cytosolic DNA134-138. 
 
DNA does not only appear in the cytoplasm upon infections, but also if endolysosomal 
degradation of exogenous DNA is impaired, or due to an imbalanced control of 
endogenous DNA products and turnover139. Cellular DNases usually prevent unwanted 
accumulation of DNA in the cytosol. DNase II digests pathogenic DNA or DNA derived 
from engulfed apoptotic cells in the lysosome of macrophages. In cells derived from 
DNase II-deficient mice, DNA can leak into the cytoplasm and stimulate cytosolic DNA 
sensors140. Another cellular DNase, Trex1, is the major 3`5` DNA exonuclease in 
mammalian cells. Trex1 localizes to the cytoplasm, but is associated with the ER 
membrane via its C-terminal hydrophobic domain141. In humans, mutations in the 
1. Introduction 18 
TREX1 gene are associated with Aicardi-Goutières syndrome (AGS), familial chilblain 
lupus, and systemic lupus erythematosus (SLE)142-144. Trex1 has been reported to 
degrade DNA replication byproducts and DNA derived from endogenous retroelements 
in the cytoplasm to prevent autoimmune responses141,145. Additionally, Trex1 has been 
shown to metabolize human immunodeficiency virus (HIV) DNA in infected cells and 
thereby prevents triggering of DNA sensors in HIV-infected cells146. Oxidized DNA has 
been shown to be less susceptible to Trex1-mediated degradation, leading to its 
accumulation in the cytoplasm and subsequent activation of the type I IFN response147. 
Trex1-deficient mice develop inflammatory myocarditis and exhibit a dramatically 
reduced survival148. Trex1-deficient mice can be completely rescued from mortality and 
autoimmune disease by crossing Trex1-deficient mice with STING-deficient mice122. 
This suggests Trex1 as a specific negative regulator of the cytosolic DNA response 
triggered through STING-dependent signaling. Trex1 also regulates lysosomal 
biogenesis and the IFN-independent activation of antiviral genes in macrophages149. 
Recently, expression of Trex1 has been found to be upregulated upon TLR or type I 
IFN stimulation of macrophages, cDC, and pDC150,151. These studies suggest that the 
expression of Trex1 is upregulated by proinflammatory stimuli in general and Trex1 
thereby contributes to the regulation of the host immune response. 
 
 
1.2. Protein tyrosine phosphatase 1B 
Tyrosine phosphorylation is a fundamental post-translational mechanism regulating a 
large number of cellular processes including cellular signaling and communication, 
proliferation, differentiation, migration as well as gene regulation and transcription. 
Dysregulation of tyrosine phosphorylation is associated with the pathogenesis of 
numerous human diseases from cancer to immune deficiencies152,153. Tyrosine 
phosphorylation is regulated by protein tyrosine kinases and protein tyrosine 
phosphatases (PTPs). Protein tyrosine phosphatase 1B (PTP1B, also known as 
PTPN1) is the best characterized tyrosine phosphatase153. 
In humans, 107 PTP genes have been identified, 105 of which have a mouse 
ortholog152. PTPs are classified into four different families based on the amino acid 
sequences of their catalytic domains. Class I represents the largest PTP family and 
contains over 100 cysteine-based PTPs including PTP1B. Class I PTPs can be 
subdivided into “classical” PTPs and “dual specificity” PTPs. Dual specificity PTPs have 
the ability to dephosphorylate serine and threonine residues in addition to tyrosine 
residues. PTP1B belongs to the group of classical PTPs which only have an affinity for 
phosphotyrosine residues. The group of classical PTPs can be further subdivided into 
1. Introduction 19 
receptor and non-receptor PTPs based on the presence of a transmembrane domain. 
PTP1B belongs to the group of non-receptor PTPs since it does not contain a 
transmembrane domain. However, PTP1B has a 35-residue C-terminal hydrophobic 
anchor sequence which mediates localization of PTP1B to the cytoplasmic face of the 
ER membrane154,155. Under certain circumstances, PTP1B can also be released from 
the ER, but the full-length ER-localized protein is the predominant form of PTP1B156. In 
addition to the N-terminal catalytic PTP domain and the C-terminal membrane anchor, 
PTP1B contains two tandem proline-rich motifs following the catalytic domain, which 
mediate interactions with other proteins153. So far, more than 30 substrates have been 
described for PTP1B with more suspect substrates remaining to be identified157. 
 
A role for PTP1B has been implicated in the regulation of trafficking of receptor tyrosine 
kinases (RTKs)158. When PTP1B was first identified, the insulin receptor, which belongs 
to the family of RTKs, was suggested as a substrate for PTP1B159. Further studies 
identified PTP1B as a negative regulator of the insulin receptor and its signaling160-163. 
Subsequently, direct interaction between PTP1B and the activated insulin receptor was 
shown164,165. The importance of PTP1B for the regulation of the insulin receptor was 
confirmed using PTP1B knockout (PTP1B-/-) mice. PTP1B-/- mice have been generated 
independently by two different groups166,167. Both groups reported an enhanced insulin 
sensitivity of PTP1B-/- mice together with increased phosphorylation of the insulin 
receptor. Furthermore, due to the insulin hypersensitivity, PTP1B-/- mice were resistant 
to diet-induced obesity. These results indicate a major role for PTP1B in the modulation 
of insulin sensitivity and suggest PTP1B as a potential therapeutic target in the 
treatment of obesity and type 2 diabetes. However, specific targeting of PTP1B by 
small molecule inhibitors is complicated by its similarity to the closely related T cell PTP 
(TC-PTP, also known as PTPN2)153. 
Human PTP1B and TC-PTP have a sequence identity of about 74% in their catalytic 
domains168. Human PTP1B has a molecular weight of 50 kDa. For TC-PTP, two 
different splice variants are expressed in humans, a 48 kDa form and a 45 kDa form, 
which lacks the hydrophobic C-terminus. In mice, only the 45 kDa form of TC-PTP is 
expressed. Similar to PTP1B, the 48 kDa form of TC-PTP is targeted to the ER169. The 
45 kDa form of TC-PTP primarily localizes to the nucleus but also has the ability to 
translocate to the cytoplasm170. In contrast to PTP1B-/- mice, which have a normal life 
span, knockout of TC-PTP is lethal and TC-PTP-/- mice die soon after birth171. Like 
PTP1B, TC-PTP has been implicated to play a role in the regulation of insulin 
signaling172. Although PTP1B and TC-PTP are highly related, they have been shown to 
act specifically and to play nonredundant roles in cellular signaling processes173-175. 
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Because the interactions of phosphatases with their substrates are transient and 
therefore difficult to detect, a substrate trapping mutant of PTP1B (D181A) was 
developed for the identification of new substrates of PTP1B176. Compared to the wild 
type enzyme, the catalytic activity of the D181A mutant is reduced 105-fold. Thus, the 
D181A mutant of PTP1B can be used to isolate and study complexes of PTP1B with its 
substrates.  
 
Using the D181A substrate-trapping mutant, the RTK epidermal growth factor receptor 
(EGFR) was identified as a substrate of PTP1B. It was shown that autophosphorylation 
of the EGFR is required for its interaction with PTP1B and co-expression with mutant 
PTP1B leads to intracellular accumulation of the EGFR and co-localization with 
PTP1B176. Upon EGF stimulation, the EGFR is endocytosed from the plasma 
membrane, ubiquitinated, and subsequently invaginated into multivesicular bodies 
(MVBs) where the receptors are degraded upon fusion of MVBs with lysosomes, a 
process that is mediated by ESCRT complexes177. In order to find out how PTP1B, 
which is localized at the ER membrane, can interact with cell surface RTKs like the 
EGFR, fluorescence resonance energy transfer (FRET) experiments were performed. 
FRET analysis revealed that PTP1B interacts with RTKs after internalization of the 
activated receptors from the cell surface and that PTP1B catalyzes dephosphorylation 
of RTKs at specific sites on the ER surface178. Direct sites of membrane contact 
between MVB and the ER facilitating the interaction between EGFR and PTP1B were 
shown by electron microscopy179. This study suggested that PTP1B plays a central role 
in the coordination of MVB maturation, which occurs during the movement of MVB from 
the periphery to the cell center, a hypothesis which fits well with a reported gradient of 
PTP1B activity from low at the cell periphery to high in the cell center180. Besides 
internalized RTKs, PTP1B likely dephosphorylates activated RTKs at the cell surface. 
Direct contact between ER-anchored PTP1B and plasma membrane-anchored RTKs 
has been shown by bimolecular fluorescence complementation (BiFC)181,182.  
In summary, PTP1B has been proposed to dephosphorylate activated RTKs at sites of 
membrane contact between the ER and the plasma membrane and upon trafficking of 
internalized RTKs in close proximity to the ER158. Furthermore, after their biosynthesis, 
RTKs can become autophosphorylated in a ligand-independent manner and the 
phosphorylation of these immature RTKs is particularly sensitive to PTP1B183. Thus, 
PTP1B might also be important to prevent ligand-independent activation of newly 
synthesized RTKs at the ER (Figure 7)158. 
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Figure 7: PTP1B regulates intracellular trafficking of receptor tyrosine kinases. Receptor 
tyrosine kinases (RTKs) become autophosphorylated upon ligand binding. PTP1B 
dephophorylates RTKs at the plasma membrane (A) or upon internalization (B) which down-
regulates RTK signaling. PTP1B might also prevent ligand-independent activation of newly 
synthesized RTKs at the ER (C). 
 
Further evidence for the central role of PTP1B in the regulation of RTK downregulation 
has been provided by a study which identified signal transducing adaptor molecule 2 
(STAM2), an endosomal protein involved in sorting of activated RTKs for lysosomal 
degradation, as a substrate for PTP1B184. STAM2 is part of the ESCRT-0 complex 
which is implicated in the recognition of ubiquitinated endosomal RTKs. ESCRT-0 
recruits ESCRT complexes I, II, and III, which mediate the internalization of RTKs, like 
the EGFR, into MVBs and target them for lysosomal degradation185,186. 
 
PTP1B has also been linked to several immune pathways. It has been shown that 
Janus kinase 2 (JAK2) and tyrosine kinase 2 (TYK2) are substrates of PTP1B187. TYK2 
is involved in the signaling in response to colony-stimulating factor 1 (CSF-1, also 
known as macrophage colony-stimulating factor MSCF), a cytokine that is important for 
myeloid development. In the absence of PTP1B, the sensitivity of the CSF-1 receptor is 
increased which results in augmented monocytic development and an increased 
inflammatory activity in PTP1B-deficient macrophages in vitro and in vivo188. 
Additionally, nonredundant roles for PTP1B and TC-PTP were implicated in the 
regulation of IFNγ signaling, which is partially dependent on JAK2174. Splenic T cells 
from TCPTP+/-/PTP1B-/- mice were able to produce higher amounts of IFNγ than T cells 
from TCPTP+/+/PTP1B-/- or TCPTP+/-/PTP1B+/- mice. 
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Recent evidence suggests that obesity can be considered as an inflammatory state189. 
It was shown that PTP1B is overexpressed in adipose tissues in vivo which is mediated 
by tissue inflammation and the proinflammatory cytokine TNF190. Additionally, chronic 
exposure to IL-6, another proinflammatory cytokine, leads to insulin resistance in wild 
type mice, whereas PTP1B-/- mice are protected against the effects of chronic IL-6 
exposure191. Moreover, PTP1B-/- mice have been shown to be protected against age-
induced obesity and insulin resistance due to a low grade of inflammation in adipose 
tissues192. Thus, PTP1B is important for the regulation of inflammation which is linked 
to obesity-induced metabolic changes. 
 
Altogether, PTP1B has multiple functions and a variety of substrates which have been 
described since its discovery over 25 years ago. Besides its role in the regulation of 
metabolism, trafficking of RTKs, and inflammation, which have been summarized here, 
PTP1B has also been implicated as a key player in cancer and as a regulator of 
numerous additional signaling cascades153. 
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1.3. Aim of the study 
Immune sensing of foreign nucleic acids is important for the activation of the early 
immune response to infections as well as the subsequent activation of specific adaptive 
immune responses. Intracellular TLRs 3, 7, and 9 are a crucial part of the nucleic acid 
sensing machinery of the innate immune system and sense nucleic acids in the 
endolysosomal compartment. After their synthesis in the ER, intracellular TLRs traffic 
to the endolysosome in order to meet their ligands and initiate proinflammatory 
cytokine and type I IFN responses. The regulation of TLR localization and trafficking is 
also important to prevent autoimmunity. 
The polytopic membrane protein UNC93B interacts with TLRs 3, 7, and 9 and delivers 
them from the ER to the endolysosome. The point mutation H412R in UNC93B disrupts 
binding of UNC93B to TLRs and UNC93B H412R as well as intracellular TLRs fail to 
leave the ER.  
 
This study aims to investigate the role of UNC93B for innate immunity using two 
approaches:  
1. A thorough comparison of innate immune cells derived from UNC93B H412R 
and UNC93B knockout mice. 
2. The characterization of novel UNC93B interaction partners and their role for 
trafficking and signaling of intracellular TLRs and UNC93B. 
 
To achieve the first aim, proinflammatory cytokine and type I IFN responses were 
analyzed upon stimulation of TLRs and cytosolic PRRs with synthetic agonists as well 
as upon herpesviral infection in macrophages and dendritic cells derived from wild 
type, UNC93B H412R, and UNC93B knockout mice. 
To achieve the second aim, the novel UNC93B interaction partners Clptm, Trex1, and 
PTP1B were studied. The interaction of these proteins with UNC93B was verified by 
co-immunoprecipitation experiments. The functional role of Clptm for the TLR-
dependent innate immune response was analyzed upon shRNA-mediated knockdown 
of Clptm in macrophages. The role of PTP1B for signaling of intracellular TLRs was 
analyzed upon TLR stimulation or herpesviral infection in macrophages and bone 
marrow cells from PTP1B-deficient mice, as well as upon stimulation of TLR9 in vivo. 
Furthermore, the role of PTP1B for intracellular trafficking and endosomal processing 
of TLR9 was investigated. 
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2. Materials and methods 
2.1. Buffers and solutions 
 
Annexin V binding buffer 10 mM HEPES/KOH, pH7.4 
140 mM NaCl 
2.5 mM CaCl2 
in H2O 
Digitonin lysis buffer 50 mM Tris-HCl, pH 7.4 
150 mM NaCl 
5 mM EDTA 
1% digitonin 
in H2O 
Digitonin wash buffer 50 mM Tris-HCl, pH 7.4 
150 mM NaCl 
5 mM EDTA 
0.2% digitonin 
in H2O 
HBS 20 mM HEPES 
150 mM NaCl 
in H2O, pH 7.4 
MACS buffer 0.5% BSA 
2 mM EDTA 
in PBS 
NP-40 lysis buffer 50 mM Tris-HCl, pH 7.4 
150 mM NaCl 
0.5 mM EDTA 
0.5-1% Nonidet P-40 (IGEPAL CA-630) 
in H2O 
PBS 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 x 2 H2O 
1.8 mM KH2PO4 
in H2O, pH 7.4 
RIPA 100 lysis buffer 20 mM Tris-HCl, pH 7.5 
1 mM EDTA 
100 mM NaCl 
1% Triton X-100 
0.5% sodium deoxycholate (DOC) 
0.1% SDS 
in H2O 
SDS electrophoresis buffer 25 mM Tris base 
192 mM glycine 
0.1% SDS 
in H2O 
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SDS loading buffer (4x) 250 mM Tris-HCl, pH 6.8 
8% SDS 
0.04% bromophenol blue 
40% glycerol 
in H2O 
add 10% 2-mercaptoethanol before use 
SDS stacking gel,  
7.5% acrylamide (for 2 gels) 
5.9 ml H2O 
3 ml 1.5 M Tris-HCl, pH 8.8 
3 ml 30% acrylamide-bisacrylamide 
120 µl 10% SDS 
16 µl TEMED 
16 µl 25% APS 
SDS separating gel,  
5% acrylamide (for 2 gels) 
2.3 ml H2O 
1 ml 0.5 M Tris-HCl, pH 6.8 
0.68 ml 30% acrylamide-bisacrylamide 
40 µl 10% SDS 
8 µl TEMED 
12 µl 25% ammonium persulfate (APS) 
TBS 20 mM Tris base 
137 mM NaCl 
in H2O, pH 7.6 
Transfer buffer (for tank blotting) 25 mM Tris base 
192 mM glycine 
0.05% SDS 
20% methanol 
in H2O 
 
 
2.2. Constructs and DNA cloning 
All constructs generated in this study are listed in Table 2. DNA was amplified from 
indicated templates by PCR with Pfu Polymerase and indicated primers (Table 2 and 
Table 3). cDNA was cloned into destination vectors using restriction sites as indicated. 
Trex1 D18N and PTP1B D181A point mutants were generated by sequential PCR with 
primers carrying the point mutation (Table 3, point mutation is underlined) followed by 
PCR with primers for ligation into pMSCV destination vectors. Wild type and D181A 
HA-PTP1B were cut from pMSCVpuro by restriction digest and ligated into 
pcDNA3.1(+) as indicated (Table 2). All constructs generated by PCR were completely 
sequenced. Expression of all constructs was verified by transfection of HEK 293T cells 
or retroviral transduction of BMDM followed by immunoblot analysis (2.7). All 
constructs which have been used, but were not generated in this study, are listed in 
Table 4. Plasmid DNA was prepared using the Plasmid Maxi Kit (Qiagen) according to 
the manufacturer`s instructions. 
 
 
 
2. Materials and methods 26 
Table 2: List of constructs generated in this study. 
Construct 
(Code) 
Template Primers Restriction 
sites 
Destination 
vector 
Clptm-HA (L22) HA-Clptm pMSCVhygro 150 + 153 BglII/HpaI pMSCVhygro 
GFP-Clptm 
(L20) 
HA-Clptm pMSCVhygro 39 + MB BglII/EcoRI pEGFP-C1 
GFP-Clptm 
(L21) 
GFP-Clptm pEGFP-C1 43 + MB XhoI/EcoRI pMSCVpuro 
Clptm-GFP 
(L24) 
HA-Clptm pMSCVhygro 150 + 40 BglII/SmaI pEGFP-N1 
Clptm-GFP 
(L23) 
Clptm-GFP pEGFP-N1 150 + 152 BglII/EcoRI pMSCVpuro 
cherry-Trex1 
(L33) 
MGC Mouse Trex1 cDNA 
(MMM1013-65426, Open 
Biosystems) 
64 + 61 EcoRI/XmaI pmCherry-C1 
cherry-Trex1 
(L36) 
cherry-Trex1 pmCherry-C1 63 + 61 HpaI/HpaI pMSCVhygro 
cherry-Trex1 
1-235 (L34) 
MGC Mouse Trex1 cDNA 
(MMM1013-65426, Open 
Biosystems) 
64 + 62 EcoRI/XmaI pmCherry-C1 
cherry-Trex1 
1-235 (L37) 
cherry-Trex1 1-235 
pmCherry-C1 
63 + 62 HpaI/HpaI pMSCVhygro 
cherry-Trex1 
236-314 (L35) 
MGC Mouse Trex1 cDNA 
(MMM1013-65426, Open 
Biosystems) 
65 + 61 EcoRI/XmaI pmCherry-C1 
cherry-Trex1 
236-314 (L38) 
cherry-Trex1 236-315 
pmCherry-C1 
63 + 61 HpaI/HpaI pMSCVhygro 
cherry-Trex1 
D18N (L39) 
cherry-Trex1 pMSCVhygro 66 + 67, 
61 + 63 
 
HpaI/HpaI 
 
pMSCVhygro 
HA-PTP1B 
(L41) 
MGC Mouse Ptpn1 cDNA 
(EMM1002-3695563, Open 
Biosystems) 
110 + 111 BglII/EcoRI pMSCVpuro 
HA-PTP1B  
D181A (L40) 
HA-PTP1B pMSCVpuro 112 + 113, 
110 + 111 
 
BglII/EcoRI 
 
pMSCVpuro 
HA-PTP1B 
(L32) 
HA-PTP1B pMSCVpuro  BamHI/EcoRI pcDNA3.1(+) 
HA-PTP1B  
D181A (L31) 
HA-PTP1B D181A 
pMSCVpuro 
 BamHI/EcoRI pcDNA3.1(+) 
HA-PTP1B 
(L125) 
HA-PTP1B pMSCVpuro 477 + 478 BglII/HpaI pMSCVhygro 
mRuby2-HA-
PTP1B (L163) 
pcDNA3-mRuby2 407 + 409 BglII/BglII HA-PTP1B 
pMSCVpuro 
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Table 3: List of primers used for DNA cloning. 
No. Name Sequence, 5`3` Tm 
MB CleftLipEcoRIrev GCTAGAATTCTAATCCTTTTTCTTGTCCTCTGC 64°C 
39 BglIIClptmfor GCATAGATCTGCGGCGGCGCAGGAGGC 64°C 
40 SmaIClptmrev GCTACCCGGGCATCCTTTTTCTTGTCCTCTGC 60°C 
43 XhoIGFPfor GCATCTCGAGGCCACCATGGTGAGCAAGGGCGAG 58°C 
61 TrexHpaIXmaIrev GCATCCCGGGGTTAACTTACTGCCCAGGTGAGGC 58°C 
62 Trex705HpaIXmaIr GCATCCCGGGGTTAACTTAAGTGCCGTACATGGGC 58°C 
63 HpaImCherryfor GCATGTTAACCGCCACCATGGTGAGCAA 58°C 
64 EcoRITrexfor GCATGAATTCAGGCTCACAGACCCTGCC 58°C 
65 EcoRITrex706for GCATGAATTCACCGGCTACCACTGGAACA 58°C 
66 Trex D18N for CCCTCATCTTCTTAAACCTGGAAGCCACTGGCCTGC
C 
 
67 Trex D18N rev GGCAGGCCAGTGGCTTCCAGGTTTAAGAAGATGAG
GG 
 
110 BglIIHAPTP1Bfor GCATAGATCTGCCACCATGTATCCGTACGACGTACC
AGACTACGCAATCGAGGAGATGGAGAAGGAGTTCG 
58°C 
111 PTP1BEcoRISalIre GCTAGTCGACGAATTCTCAGTGAAAACACACCCGG 58°C 
112 PTP1B D181A for CCACATGGCCTGCCTTTGGAGTCCCCGAGTCACCG
GC 
 
113 PTP1B D181A rev GCCGGTGACTCGGGGACTCCAAAGGCAGGCCATGT
GG 
 
150 BglIIClptmStartf GCATAGATCTGCCACCATGGCGGCGGCGCAGGA 60°C 
152 EcoRIGFPrev GCTAGAATTCTTACTTGTACAGCTCGTCCAT 60°C 
153 HpaIHAClptmrev GCATGTTAACCTATGCGTAGTCTGGTACGTCGTACG
GATAATCCTTTTTCTTGTCCTCTGC 
60°C 
407 BglIIEcoRIRuby2f GCATAGATCTGAATTCGCCACCATGGTGTCTAAGGG
CGAAG 
58°C 
409 CherRuby2BglIIr GCTAAGATCTCTTGTACAGCTCGTCCAT 54°C 
477 BglIIHAPTP1Bfor GCATAGATCTGCCACCATGTATCCGTACGACGTACC 60°C 
478 PTP1BHpaIrev GCTAGTTAACTCAGTGAAAACACACCCGGT 60°C 
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Table 4: List of used vectors and constructs. 
Construct/Vector (Code) Vector backbone Origin 
VSV-G, retrovirus (V43)  M. Brinkmann 
gag-pol, retrovirus (V44)  M. Brinkmann 
HA-Clptm (L273) pMSCVhygro M. Brinkmann  
pcDNA3.1(+) (V20)  Invitrogen 
pcDNA3-mRuby2 (V17) pcDNA3 Addgene, plasmid 40260 
pEGFP-C1 (V2)  Clontech 
pEGFP-N1 (V1)  Clontech 
pmCherry-C1 (V4)  Clontech 
pMSCVhygro (V27)  Clontech 
pMSCVpuro (V28)  Clontech 
pMSCVneo (V29)  Clontech 
sh-control1 pMSCVpuro see 2.15 
sh-control2 pMSCVpuro see 2.15 
sh-UNC1 pMSCVpuro see 2.15 
sh-UNC2 pMSCVpuro see 2.15 
sh-UNC3 pMSCVpuro see 2.15 
sh-Clptm1 pMSCVpuro see 2.15 
sh-Clptm2 pMSCVpuro see 2.15 
TLR9-GFP (L15) pMSCVpuro M. Brinkmann 
UNC93B-HA (L5) pMSCVneo M. Brinkmann 
UNC93B-HA H412R (L6) pMSCVneo M. Brinkmann 
UNC93B-GFP (L7) pMSCVneo M. Brinkmann 
UNC93B-GFP H412R (L8) pMSCVneo M. Brinkmann 
 
2.3. Cell lines and cell culture 
The cell lines used in this study are listed in Table 5. All cell lines were cultured at 37°C 
in a humidified incubator with 7.5% CO2. DMEM (high glucose, Gibco/Life 
Technologies) supplemented with 10% FCS (Sigma), 2 mM glutamine (Gibco/Life 
Technologies), 1% penicillin/streptomycin (P/S) (Gibco/Life Technologies), and 50 µM 
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2-mercaptoethanol (Gibco/Life Technologies) was used as the standard medium for all 
cell lines. Cells were trypsinized and split every 2-3 days. Stable cell lines generated by 
retroviral transduction (2.4) were put under selection with indicated antibiotics 
(Table 5). 
 
Table 5: List of cell lines. 
Cell line Antibiotic, 
final concentration 
Origin 
HEK 293T  ATCC (CRL-11268) 
BMDM, immortalized  M. Brinkmann193 
BEI Resources (NR-9456) 
BMDM TLR9-GFP Puromycin, 10 µg/ml M. Brinkmann74 
BMDM HA-PTP1B Puromycin, 10 µg/ml this study 
BMDM HA-PTP1B Hygromycin, 250 µg/ml this study 
BMDM HA-PTP1B D181A Puromycin, 10 µg/ml this study 
BMDM TLR9-GFP + HA-PTP1B Puromycin, 10 µg/ml; 
Hygromycin, 250 µg/ml 
this study 
BMDM GFP-Clptm Puromycin, 10 µg/ml this study 
BMDM cherry-Trex1 Hygromycin, 250 µg/ml this study 
BMDM GFP-Clptm +  
cherry-Trex1 
Puromycin, 10 µg/ml; 
Hygromycin, 250 µg/ml 
this study 
RAW 264.7 macrophages  ATCC (TIB-71) 
RAW UNC93B-HA G418, 750 µg/ml M. Brinkmann 
RAW UNC93B-HA H412R G418, 750 µg/ml M. Brinkmann 
RAW HA-Clptm Hygromycin, 250 µg/ml M. Brinkmann 
RAW Clptm-HA Hygromycin, 250 µg/ml this study 
RAW GFP-Clptm Puromycin, 10 µg/ml this study 
RAW Clptm-GFP Puromycin, 10 µg/ml this study 
RAW cherry-Trex1 Hygromycin, 250 µg/ml this study 
RAW cherry-Trex1 1-235 Hygromycin, 250 µg/ml this study 
RAW cherry-Trex1 236-314 Hygromycin, 250 µg/ml this study 
RAW cherry-Trex1 + GFP-Clptm Hygromycin, 250 µg/ml;  
Puromycin, 10 µg/ml 
this study 
RAW cherry-Trex1 1-235 +  
GFP-Clptm 
Hygromycin, 250 µg/ml; 
Puromycin, 10 µg/ml 
this study 
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RAW cherry-Trex1 236-314 +  
GFP-Clptm 
Hygromycin, 250 µg/ml; 
Puromycin, 10 µg/ml 
this study 
RAW sh-control1 Puromycin, 10 µg/ml this study 
RAW sh-control2 Puromycin, 10 µg/ml this study 
RAW sh-UNC1 Puromycin, 10 µg/ml this study 
RAW sh-UNC2 Puromycin, 10 µg/ml this study 
RAW sh-UNC3 Puromycin, 10 µg/ml this study 
RAW sh-Clptm1 Puromycin, 10 µg/ml this study 
RAW sh-Clptm1 Puromycin, 10 µg/ml this study 
 
2.4. Preparation of retroviral particles for the generation of stable cell 
lines 
2.4.1. Production of retroviral particles 
Low passage HEK 293T cells were seeded in a 6 well plate or 10 cm dish. The cells 
were 70-90% confluent at the time of transfection. The following day, cells were 
transfected with a mix of DNA and Lipofectamine 2000 (Invitrogen), both diluted in 
OptiMEM (Invitrogen). The DNA mix contained plasmids encoding the retroviral 
envelope and packaging proteins VSV-G and gag-pol as well as the desired construct 
in a pMSCV retroviral expression vector. For a 10 cm dish, 4.8 µg of the expression 
construct in pMSCV, 3.6 µg of gag-Pol, 3.6 µg of VSV-G, and 60 µl of Lipofectamine 
2000 were used for the transfection. 24-30 h post transfection, the medium containing 
viral particles was collected, filtered through a 0.45 µm membrane, aliquoted, and 
stored at -70°C. 
 
2.4.2. Generation of stable macrophage cell lines by retroviral transduction 
For the retroviral transduction of immortalized macrophage cell lines, cells were seeded 
in 6 well plates. Supernatants with viral particles were diluted in medium and 8 µg/ml of 
Polybrene (Santa Cruz) were added to increase the infection efficiency. Medium was 
removed and diluted supernatants containing viral particles were added onto the cells. 
Spin infection was carried out for 2 h at 2000 rpm at RT. After an additional incubation 
for 2 h at 37°C, the medium was replaced. Antibiotic selection was started one day post 
transduction. 
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2.5. Mice 
All mouse strains used in this study are listed in Table 6. 
To establish the UNC93B-/- mouse line in the HZI animal facility, in vitro fertilization 
(IVF) was performed with frozen Unc93b1-/- sperm (parental ES cell line: VGB6; 
background: C57BL/6NTac; ES cell clone 10049A-G9, obtained from the NCRR-NIH 
supported KOMP Repository (www.komp.org) and generated by Regeneron 
Pharmaceuticals, Inc. for the NIH funded Knockout Mouse Project (KOMP)194). 
 
For this study, TLR9-GFP mice74 were crossed with UNC93B-/- and PTP1B-/- mice to 
obtain TLR9-GFP/UNC93B-/- and TLR9-GFP/PTP1B-/- mouse strains and PTP1B-/- mice 
were crossed with IFNβ ∆β-luc/∆β-luc reporter mice195 to obtain IFNβ +/∆β-luc/PTP1B-/- mice. 
 
All animals were maintained under specific pathogen-free (SPF) conditions in the HZI 
central animal facility. Health monitoring was performed according to FELASA 
recommendations. 
 
Table 6: List of mouse strains. 
Mouse strain Genetic 
background 
Origin 
C57BL/6J wild type  HZI animal facility 
C57BL/6N wild type  HZI animal facility 
UNC93B-/-, UNC93B+/- C57BL/6N KOMP Repository, HZI animal facility 
3d C57BL/6J HZI animal facility52 
TLR3-/- C57BL/6J Mathias Hornef, MHH, Hannover196 
TLR7-/- C57BL/6J Sabine Stegemann-Koniszewski/Dunja Bruder,  
HZI animal facility197 
TLR9-/- C57BL/6J HZI animal facility24 
TLR9-GFP C57BL/6J HZI animal facility74 
PTP1B-/- (PTPN1-/-) C57BL/6J Jackson Laboratory (MMRRC, stock number: 
032240-JAX), HZI animal facility167 
TLR9-GFP/PTP1B-/- C57BL/6J this study, HZI animal facility 
TLR9-GFP/UNC93B-/- C57BL/6J this study, HZI animal facility 
IFNβ+/∆β-luc/PTP1B-/- C57BL/6J this study, HZI animal facility 
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2.6. Generation of primary BMDM, FL-DC, and total bone marrow cells 
Primary bone marrow-derived macrophages (BMDM) were cultivated in DMEM (high 
glucose) supplemented with 10% FCS, 2 mM glutamine, 1% P/S, 50 µM 
2-mercaptoethanol, and 5% self-made MCSF. Flt3 ligand-induced dendritic cells 
(FL-DC) and total bone marrow (BM) cells were cultured in RPMI (Gibco/Life 
Technologies) supplemented with 10% FCS, 2 mM glutamine, 1% P/S, and 50 µM 
2-mercaptoethanol. For the generation of FL-DC, 2.5% of self-made Flt3 ligand were 
added to the culture medium. Primary BMDM, FL-DC, and total BM cells were cultured 
at 37°C and 7.5% CO2.  
For the preparation of MCSF, 3T3-MCSF cells (M. Brinkmann) were grown in tissue 
culture flasks in DMEM supplemented with 10% FCS without P/S. Cell supernatant was 
collected and centrifuged for 5 min at 2000 rpm. The supernatant was filtered through a 
0.2 µm membrane, aliquoted, and stored at -70°C. For the preparation of Flt3 ligand, 
B16 Flt-3L cells198 were grown in FL-DC medium. Cell supernatant was collected and 
centrifuged at 3000 rpm for 10 min. The supernatant was transferred into new tubes 
and centrifuged at 3000 rpm for 10 min. The supernatant was filtered through a 0.2 µm 
membrane, aliquoted, and stored at -70°C. Optimal amounts of self-made MCSF and 
Flt3 ligand for the generation of BMDM and FL-DC were determined by flow cytometry 
phenotypic analysis of macrophages and dendritic cells (cDC and pDC), respectively. 
 
For bone marrow preparation, femur and tibia were removed from the mouse and the 
bone marrow was extruded from the opened bone with DMEM or RPMI using a syringe 
and a 0.5 x 16mm, 25 G x 5/8’’ needle. Cells were resuspended to obtain a single cell 
suspension followed by centrifugation for 5 min at 1000 rpm. 
 
For the generation of BMDM, pellets were resuspended in medium containing MCSF 
and transferred into a 10 cm dish (day 0). On day 1, non-adherent cells were 
transferred into 6-7 10 cm or 3 15 cm dishes. On day 3, fresh medium was added to 
the cells. On day 5, the medium was completely replaced by fresh medium. Cells were 
used for experiments on days 7 or 8 using medium without MCSF. 
 
For FL-DC or total BM cells, pellets of bone marrow cells were resuspended in 0.5 ml 
of Red Blood Cell Lysing Buffer (Sigma-Aldrich) and incubated for 1-2 min at RT. 
Medium was added and cells were centrifuged for 5 min at 1000 rpm, resuspended in 
medium, and counted with Tuerk`s Solution. For experiments with total BM cells, these 
cells were directly seeded in 96 well plates. To generate FL-DC, cell numbers were 
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adjusted to 1.5 x 106 cells/ml, 2.5 % of Flt3 ligand were added, and cells were cultured 
in tissue culture flasks (day 0). FL-DC were used for experiments on day 8. 
 
The genotypes of all mice used for the preparation of primary cells were confirmed by 
genotyping or immunoblotting. 
 
2.7. Immunoblotting 
If not specified elsewhere, cells were lysed in RIPA 100 lysis buffer supplemented with 
protease inhibitors (Complete EDTA-free, Roche) for at least 10 min on ice followed by 
centrifugation for 10 min at 14,000 g and 4°C to remove cell debris.  
Prior to SDS-Polyacrylamide gel electrophoresis (SDS-PAGE), SDS loading buffer was 
added to cell lysates and lysates were subjected to a 7.5% SDS-PAGE (10% for 
Figure 21B). Proteins were transferred to a nitrocellulose membrane (Protran BA85, 
pore size 0.45 µm, GE Healthcare) by tank blotting at 0.35 A for 1 h. 
For immunoblots shown in Figure 22, Figure 25B, Figure 42A, and Figure 43A, Bolt 
LDS Sample Buffer and Bolt Sample Reducing Agent (Life Technologies) were added 
to cell lysates instead of SDS loading buffer and lysates were separated by Bolt 4-12% 
Bis-Tris Gels (Life Technologies) using Bolt MOPS SDS Running Buffer (Life 
Technologies). Proteins were transferred to a nitrocellulose membrane using Bolt 
Transfer Buffer (Life Technologies) supplemented with 20% methanol as described 
above. 
 
Membranes were blocked with 5% milk powder in TBS/0.1% Tween 20 (TBS-T) for 1 h 
at RT or overnight at 4°C. Antibodies were diluted in 5% milk powder in TBS-T 
(Table 7). Membranes were incubated with diluted antibodies for 1 h at RT and 
subsequently washed three times with TBS-T for 10 min. For detection of peroxidase 
activity and immunoblot imaging, membranes were incubated with Lumi-Light Western 
Blotting Substrate (Roche) for 1 min and chemiluminescence was visualized on 
chemiluminescence films (GE Healthcare). If signals were very weak, membranes were 
reincubated with Super Signal West Femto Chemiluminescent Substrate (Thermo 
Scientific) for 1 min. 
 
Antibodies against the N-terminal (aa 1-354) and C-terminal (aa 530-664) region of 
murine Clptm were generated according to the generation of antibodies against murine 
UNC93B described by Brinkmann et al.54. N-terminal Clptm peptides were as follows: 
1N, C-HPDPRQKALYRRLA; 2N, C-RMINKYKRRRFQKTK; 3N, C-KFDAVSGDYYPIIY 
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FND. C-terminal Clptm peptides were as follows: 1C, C-QRWIYRVDPTRVNEFG; 2C, 
C-GEDVSAAAS RAQASTAAGA; 3C, C-QPQEAPPKPAEDKKKD. 
 
Table 7: List of antibodies used for immunoblotting. 
Antibody Species Source Order number Dilution 
Primary antibodies    
Anti-α-tubulin mouse, monoclonal Sigma-Aldrich T6199 1:1000 
Anti-GFP rabbit, polyclonal Abcam ab290 1:6000 
Anti-PTP1B Antibody rabbit, polyclonal Millipore ABS40 1:500 
Anti-GFP HRP (B-2) mouse, monoclonal Santa Cruz sc-9996 HRP 1:1000 
Anti-HA-Peroxidase 
High Affinity (3F10) 
rat, monoclonal Roche 12013819001 1:4000 
Anti-RFP (5F8) rat, monoclonal Chromtek 5F8 1:1000 
Anti-uncC, 6055 
4th or final bleed 
rabbit, polyclonal M. Brinkmann54  1:2000 
Anti-uncC, 6055 
purified from 6th bleed 
rabbit, polyclonal M. Brinkmann54  1:1000 
Anti-ClptmC, 6804 
3rd bleed 
rabbit, polyclonal M. Brinkmann  1:5000 
Anti-ClptmC, 6804 
purified from final bleed 
rabbit, polyclonal M. Brinkmann  1:2000 
Secondary antibodies    
Anti-mouse IgG + IgM 
(H+L)-HRPO (A4a) 
goat, polyclonal Dianova 115-035-068 1:5000 
Anti-rabbit IgG  
(H+L)-HRPO (B4c) 
goat, polyclonal Dianova 111-035-045 1:20000 
Anti-rat IgG  
(H+L)-HRPO (C4c) 
goat, polyclonal Dianova 112-035-062 1:5000 
 
2.8. Stimulation of PRRs 
2.8.1. PRR agonists 
Pam3CSK4, FSL-1, Poly(I:C) (HMW), R848, Poly(U), and 5`ppp-dsRNA were 
purchased from Invivogen. LPS was purchased from Sigma-Aldrich.  
CpG oligonucleotides (ODN) and ISD 45bp107 and ISD 85bp141 were synthesized by 
Eurofins MWG Operon and reconstituted in endotoxin-free water (Table 8). 
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To obtain double stranded ISD, equal amounts of forward and reverse ODN were 
mixed and incubated for 10 min at 95°C followed by cooling at RT. 
 
Table 8: List of oligonucleotides used for PRR stimulation. Bases in capital letters are 
phosphodiester, bases in lower case are phosphorothioate. 
Name Sequence, 5`3` 
CpG 1826, type B tccatgacgttcctgacgtt 
CpG 1585, type A ggGGTCAACGTTGAgggggg 
CpG 2336, type A gggGACGACGTCGTGgggggg 
CpG 2216, type A ggGGGACGATCGTCgggggg 
GpC 2216 control ggGGGAGCATGCTCgggggg 
ISD 45bp forward TACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTACA 
ISD 45bp reverse TGTAGATCATGTACAGATCAGTCATAGATCACTAGTAGATCTGTA 
ISD 85bp forward ACATCTAGTACATGTCTAGTCAGTATCTAGTGATTATCTAGACATA
CATGATCTATGACATATATAGTGGATAAGTGTGGACATC 
ISD 85bp reverse GATGTCCACACTTATCCACTATATATGTCATAGATCATGTATGTCT
AGATAATCACTAGATACTGACTAGACATGTACTAGATGT 
 
2.8.2. Stimulation of PRRs with PRR agonists for cytokine measurements by 
ELISA 
To stimulate cell surface and intracellular TLRs as well as cytosolic PRRs, primary 
BMDM, FL-DC, RAW 264.7 macrophages, and total BM cells were seeded in 96 well 
plates and stimulated with TLR agonists. 
 
1.5 x 105 primary BMDM per well were seeded in 96 well plates. When the cells were 
adherent, they were stimulated with PRR agonists for 16 to 18 h as indicated in figure 
legends. 5 x 105 FL-DC per well were seeded in 96 well plates (round bottom) and 
stimulated or transfected with indicated PRR agonists for 18 h. 1 x 105 RAW 264.7 
macrophages stably expressing shRNAs were seeded per well in 96 well plates. When 
the cells were adherent, they were stimulated with indicated TLR agonists for 4 h. 
1 x 106 total BM cells per well were seeded in 96 well plates (round bottom) and 
stimulated or transfected with indicated TLR agonists for 22 h. 
 
For stimulation of cells with Pam3CSK4, FSL-1, LPS, Poly(I:C), R848, CpG 1826, and 
CpG 2336, stimuli were diluted directly into the medium and added to the cells. For 
stimulation with Poly(U), 5`ppp-dsRNA, ISD 85bp, or ISD45bp, cells were transfected 
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with 200 ng of RNA/DNA and 1.2 µl of DOTAP (Roche) diluted in HBS according to the 
manufacturer’s instructions. Transfection mixes were diluted in medium and added to 
the cells (final volume: 200 µl per well, final DNA/RNA concentration: 1 µg/ml). 
After stimulation, supernatants were stored at -20°C for analysis of proinflammatory 
cytokine and type I IFN responses by ELISA as described in 2.10. 
 
2.8.3. Stimulation of TLR9 for qPCR analysis 
To analyze the TLR9-dependent type I IFN response in macrophages, primary BMDM 
were stimulated with two different kinds of CpG A. 1.5 x 106 primary BMDM in 1 ml per 
well were seeded in a 6 well plate. When the cells were adherent, they were 
transfected with 6.8 µg of CpG 1585 or CpG 2336 and 30 µl of DOTAP (Roche) diluted 
in HBS according to the manufacturer’s instructions per well (final concentration of CpG 
DNA: 1 µM). After 6 h of incubation, cells were lysed in 350 µl of RLT buffer with 
2-mercaptoethanol per well. RNA isolation and qPCR analysis of IFNα4 mRNA 
expression were carried out as described in 2.17. 
 
2.8.4. Stimulation of TLRs for immunoblot analysis of PTP1B expression 
levels 
1.5 x 106 primary BMDM were seeded per well of a 6 well plate. The next day, cells 
were stimulated with 100 ng/ml LPS, 1 µM of CpG 1826, or 1 µM of R848. BMDM were 
incubated with TLR agonists for 6, 12, or 24 h, lysed in 200 µl RIPA 100 lysis buffer, 
and protein levels of PTP1B were determined by immunoblotting as described in 2.7 
using an antibody against endogenous PTP1B. 
 
2.9. Viral infections with MCMV-GFP and MHV-68 
2.9.1. Viruses 
MCMV-GFP199 was purified as described by Scheibe et al.200. MHV-68 WUMS strain 
was purchased from ATCC (VR-1465) and purified from infected M2-10B4 cells as 
described by Bussey et al.201. Purified viruses were titered using the median tissue 
culture infective dose (TCID50) method on M2-10B4 cells. 
 
2.9.1. Viral infections for cytokine measurements by ELISA 
Primary BMDM, FL-DC, or total BM cells were seeded in 96 well plates as described in 
2.8.2. For viral infections of the cells with MCMV-GFP or MHV-68 at indicated MOIs, 
respective amounts of virus were added into the medium. Cells were incubated with 
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viruses for 16 to 22 h as indicated in figure legends. Supernatants were frozen at -20°C 
for analysis of proinflammatory cytokine and type I IFN responses by ELISA as 
described in 2.10. 
 
2.9.2. MCMV infection for qPCR analysis 
To analyze the type I IFN response in macrophages, primary BMDM were infected with 
MCMV-GFP at an MOI of 0.5. 1.5 x 106 primary BMDM per well were seeded in a 
6 well plate. Prior to infection, the medium was removed from adherent cells. 
MCMV-GFP was diluted in 2.5 ml of medium per well. Spin infection was carried out for 
30 min at 2000 rpm and 4°C followed by incubation at 37°C for 2 or 6 h. Cells were 
lysed in 350 µl of RLT buffer with 2-mercaptoethanol per well. RNA isolation and qPCR 
analysis of IFNα4 mRNA expression were carried out as described in 2.17. 
 
2.10. ELISA 
2.10.1. TNF ELISA 
To quantify amounts of secreted TNF in cell culture supernatants or mouse serum, 
96 well plates (NUNC, Maxisorp) were coated with 50 µl of Purified Hamster Anti-
Mouse/Rat TNF antibody (BD Biosciences, #557516), diluted to a concentration of 
2 µg/ml in PBS, overnight at 4°C. Wells were blocked with 200 µl of 2% BSA in PBS for 
1 h at 37°C, followed by incubation with 50 µl of diluted samples or standard for 1 h at 
37°C. Recombinant Mouse TNF (BD Bioscience, #554589) with concentrations ranging 
from 31.25 to 2000 pg/ml was used as a standard. For detection of TNF, plates were 
incubated with 50 µl of Biotin Rabbit Anti-Mouse/Rat TNF antibody (BD Biosciences, 
#557432), diluted to a concentration of 1 µg/ml, for 45 min at RT followed by incubation 
with 50 µl of HRP-Conjugated Streptavidin antibody (Thermo Scientific, #N100), diluted 
1:4000 (0.31 µg/ml), for 30 min at RT. Antibodies, samples, and standard were diluted 
in 2% BSA in PBS. After each incubation step, plates were washed 3-4 times with 
200 µl PBS/0.01% Triton X-100 per well. To develop the assay, 50 µl of TMB substrate 
solution (Sigma-Aldrich) were added to each well and incubated for 5 to 15 min at RT 
followed by addition of 50 µl stop solution (1 N H2SO4) per well. Absorption was 
measured at a wavelength of 450 nm. 
 
2.10.2. IFNα ELISA 
To measure amounts of IFNα in cell culture supernatants from FL-DC or total bone 
marrow cells, 96 well plates (NUNC, Maxisorp) were coated with 50 µl of Rat Anti-
Mouse Interferon Alpha antibody (PBL Assay Science, #22100-1), diluted to a 
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concentration of 2.5 µg/ml in PBS, overnight at 4°C. For blocking, 200 µl of 1% BSA in 
PBS were used per well and incubation was carried out for 2 h at RT followed by 
incubation with of 50 µl of standard or diluted samples per well overnight at 4°C. Mouse 
Interferon Alpha A (PBL Assay Science, #12100-1) with concentrations ranging from 
78.12 to 5000 pg/ml was used as a standard. For detection of IFNα, plates were 
incubated with 50 µl of Rabbit Anti-Mouse Interferon Alpha antibody (PBL Assay 
Science, #32100-1), diluted to a final concentration of 16 ng/ml. Incubation was carried 
out for 4 h at RT. After detection, plates were incubated with 50 µl of Peroxidase-
conjugated AffiniPure F(ab’)2 Fragment Donkey Anti-Rabbit IgG (H+L) (Jackson 
Immunoresearch, #711-036-152), diluted to a final concentration of 80 ng/ml per well, 
for 1.5 h at RT. Antibodies, samples, and standard were diluted in 1% BSA in PBS. 
After each incubation step, plates were washed 3-4 times with 200 µl PBS/0.05% 
Tween 20 per well. The assay was developed as described in 2.10.1. For detection of 
IFNα in cell culture supernatants from BMDM or mouse serum, the more sensitive 
ELISA Kit from PBL Assay Science was used as described in 2.10.4. 
 
2.10.3. IL-6 and IL-12p40 ELISA 
For detection of IL-6 and IL-12p40 in cell culture supernatants or mouse serum, the BD 
OptEIATM Mouse IL-6 and Mouse IL-12(p40) ELISA Sets (BD Biosciences, #555240 
and #555165) were used according to the manufacturer’s instructions with the 
modification that instead of using 100 µl, plates were incubated with 50 µl of diluted 
antibodies, standard, and diluted samples. 
 
2.10.4. IFNα and IFNβ ELISA 
To detect type I IFN secreted by BMDM upon viral infection or in mouse serum, the 
VeriKine Mouse Interferon Alpha and Mouse Interferon Beta ELISA Kits (PBL Assay 
Science, #42120-2 and #42400-2) were used according to the manufacturer’s 
specifications. 
 
2.11. Microarray 
Primary BMDM derived from wild type and UNC93B-/- mice were seeded in 12 well 
plates and infected with MCMV-GFP at an MOI of 0.5 the following day. Spin infection 
was carried out for 30 min at 2000 rpm and 4°C followed by incubation at 37°C for 2 or 
6 h. Uninfected cells and cells 2 or 6 h post infection were lysed in RLT buffer and total 
RNA was prepared using the RNeasy Mini Kit (Qiagen). RNA quality was assessed 
with an Agilent 2100 Bioanalyzer using the Agilent RNA 6000 Pico Kit. RNA integrity 
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numbers (RIN) of all samples used for microarray analysis were 10. Gene expression 
analysis was performed using the Whole Mouse Genome Microarray, 4x44k (Agilent). 
RNA quality control, microarray, and data analysis were performed by the HZI 
Microarray Core unit. 
 
2.12. Large scale immunoprecipitation and mass spectrometry 
analysis of UNC93B and Clptm 
For large scale immunoprecipitation and mass spectrometry analysis using UNC93B as 
a bait, RAW 264.7 macrophages stably expressing wild type UNC93B-Flag-TEV-HA or 
mutant UNC93B-myc-TEV-HA H412R were lysed and subjected to an anti-HA 
immunoprecipitation. Proteins were released by digestion with TEV protease, 
separated by liquid chromatography, and analyzed by mass spectrometry (LC-MS/MS) 
as described by Brinkmann et al.54. 
Large scale immunoprecipitation and mass spectrometry analysis using Clptm as a bait 
was carried out with RAW 264.7 macrophages stably expressing HA-Clptm as 
described for UNC93B except for TEV protease digest. UNC93B and Clptm large scale 
immunoprecipitation experiments were performed by M. Brinkmann prior to this study. 
 
2.13. PNGase F assay 
RAW 264.7 macrophages stably expressing Clptm-GFP were lysed in 1% NP-40 lysis 
buffer for 30 min on ice followed by centrifugation for 10 min at 14,000 g and 4°C to 
remove cell debris. For digestion with PNGase F (New Englang Biolabs), Denaturing 
Buffer was added to 50 µl of cell lysates and samples were incubated for 1 h at 37°C. 
According to the manufacturer`s instructions, G7 Reaction Buffer, 10% NP-40 and 
0.5 µl PNGase F were added and incubated with the lysate for another hour at 37°C. 
Samples were analyzed by immunoblotting as described in 2.7. 
 
2.14. Co-immunoprecipitation 
2.14.1. Co-immunoprecipitations with macrophages 
One confluent 10 cm dish of cells was lysed in 1 ml 1% digitonin lysis buffer or 0.5% 
NP-40 lysis buffer supplemented with protease inhibitors (Complete EDTA-free, Roche) 
as indicated in figure legends for at least 1 h or 30 min at 4°C, respectively. Lysates 
were centrifuged for 10 min at 14,000 g and 4°C to remove cell debris. An aliquot was 
taken as input lysate and put aside for immunoblot analysis. 0.5-1 ml of cell lysate were 
used per immunoprecipitation. 
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Lysates were mixed with antibodies for immunoprecipitation as indicated (Table 9) and 
incubated for at least 3 h or overnight at 4°C. 20-30 µl of Protein A beads, equilibrated 
in lysis buffer, were added per IP and incubation was carried out for 1.5 h or overnight 
at 4°C. Lysates and beads were centrifuged for 2 min at 2500 rpm and 4°C and 
washed 3-5 times with 0.5-1 ml of 0.2% digitonin wash buffer or 0.5% NP-40 lysis 
buffer. SDS loading buffer was added to beads and input lysates followed by 0.5 to 1 h 
shaking at 37°C. Input lysates and immunoprecipitations were subjected to SDS-PAGE 
and analyzed by immunoblotting as described in 2.7. 
For anti-HA immunoprecipitations, 50 µl of Anti-HA Affinity Matrix (Roche, 13053900), 
equilibrated in lysis buffer, were added to cell lysates and incubated for 1 to 1.5 h at 
4°C (Figure 22D-F and Figure 23C). To precipitate GFP fusion proteins, the GFP-Trap 
(Chromotek) was used as an alternative to immunoprecipitations with antibodies 
(Figure 23B). The GFP-Trap is a GFP-binding protein coupled to agarose beads. 
Control beads (Chromotek) were used for control precipitations. 50 µl of GFP-Trap or 
control beads, equilibrated in lysis buffer, were added per sample and incubated for 
1.5 h at 4°C. Washing and preparation of samples was carried out as described above. 
 
2.14.2. Co-immunoprecipitations with HEK 293T cells 
HEK 293T cells were seeded in 6 well plates. The following day, cells were transfected 
with 1.25 µg of each of the indicated expression constructs in pMSCV (total amount of 
DNA: 2.5 µg) and 10 µl of Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. 48 h post transfection, cells were lysed in 500 µl of 0.5% NP-40 
lysis buffer per well. Sample preparation an co-immunoprecipitations were performed 
as described in 2.14.1 
 
Table 9: List of antibodies used for co-immunoprecipitations. 
Antibody Origin Dilution Experiment 
Anti-uncC, 6055 
4th bleed 
M. Brinkmann 1:150-1:200 Figure 19B, 
Figure 23A 
Anti-ClptmC, 6804 
3rd bleed 
M. Brinkmann 1:150-1:200 Figure 19A, 
Figure 23A 
Anti-TLR7 Imgenex (IMG-5632) 1:150 Figure 23A 
Anti-ClptmC, 6804 
prebleed (serum control) 
M. Brinkmann 1:150-1:500 Figure 19A+B, 
Figure 21B, 
Figure 23A 
Anti-GFP  Abcam (ab290) 1:500 Figure 21B, 
Figure 22A-C 
Anti-GFP (B-2) Santa Cruz (sc-9996) 1:50 Figure 42A 
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2.15. shRNA knockdown of UNC93B and Clptm in RAW 264.7 
macrophages 
Protein expression of UNC93B and Clptm in RAW 264.7 macrophages was knocked 
down using a miR30-based shRNA approach202. miR30 is a naturally occurring 
microRNA and is commonly used as pri-miRNA backbone in which the coding region of 
the mature miR30 miRNA is replaced with sequences encoding shRNAs targeting the 
gene of interest. 97bp oligonucleotides containing the 5`flanking stem sequence of 
miR30, the sequence of the UNC93B or Clptm target site (sense orientation), the 
miR30 loop sequence, the sequence of the UNC93B or Clptm target site (antisense 
orientation), and the 3`flanking stem sequence of miR30 were designed (T. Wüstefeld, 
HZI) and synthesized by Eurofins MWG Operon (Table 10). Three and two shRNAs 
targeting UNC93B and Clptm were used, respectively. shRNAs targeting the human 
retinoblastoma protein (sh-control1) or Renilla Luciferase (sh-control2) were used as 
controls (obtained from T. Wüstefeld/L. Zender, HZI). 
 
Table 10: Sequences of miR30 based shRNAs. The sequences of the target sites in 
UNC93B, Clptm, and controls are shown in red (sense orientation) and blue (antisense 
orientation). The miR30 loop sequence is shown in green. 5`and 3` flanking miR30 sequences 
are underlined. 
shRNA Sequence, 5`3` (5`miR30-sense-loop-antisense-3`miR30) 
sh-control1 TGCTGTTGACAGTGAGCGCGCAGTTCGATATCTACTGAAATAGTGAAGCC
ACAGATGTATTTCAGTAGATATCGAACTGCTTGCCTACTGCCTCGGA 
sh-control2 TGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCTATAGTGAAGCCA
CAGATGTATAGATAAGCATTATAATTCCTATGCCTACTGCCTCGGA 
sh-UNC1 TGCTGTTGACAGTGAGCGCCACCAGGATGTCCCAGAAGTATAGTGAAGC
CACAGATGTATACTTCTGGGACATCCTGGTGATGCCTACTGCCTCGGA 
sh-UNC2 TGCTGTTGACAGTGAGCGACAGGATGTCCCAGAAGTACTATAGTGAAGCC
ACAGATGTATAGTACTTCTGGGACATCCTGGTGCCTACTGCCTCGGA 
sh-UNC3 TGCTGTTGACAGTGAGCGAAGGCAGGACTTCATCTTCACCTAGTGAAGCC
ACAGATGTAGGTGAAGATGAAGTCCTGCCTCTGCCTACTGCCTCGGA 
sh-Clptm1 TGCTGTTGACAGTGAGCGACCGGATGATCAACAAATACAATAGTGAAGCC
ACAGATGTATTGTATTTGTTGATCATCCGGGTGCCTACTGCCTCGGA 
sh-Clptm2 TGCTGTTGACAGTGAGCGCCACCACAGCTCTTCATCAACTTAGTGAAGCC
ACAGATGTAAGTTGATGAAGAGCTGTGGTGTTGCCTACTGCCTCGGA 
 
The miR30 backbone was excised from the retroviral vector MLP carrying the 
extending miR30 flanking sequence (obtained from T. Wüstefeld/L. Zender, HZI) and 
ligated into the retroviral vector pMSCVpuro with BglII and AgeI. The ordered shRNA 
oligonucleotides targeting UNC93B or Clptm were amplified by PCR using primers 
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adding XhoI and EcoRI restriction sites to the 5` and 3`flanking miR30 precursor 
sequences. The PCR products were digested with XhoI and EcoRI and ligated into 
XhoI and EcoRI digested pMSCVpuro containing the miR30 backbone. shRNA 
sequences were verified by sequencing. 
Retroviral particles were produced with pMSCVpuro retroviral vectors containing 
control shRNAs or shRNAs targeting UNC93B or Clptm as described in 2.4.1. RAW 
264.7 macrophage cell lines stably expressing respective shRNAs were generated by 
retroviral transduction and put under selection with Puromycin as described in 2.4.2. 
Six days after retroviral transduction, cells were seeded and stimulated with TLR 
agonists as described in 2.8.2. 
 
2.16. Live cell imaging 
Immortalized BMDM expressing GFP-Clptm and cherry-Trex1, TLR9-GFP and Ruby-
PTP1B, or primary BMDM derived from TLR9-GFP/WT or TLR9-GFP/PTP1B-/- mice 
were seeded in 8 well coverglass cell culture chambers (Sarstedt). Cells were 
maintained in phenol-red free DMEM (high glucose, 25 mM HEPES) supplemented 
with 10% FCS, 2 mM glutamine, and 1% P/S. Cells were incubated with 50 nM 
lysotracker red (Life Technologies) or stimulated with 1 µM CpG 1826 or CpG 1826-
Alexa647 (Eurofins MWG Operon, 2.8.1) for the indicated time periods. Medium 
containing CpG 1826-Alexa647 was replaced prior to imaging in order to reduce 
background fluorescence. Images were taken using a Nikon ECLIPSE Ti-E inverted 
microscope equipped with a spinning disc confocal device (UltraView VOX, Perkin 
Elmer), solid state diode lasers (Perkin Elmer), an OrcaR2 CCD camera (Hamamatsu), 
and a Nikon 60x 1.4 N.A. planapochromat objective. During imaging, cells were 
maintained in a climate chamber (EMBLEM, Germany) at 37°C and 5% CO2. Image 
processing was performed using Volocity and Photoshop. 
 
2.17. Real-time quantitative PCR 
2.17.1. RNA isolation 
Total RNA was purified from RLT lysates of primary BMDM (2.8.3) or MEF (2.20) using 
the RNeasy Mini Kit (Qiagen) according to the manufacturer`s instructions. RNA was 
quantified using a NanoDrop (Thermo Scientific). Ratios of the readings at 260 nm and 
280 nm (A260/A280) were between 1.9 and 2.1 indicating a good RNA quality. 
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2.17.2. qPCR analysis of IFNα4, PTP1B, and TLR9 mRNA expression 
To analyze mRNA expression of IFNα4, PTP1B, and TLR9, real-time quantitative PCR 
(qPCR) analysis was performed with RNA isolated from primary BMDM or MEF 
(2.17.1). The Universal ProbeLibrary (UPL, Roche) was used for qPCR assays and 
primers were designed using the UPL Probe Finder software (Version 2.50, Roche) 
(Table 11). The murine ribosomal protein L8 (Rpl8) was used as a housekeeping gene. 
Primers were synthesized by Eurofins MWG Operon. 
 
qPCR assays were performed using the EXPRESS One-Step SuperScript qRT-PCR 
Kit (Life Technologies). For MEF, 100 ng of RNA were used per reaction, for primary 
BMDM, 100 to 200 ng of RNA were used per reaction. Reactions were set up in 
duplicates in 96 multiwell plates for qPCR (Roche) as follows: 
 
EXPRESS SuperScript qPCR SuperMix Universal (2x)  10 µl 
EXPRESS SuperScript Mix for One-Step qPCR      2 µl 
Forward primer (20 µM)     0.4 µl 
Reverse primer (20 µM)     0.4 µl 
UPL probe (10 µM)      0.4 µl 
RNA          100-200 ng 
H2O          up to 20 µl 
 
Plates were sealed with sealing foil and centrifuged for 2 min at 2000 rpm. qPCR 
analysis was carried out using the LightCycler 96 (Roche) with the following program 
setup: 
 
cDNA synthesis  15 min  60°C 
Denauration     5 min  95°C 
Amplification      10 s  95°C 
       30 s  60°C        65 cycles 
         1 s   72°C 
Cooling      30 s  40°C 
 
Ct values were obtained using the LightCycler 96 software (Roche). Relative 
quantification was performed according to the 2-∆∆Ct method using Rpl8 as reference 
gene203: ∆∆Ct = (Ct,gene of interest – Ct,reference)treated – (Ct,gene of interest – Ct,reference)untreated, relative 
mRNA induction of gene of interest = 2-∆∆Ct. 
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Table 11: List of primers and probes used for qPCR analysis. 
Gene of interest Forward primer Reverse primer UPL probe  
Rpl8 caacagagccgttgttggt cagcctttaagataggcttgtca #5 
IFNα4 tcaagccatccttgtgctaa gtcttttgatgtgaagaggttcaa #3 
PTP1B  acctgtggggatgaagacag cttcagtgtctggactcatgct #13 
TLR9 gaatcctccatctcccaacat ccagagtctcagccagcact #79 
 
2.18. Flow cytometry 
2.18.1. Determination of proportions of cDC, pDC, B cells, and T cells in 
FL-DC cultures or lymphoid organs 
To determine proportions of cDC and pDC in FL-DC cultures, FL-DC derived from wild 
type and PTP1B-/- mice were analyzed by flow cytometry. 1 x 106 cells were centrifuged 
for 6 min at 1200 rpm in a 5 ml FACS tube and washed once with 1 ml of PBS. 
Supernatants were poured off and cells were resuspended in 100 µl of PBS containing 
premixed antibodies in specific dilutions (Table 12). Cells were incubated with 
antibodies for 15 min at 4°C followed by addition of 1 ml of PBS per sample. Cells were 
centrifuged and washed with PBS once more. Supernatants were poured off and cells 
were resuspended in 50 µl of PBS. 50 µl of LIVE/DEAD Fixable Aqua Dead Cell Stain 
(Life Technologies) prediluted in PBS were added to the cells. The final dilution of 
LIVE/DEAD Fixable Aqua Dead Cell Stain was 1:1000. Cells were incubated with 
LIVE/DEAD Fixable Aqua Dead Cell Stain for 30 min at 4°C followed by addition of 
1 ml of PBS. Cells were centrifuged for 6 min at 1200 rpm and again washed with 1 ml 
of PBS. Supernatants were poured off, cells were resuspended in PBS and data was 
acquired with a LSR II flow cytometer and FACSDiva software (BD Biosciences). FCS 
files were exported and data were analyzed with FlowJo software (Version 10, Tree 
Star, Inc.). 
 
For the analysis of proportions of B cells, T cells, cDC, and pDC in lymphoid organs, 
bone marrow, spleen and inguinal lymph nodes were prepared from wild type and 
PTP1B-/- mice. For bone marrow preparation femur and tibia were removed from the 
mouse and the bone marrow was extruded from the opened bone with RPMI using a 
syringe and a 0.5 x 16mm, 25 G x 5/8’’ needle. To prepare single cell suspensions for 
flow cytometry analysis, bone marrow, spleens, and inguinal lymph nodes were 
collected in 4 ml RPMI and passed through a 100 µm cell strainer. Cells were 
centrifuged for 5 min at 1500 rpm at RT. Bone marrow and splenic cells were 
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resuspended in 0.5 ml or 1 ml of Red Blood Cell Lysing Buffer (Sigma-Aldrich) for bone 
marrow from one mouse or per spleen, respectively. Lysis of red blood cells was 
carried out for 1-2 min at RT. 15 or 30 ml of medium were added, respectively, and 
cells were again centrifuged for 5 min at 1500 rpm. Total bone marrow cells, 
splenocytes and cells from inguinal lymph nodes were resuspended in medium and 
counted with Tuerk`s Solution. 
Preparation of cells for analysis by flow cytometry was carried out as described for 
FL-DC with an additional blocking step to block Fc-receptors prior to antibody staining. 
Cells were resuspended in 100 µl of PBS (after they had been washed with PBS) and 
1 µg of Mouse BD Fc Block (BD Biosciences) was added. Cells were incubated with 
Mouse BD Fc Block for 10 min at 4°C followed by addition of 1 ml of PBS and 
centrifugation for 6 min at 1200 rpm. Supernatant was poured off and cells were 
stained with two different sets of antibodies as described above (Table 12).  
 
Table 12: List of antibodies used for flow cytometry analysis. 
Antibody Source Order number Dilution 
cDC/pDC FL-DC (Figure 33) 
Anti-Human/Mouse B220 PerCp-Cy5.5 eBioscience 45-0452 1:500 
Anti-Mouse CD11b PE eBioscience 12-0112 1:4000 
Anti-Mouse CD11c APC eBioscience 17-0114 1:400 
Anti-Mouse Siglec-H FITC eBioscience 11-0333 1:1000 
B and T cells lymphoid organs (Figure 41) 
Anti-Mouse CD3 PE BD Biosciences 555275 1:200 
Anti-Mouse CD4 FITC eBioscience 11-0042 1:500 
Anti-Mouse CD19 APC BD Biosciences 550992 1:200 
Anti-Mouse CD8α PE-Cy7 BioLegend 100722 1:1000 
cDC/pDC lymphoid organs (Figure 41) 
Anti-Human/Mouse B220 PerCp-Cy5.5 eBioscience 45-0452 1:500 
Anti-Mouse CD11b PE eBioscience 12-0112 1:4000 
Anti-Mouse CD11c PE-Cy7 BioLegend 117318 1:1000 
Anti-mPDCA-1 FITC Miltenyi Biotec 130-091-961 1:10 
Anti-Mouse Siglec-H APC (eFluor 660) eBioscience 51-0333 1:1000 
 
2.18.2. Determination of proportions of dead and apoptotic FL-DC after 
treatment with inhibitors 
In order to analyze amounts of dead and apoptotic cells in wild type FL-DC after 
treatment of the cells with PTP Inhibitor XXII or z-FA-fmk, cells were stained with 
2. Materials and methods 46 
Annexin V, which binds to phosphatidylserine exposed on the surface of apoptotic 
cells, and 7-Aminoactinomycin (7-AAD), a fluorescent intercalator which undergoes a 
spectral shift upon association with DNA. 1 x 106 unstimulated wild type FL-DC treated 
with PTP Inhibitor XXII, z-FA-fmk or DMSO were collected in a 5 ml FACS tube. 1 ml of 
PBS was added. Cells were centrifuged for 5 min at 1500 rpm and washed with 1 ml of 
PBS. Supernatants were poured off and cells were resuspended in 250 µl of Annexin V 
binding buffer. 5 µl of Annexin V FITC (BD Biosciences, 556419) and 2.5 µl of 7-AAD 
(Sigma, 0.1 mg/ml) were added per sample. Incubation was carried out for 15 min at 
RT. 250 µl of Annexin V binding buffer were added and cells were directly analyzed by 
flow cytometry. 
 
2.19. Treatment of FL-DC with PTP1B Inhibitors 
To study the role of the enzymatic function of PTP1B, FL-DC derived from wild type 
and PTP1B-/- mice were treated with specific PTP1B inhibitors, stimulated with TLR 
agonists, and amounts of IFNα in supernatants were determined by ELISA. To verify 
that IFNα responses upon stimulation with TLR agonists were dependent on TLRs, 
cells were treated with z-FA-fmk which inhibits processing and signaling of TLR7 and 
TLR971. PTP1B inhibitors MSI-1436 (Ohr Pharma-ceutical) and PTP Inhibitor XXII 
(Merck, 539741) and the cysteine protease inhibitor z-FA-fmk (Sigma-Aldrich, C1480) 
were reconstituted in DMSO. 
5 x 105 FL-DC in a volume of 50 µl per well were seeded in 96 well plates (round 
bottom). 50 µl of medium containing indicated concentrations of PTP Inhibitor XXII, 
z-FA-fmk or respective amounts of DMSO were added and cells were incubated for 4 h 
at 37°C. After pretreatment of the cells with inhibitors, they were stimulated with CpG 
2336 and Poly(U). CpG 2336 was directly diluted into 50 µl medium and added to the 
cells. For stimulation with Poly(U), cells were transfected with 150 ng of RNA and 1.2 µl 
of DOTAP (Roche) diluted in HBS according to the manufacturer’s instructions. The 
transfection mix was diluted in 50 µl medium and added to the cells (final RNA 
concentration: 1 µg/ml). Cells were stimulated for 6 h at 37°C. After stimulation, 
supernatants were stored at -20°C for the analysis of IFNα in supernatants by ELISA 
as described in 2.10.2. 
 
2.20. Preparation and retroviral transduction of MEF 
Mouse embryonic fibroblasts (MEF) were cultivated in DMEM (high glucose) 
supplemented with 15% FCS, 2 mM glutamine, 1% P/S, 1% NEAA, and 50 µM 
2-mercaptoethanol. For preparation of wild type and PTP1B-/- MEF, breeding pairs 
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were set up for wild type and PTP1B-/- mice. Every day, female mice were checked for 
vaginal plug to verify that mating had occurred. 13.5 days after the plug check had 
been positive (day 0.5), the pregnant female was euthanized. Both uterine horns 
containing the embryos were removed and washed twice in 70% ethanol and twice in 
PBS for 1 min, respectively. Single embryos were separated by opening the uterine 
wall with scissors. Using two pairs of forceps, the amniotic sac and placenta were 
removed from the embryo. Next, liver, heart, and head were removed from the embryo. 
Embryos were placed in a new 15 cm dish and 100 µl of 0.15% trypsin were added 
onto the embryo. Each embryo was thoroughly minced with two scalpels and incubated 
for 5 to 10 min at 37°C. Cells were carefully resuspended in 5 ml of medium and 
another 20 ml of medium were added. Cells were cultivated at 37°C and 7.5% CO2 
(day 0). On day 3, 15 ml of medium were removed and replaced by fresh medium. 
When cells were confluent, they were frozen or cultured for several passages until 
growth stopped. 
For retroviral transduction, MEF were seeded in 6 well plates and transduced with 
empty vector (pMSCVpuro), wild type HA-PTP1B, or HA-PTP1B D181A in pMSCVpuro 
as described for macrophage cell lines in 2.4.2. Antibiotic selection with 5 µg/ml 
Puromycin was started one day after transduction. 3 days after transduction, 2 x 105 
cells per well were seeded in 12 well plates. The next day, MEF were lysed in 350 µl of 
RLT buffer with 2-mercaptoethanol per well for qPCR analysis or in 200 µl of RIPA 100 
lysis buffer for immunoblot analysis. RNA isolation and qPCR analysis of PTP1B and 
TLR9 expression were carried out as described in 2.17. Immunoblot analysis of PTP1B 
was carried out as described in 2.7. 
 
2.21. In vivo experiments 
To measure type I IFN and proinflammatory cytokine responses upon stimulation of 
TLR9 in vivo, wild type, PTP1B-/-, and TLR9-/- mice were injected with CpG DNA and 
serum levels of IFNα, IL-12p40, TNF, and IL-6 were determined by ELISA. 
For induction of IFNα and IL-12p40 responses, mice were challenged with CpG A. Wild 
type, PTP1B-/-, and TLR9-/- mice were intravenously injected with a total volume of 
200 µl containing 10 µg CpG 2216 or GpC 2216 control (2.8.1) complexed with 30 µl 
DOTAP (Roche) in PBS. 6 h post injection, mice were sacrificed and total blood was 
collected from the heart. 
To measure TNF and IL-6 responses, mice were challenged with CpG B. Wild type, 
PTP1B-/-, and TLR9-/- mice were intraperitoneally injected with 60 µg of CpG 1826 in a 
total volume of 200 µl in PBS. 2 h post injection, mice were sacrificed and total blood 
was collected from the heart. 
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For serum preparation, blood was kept at RT for at least 1 h, centrifuged for 8 min at 
5000 rpm, and supernatants were collected. Serum levels of IFNα and proinflammatory 
cytokines were determined by ELISA as described in 2.10. 
 
2.22. Cell sorting 
2.22.1. Magnetic-activated cell sorting (MACS) 
pDC were sorted from FL-DC derived from wild type and PTP1B-/- mice or splenocytes 
by magnetic-activated cell sorting (MACS) using the Plasmacytoid Dendritic Cell 
Isolation Kit II, LS columns, and MidiMACS or QuadroMACS separator (Miltenyi 
Biotec). Using the Plasmacytoid Dendritic Cell Isolation Kit II, murine pDC are isolated 
based on negative selection. Non-pDC are magnetically labeled with antibodies 
targeting different markers which are not expressed by murine pDC. Magnetically 
labeled cells are retained on the MACS column in the magnetic field of the MACS 
separator, whereas unlabeled pDC pass through the column. 
For the preparation of splenocytes, spleens were isolated from wild type and PTP1B-/- 
mice, passed through a 70 µm cell strainer and erythrocytes were lysed as described in 
2.18.1. Isolation of pDC from FL-DC cultures or splenocytes with the Plasmacytoid 
Dendritic Cell Isolation Kit II was performed according to the manufacturer`s 
instructions. Up to 1 x 108 cells were used per column. After MACS, the enrichment of 
pDC sorted from FL-DC cultures was verified by flow cytometry analysis of proportions 
of pDC and cDC according to 2.18.1. Upon MACS, the percentage of pDC was 
enriched from 30-40% to 80-90% as verified by flow cytometry analysis. 
Wild type and PTP1B-/- pDC were stimulated with Poly(U), CpG 2336, or infected with 
MCMV as described in 2.8.2 and 2.9.1. Levels of IFNα, TNF, and IL-6 were determined 
by ELISA as described in 2.10. 
 
2.22.2. Fluorescence-activated cell sorting (FACS) 
Siglec-H-positive pDC were sorted from FL-DC derived from wild type and PTP1B-/- 
mice by fluorescence-activated cell sorting (FACS) in order to measure type I IFN 
responses upon TLR stimulation by ELISA. To analyze processing of TLR9-GFP in 
dendritic cells, cDC and pDC were sorted from FL-DC derived from TLR9-GFP/WT, 
TLR9-GFP/UNC93B-/-, and TLR9-GFP/PTP1B-/- mice using specific antibodies against 
CD11b and B220. 
4-6 x 107 FL-DC were centrifuged for 6 min at 1200 rpm in 15 ml tubes. Supernatants 
were poured off and cells were washed with 15 ml of PBS. Cells were resuspended in 
4 ml of PBS containing diluted antibodies (Table 13) and incubated for 15 min at 4°C 
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followed by addition of 10 ml PBS. Cells were centrifuged for 6 min at 1200 rpm and 
washed with 15 ml PBS. Supernatants were poured off and cells were resuspended in 
1 ml of FL-DC medium. Sorting of Siglec-H+ pDC or B220-CD11b+ cDC and 
B220+CD11b- pDC was performed by the HZI Flow Cytometry and Cell Sorting unit. 
 
FACS-sorted pDC from wild type and PTP1B-/- mice were stimulated with Poly(U), 
CpG 2336, or infected with MCMV as described in 2.8.2 and 2.9.1. Levels of IFNα, 
TNF, and IL-6 were measured by ELISA as described in 2.10. 
Sorted cDC and pDC derived from TLR9-GFP/WT, TLR9-GFP/UNC93B-/-, and 
TLR9-GFP/PTP1B-/- mice were used to analyze proteolytic processing of TLR9-GFP as 
described in 2.23. 
 
Table 13: List of antibodies used for cell sorting. 
Antibody Source Order number Dilution 
Sorting of pDC from FL-DC (3.4.7) 
Anti-Mouse Siglec-H FITC eBioscience 11-0333 1:1000 
Sorting of cDC/pDC from FL-DC (Figure 43) 
Anti-Mouse CD45R/B220 APC-Cy7 BD Biosciences 561102 1:150 
Anti-Mouse CD11b PE eBioscience 12-0112 1:1000 
 
2.23. Analysis of TLR9-GFP proteolytic processing 
In order to find out whether proteolytic endosomal processing of TLR9 in macrophages, 
cDC, and pDC is intact in the absence of PTP1B, BMDM derived from TLR9-GFP/WT 
and TLR9-GFP/PTP1B-/- mice or cDC and pDC sorted from FL-DC derived from 
TLR9-GFP/WT, TLR9-GFP/UNC93B-/-, and TLR9-GFP/PTP1B-/- mice were analyzed 
by anti-GFP immunoblotting. 
One confluent 10 cm dish of BMDM derived from TLR9-GFP/WT or TLR9-GFP/ 
PTP1B-/- mice was treated with 10 µM z-FA-fmk (Sigma-Aldrich, C1480) for 15 h and 
lysed in 1 ml RIPA 100 lysis buffer. 4.5 x 106 - 8.5 x 106 cDC and pDC sorted from 
FL-DC derived from TLR9-GFP/WT, TLR9-GFP/UNC93B-/-, and TLR9-GFP/PTP1B-/- 
mice by FACS (2.22.2) were lysed in 80 µl RIPA 100 lysis buffer. Lysates of BMDM 
and sorted cDC and pDC were analyzed by immunoblotting as described in 2.7. 
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3. Results 
3.1. Characterization of innate immune signaling by UNC93B 
knockout mice 
3.1.1. BMDM and FL-DC derived from UNC93B-/- mice do not express 
UNC93B 
Until today, 3d mice have been used to study the role of UNC93B for innate immunity. 
These mice have been generated using N-ethyl-N-nitrosourea (ENU) mutagenesis, 
which induces genomic point mutations. 3d mice fail to respond to stimulation of TLRs 
3, 7, and 9. The 3d phenotype was mapped to a single point mutation, H412R, in the 
Unc93b gene52. However, due to ENU mutagenesis, 3d mice carry additional 
mutations, which makes the characterization of 3d mice more difficult204. The fact that 
UNC93B H412R is still expressed and localizes to the ER in 3d mice further 
complicates the usage of these mice for studying UNC93B biology. Recently, UNC93B 
knockout (UNC93B-/-) mice were made publicly available. These mice have not been 
characterized yet. Studying UNC93B-/- mice may reveal additional functions of UNC93B 
mediated by regions of the protein which are not affected by the H412R mutation. 
 
3d mice were generated on the C57BL/6J (B6J) background, whereas UNC93B-/- mice 
were generated on the C57BL/6N (B6N) background. Both of these wild type strains 
initially had the same origin, but were separated over 60 years ago. To exclude the 
possibility that potential differences between UNC93B-/- and 3d mice arise from the 
different genetic backgrounds of these mouse lines, both wild type strains were 
included in the following studies.  
 
Prior to any functional experiments, the absence of UNC93B in primary bone marrow-
derived macrophages (BMDM) and Flt3 ligand-induced dendritic cells (FL-DC) derived 
from UNC93B-/- mice was verified by immunoblot analysis (Figure 8, A and B). 
Expression of UNC93B could not be detected in cells derived from UNC93B-/- mice 
using an antibody against the C-terminus of murine UNC93B. Cells derived from wild 
type, heterozygous UNC93B+/-, and TLR9-/- mice showed comparable levels of 
UNC93B. As shown in earlier studies, a more distinct band pattern was observed for 
UNC93B in cells derived from 3d mice54. This characteristic band pattern allows easy 
distinction between wild type and mutant (H412R) UNC93B. 
 
3. Results 51 
  
 
Figure 8: Immunoblot analysis of UNC93B protein expression in primary BMDM and 
FL-DC. Immunoblot analysis of UNC93B protein expression in primary BMDM (A) and FL-DC 
(B) generated from B6J or B6N wild type (WT), UNC93B-/-, UNC93B+/-, 3d, and TLR9-/- mice. 
UNC93B was detected using an antibody against UNC93B. Loading of equal amounts of protein 
was verified by anti-tubulin immunoblot. 
 
3.1.2. Knockout of UNC93B abrogates proinflammatory cytokine responses 
upon stimulation of intracellular TLRs in primary BMDM 
BMDM derived from 3d (UNC93B H412R) mice do not respond to stimulation of TLRs 
3, 7, and 9, whereas signaling of cell surface TLRs (e.g. TLR2 and TLR4) is intact. In 
order to analyze whether BMDM derived from UNC93B-/- mice exhibit the same 
phenotype, primary BMDM from B6J and B6N wild type, UNC93B-/-, UNC93B+/-, 3d, 
and TLR9-/- mice were stimulated with different concentrations of TLR agonists and the 
production of the proinflammatory cytokine TNF was measured by ELISA. Upon 
stimulation of cell surface TLRs 1/2, 2/6, and 4 with Pam3CSK4, FSL-1, and LPS, 
respectively, BMDM derived from UNC93B-/- mice produced comparable amounts of 
TNF as BMDM derived from wild type mice (Figure 9, A-C). However, BMDM derived 
from UNC93B-/- mice did not secrete detectable amounts of TNF upon stimulation of 
intracellular TLRs 3, 7, and 9 with Poly(I:C), R848, and CpG 1826, respectively 
(Figure 9, D-F). Compared to wild type BMDM, BMDM derived from heterozygous 
UNC93B+/- mice did not show an impaired production of TNF upon stimulation of cell 
surface or intracellular TLRs, indicating that one functional allele of UNC93B is 
sufficient to induce a proinflammatory cytokine response. TNF responses of BMDM 
derived from 3d and TLR9-/- mice were similar to those of wild type BMDM upon 
stimulation of cell surface TLRs. As expected, BMDM derived from 3d mice did not 
respond to stimulation of intracellular TLRs. The TNF response of BMDM derived from 
TLR9-/- mice upon stimulation of the intracellular TLRs 3 and 7 with Poly(I:C) and R848 
was comparable to wild type BMDM, but, as expected, like BMDM derived from 3d 
mice, BMDM derived from TLR9-/- mice did not respond to stimulation of TLR9 with 
CpG 1826. 
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Figure 9: BMDM derived from UNC93B
-/-
 mice do not secrete TNF in response to agonists 
of intracellular TLRs. Primary BMDM derived from B6J or B6N wild type (WT), UNC93B-/-, 
UNC93B+/-, 3d, and TLR9-/- mice were stimulated with indicated concentrations of TLR agonists 
for 16 h (A-F). TNF levels in supernatants were determined by ELISA. Results are shown as 
mean ± S.D. of 3 independent experiments. Statistical significance compared to respective wild 
type controls was determined by two-tailed, unpaired t test; *, p<0.05; **, p<0.01. 
 
In agreement with the results for TNF, the production of IL-6, another proinflammatory 
cytokine, by BMDM derived from UNC93B-/- mice was comparable to wild type BMDM 
upon stimulation of cell surface TLRs 1/2, 2/6, and 4 (Figure 10, A-C), but abrogated 
upon stimulation of intracellular TLRs 3, 7, and 9 (Figure 10, D-F). IL-6 responses of 
BMDM derived from heterozygous UNC93B+/- mice were comparable to those of wild 
type BMDM. BMDM derived from 3d and TLR9-/- mice produced comparable amounts 
of IL-6 to wild type BMDM upon stimulation of cell surface TLRs. As expected, BMDM 
derived from 3d mice did not respond to stimulation of intracellular TLRs 3, 7 and 9. 
BMDM derived from TLR9-/- mice did not respond to stimulation of TLR9 with 
CpG 1826, but upon stimulation of intracellular TLRs 3 and 7 with Poly(I:C) and R848, 
respectively, amounts of secreted IL-6 were comparable to wild type BMDM. 
Thus, BMDM derived from UNC93B-/- mice exhibit a phenotype resembling the 
previously described 3d phenotype, whereas BMDM derived from UNC93B+/- mice 
behave like wild type BMDM. 
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Figure 10: BMDM derived from UNC93B
-/-
 mice do not produce IL-6 in response to 
stimulation of intracellular TLRs. Primary BMDM derived from B6J or B6N wild type (WT), 
UNC93B-/-, UNC93B+/-, 3d, and TLR9-/- mice were stimulated with indicated concentrations of 
Pam3CSK4 (A, n=3), FSL-1 (B, n=2), LPS (C, n=1 for WT B6J, WT B6N, UNC93B
-/-, and 
UNC93B+/-, n=3 for 3d and TLR9-/-), Poly(I:C) (D, n=3), R848 (E, n=3), or CpG 1826 (F, n=3) for 
16 h. IL-6 levels in supernatants were determined by ELISA. Results are shown as mean ± S.D. 
of n (as specified) independent experiments. Statistical significance compared to respective wild 
type controls was determined by two-tailed, unpaired t test; *, p<0.05; **, p<0.01. 
 
3.1.3. Intracellular TLRs only play a minor role for recognition of the murine 
herpesviruses MCMV and MHV-68 in primary BMDM 
Intracellular TLRs are important for the recognition of herpesviruses. It has been shown 
that TLR9 is crucial for the type I interferon (IFN) response against the betaherpesvirus 
mouse cytomegalovirus (MCMV) in FL-DC and that TLR 3, 7, and 9 are involved in the 
recognition of MCMV in vivo92-94. A role for TLR9 has also been implicated in the 
recognition of the gammaherpesvirus murine herpesvirus 68 (MHV-68) in FL-DC96. To 
assess the role of UNC93B and intracellular TLRs for the recognition of the DNA 
viruses MCMV and MHV-68, primary BMDM derived from B6J and B6N wild type, 
UNC93B-/-, UNC93B+/-, 3d, and TLR9-/- mice were infected with MCMV and MHV-68 at 
different multiplicities of infection (MOIs) and proinflammatory cytokine responses were 
measured by ELISA. In contrast to stimulation of BMDM with synthetic TLR agonists, 
infection of BMDM with MCMV or MHV-68 leads to the production of amounts of type I 
IFN high enough to be detected by ELISA. Therefore, IFNα and IFNβ responses of 
primary BMDM infected with MCMV or MHV-68 were measured as well. 
Infection of primary BMDM with MCMV induced the release of the proinflammatory 
cytokines TNF and IL-6 (Figure 11, A and B). This cytokine response was independent 
of TLR9, as BMDM derived from TLR9-/- mice generated cytokine responses 
comparable to those of wild type BMDM. However, recognition of MCMV seemed to be 
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at least partially dependent on intracellular TLRs, since BMDM derived from 3d mice 
showed reduced TNF and IL-6 levels compared to wild type and TLR9-/- BMDM, 
although this effect was not statistically significant. Again, as observed with synthetic 
TLR agonists (Figure 9 and Figure 10), the phenotype of BMDM derived from 
UNC93B-/- mice resembled the phenotype of BMDM generated from 3d mice, whereas 
BMDM derived from UNC93B+/- mice behaved like wild type BMDM. 
In contrast to MCMV, levels of proinflammatory cytokines secreted upon infection of 
primary BMDM with MHV-68 were close to the detection limit, even with an MOI of 5 
(Figure 11, C and D). Many viruses have developed strategies to evade the immune 
system of their hosts. MHV-68 is able to downregulate proinflammatory cytokine 
responses upon infection of primary BMDM and thereby prevents the secretion of TNF 
and IL-6 (Bussey et al., submitted)201.  
 
                   
 
Figure 11: Primary BMDM elicit proinflammatory cytokine responses upon recognition of 
MCMV, but not MHV-68, which are partially dependent on intracellular TLRs. Primary 
BMDM from B6J or B6N wild type (WT), UNC93B-/-, UNC93B+/-, 3d, and TLR9-/- mice were 
infected with MCMV-GFP (A, B) or MHV-68 (C, D) at indicated MOIs for 16 h. Levels of TNF (A, 
C) and IL-6 (B, D) in supernatants were determined by ELISA. Results are shown as mean ± 
S.D. of 3 independent experiments. Statistical significance compared to respective wild type 
controls was determined by two-tailed, unpaired t test. 
 
Upon infection of primary BMDM with MCMV, IFNα and IFNβ were detected in cell 
supernatants by ELISA (Figure 12, A and B). In contrast to the proinflammatory 
cytokine responses, type I IFN responses triggered by infection with MCMV seemed to 
be completely independent of intracellular TLRs and UNC93B as BMDM derived from 
UNC93B-/-, UNC93B+/-, 3d, and TLR9-/- mice all produced amounts of IFNα and IFNβ 
comparable to the amounts produced by wild type BMDM. Thus, the type I IFN 
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response upon infection of primary BMDM with MCMV is most likely mediated by 
cytosolic PRRs. 
Similar to proinflammatory cytokine responses, infection of primary BMDM with 
MHV-68 did not lead to the production of measurable amounts of type I IFN (data not 
shown). 
 
                   
 
Figure 12: Type I IFN responses of primary BMDM upon MCMV infection are independent 
of intracellular TLRs. Primary BMDM from B6J or B6N wild type (WT), UNC93B-/-, UNC93B+/-, 
3d, and TLR9-/- mice were infected with MCMV-GFP at MOI 0.1 and 1 for 16 h. Levels of IFNα 
(A) and IFNβ (B) in supernatants were determined by ELISA. Results are shown as mean ± 
S.D. of 3 independent experiments. Statistical significance compared to respective wild type 
controls was determined by two-tailed, unpaired t test; *, p<0.05. 
 
In the in vitro studies performed so far there was no evidence for a difference between 
cells derived from the B6J and the B6N wild type mouse strain. Therefore, only one of 
the wild type strains was included in the following experiments. 
Protein levels of UNC93B in cells derived from heterozygous UNC93B+/- and wild type 
mice did not significantly differ (Figure 8) and BMDM derived from UNC93B+/- mice did 
not show any difference in the TLR responses compared to cells derived from wild type 
mice (Figure 9 - Figure 12). This suggests that BMDM derived from UNC93B+/- mice do 
not differ from wild type BMDM and that only a complete loss of UNC93B leads to a 
different phenotype. Therefore, cells derived from heterozygous UNC93B+/- mice were 
omitted in the following studies. 
 
3.1.4. MCMV infection leads to the induction of proinflammatory cytokines 
and type I IFN followed by induction of ISGs in BMDM 
In addition to the ELISA experiments, innate immune responses upon MCMV infection 
of BMDM derived from wild type and UNC93B-/- mice were also analyzed using the 
microarray technology. The microarray experiment allowed analysis of transcript 
regulation of about 40,000 genes simultaneously. In this study, we focused on the 
regulation of genes which are involved in the innate immune response, among them 
proinflammatory cytokines, type I IFN, and IFN-stimulated genes (ISGs). Expression of 
ISGs is induced by IFN and mediates numerous antiviral effector functions205. 
3. Results 56 
Microarray analysis also allowed to distinguish between different subtypes of IFNα 
(IFNα1, IFNα2, IFNα4, IFNα5, IFNα7, IFNα11, IFNα12, IFNα13, IFNα14, and IFNαA), 
whereas detection of IFNα by ELISA (Figure 12) did not differentiate between different 
IFNα subtypes. 
As expected, microarray analysis revealed that mRNA levels of proinflammatory 
cytokines and type I IFN were upregulated 2 h post infection (Figure 13). This in turn 
led to transcriptional activation of ISGs which were highly upregulated 6 h post 
infection. The expression of most proinflammatory cytokines and type I IFN was 
already downregulated 6 h post infection. 
 
                
 
Figure 13: Infection of primary BMDM with MCMV leads to mRNA induction of 
proinflammatory cytokines and type I IFN followed by mRNA induction of ISGs. Primary 
BMDM derived from B6N wild type (WT) or UNC93B-/- mice were left untreated or spin infected 
with MCMV-GFP at an MOI of 0.5. RNA was isolated and mRNA expression was analyzed by 
microarray analysis in uninfected cells and 2 h or 6 h post infection (hpi). Shown are mRNA 
expression profiles of selected cytokines and interferon-stimulated genes (ISGs). 
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The expression patterns for the selected genes appeared very similar for BMDM from 
wild type and UNC93B-/- mice. This indicates that the response to MCMV by primary 
BMDM is largely independent on UNC93B and intracellular TLRs. These findings are in 
agreement with the type I IFN ELISA results described in 3.1.3 (Figure 12). 2 h post 
MCMV infection, TNF and IL-6 mRNA expression was induced to a similar extent in 
BMDM derived from UNC93B-/- and wild type mice. However, 6 h post infection, TNF 
and IL-6 mRNA levels in wild type BMDM were slightly higher than in BMDM derived 
from UNC93B-/- mice. This result is in agreement with the TNF and IL-6 ELISA result 
described in 3.1.3 as TNF and IL-6 levels were slightly impaired in BMDM derived from 
UNC93B-/- mice compared to wild type BMDM (Figure 11). 
In summary, the microarray experiment shows a rapid induction of proinflammatory 
cytokine and type I IFN expression upon MCMV infection of primary BMDM within 2 h 
post infection. The produced type I IFN in turn activates upregulation of the expression 
of ISGs, which was detected 6 h post infection. 
 
3.1.5. Intracellular TLRs are crucial for type I IFN responses upon infection 
or stimulation of FL-DC with MCMV and MHV-68  
Plasmacytoid dendritic cells (pDC) are important mediators of antiviral immunity and 
produce high amounts of type I IFN in response to stimulation of intracellular TLR7 and 
TLR9206. pDC lack intracellular TLR3 and predominantly express TLRs 7 and 9106,207,208. 
In vitro, pDC can be generated by cultivation of bone marrow cells with Flt3 ligand 
which stimulates the differentiation of bone marrow cells to dendritic cells209. After 10 
days of in vitro culture in the presence of Flt3 ligand, Flt3 ligand-induced dendritic cells 
(FL-DC) consist of about 40% pDC and 60% conventional dendritic cells (cDC)210. 
Upon viral infection, pDC produce large amounts of IFNα, whereas cDC secrete only 
low amounts of IFNα210. 
In order to study the importance of UNC93B and intracellular TLRs for the type I IFN 
response in dendritic cells, FL-DC were generated from wild type, UNC93B-/-, 3d, 
TLR7-/-, and TLR9-/- mice. Cells were transfected with the single stranded RNA Poly(U) 
to stimulate TLR7, stimulated with CpG 2336, an agonist for TLR9, or infected with 
MCMV or MHV-68 and amounts of IFNα were determined by ELISA. In addition, in 
order to find out if UNC93B also plays a role for the TLR-independent type I IFN 
response in FL-DC, cells were stimulated with agonists for cytosolic DNA or RNA 
sensors. A role of UNC93B for the function of cytosolic PRRs has not been described 
so far. 
The absence of TLR7 and TLR9 in FL-DC of respective knockout mice was verified by 
stimulation with Poly(U) and CpG 2336, respectively. Upon stimulation of TLR7 with 
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Poly(U), FL-DC from wild type and TLR9-/- mice secreted comparable amounts of IFNα 
(Figure 14A). As expected, FL-DC generated from UNC93B-/-, 3d, and TLR7-/- mice did 
not produce detectable amounts of IFNα upon stimulation of TLR7. Upon stimulation of 
TLR9 with CpG 2336, FL-DC from wild type and TLR7-/- mice, but not FL-DC derived 
from UNC93B-/-, 3d, and TLR9-/- mice, produced up to 100 ng/ml of IFNα (Figure 14B).  
In contrast to primary BMDM, intracellular TLRs 7 and 9 are crucial for the recognition 
of MCMV in FL-DC94. Upon MCMV infection, wild type FL-DC produced high amounts 
of IFNα, but IFNα responses were completely abolished when UNC93B was missing 
(UNC93B-/-) or not functional (3d) (Figure 14C). Compared to wild type FL-DC, FL-DC 
derived from TLR9-/- mice produced 10- or 6-fold less IFNα upon infection with MCMV 
at MOI 0.5 or MOI 1, respectively, but FL-DC from TLR7-/- mice did not show a 
significant reduction of the IFNα response upon MCMV infection. This confirms that 
TLR9 is the major receptor for recognition of MCMV in FL-DC which has been 
described previously and is consistent with the finding that TLR9 is essential for the 
type I IFN response against MCMV in vivo92,93. In contrast to FL-DC from UNC93B-/- 
and 3d mice, which showed IFNα responses that were reduced to the background 
level, FL-DC derived from TLR9-/- mice still induced the production of up to 18 ng/ml 
IFNα. This suggests that TLR7 does contribute to the IFNα response against MCMV 
and is consistent with the finding that TLR7 and TLR9 have overlapping functions for 
the immune response to MCMV in pDC and in vivo94. Only if TLR7 and TLR9 are not 
functional, like in FL-DC from 3d or UNC93B-/- mice, the cells are completely unable to 
respond to the infection (Figure 14C). 
IFNα responses by FL-DC upon infection with MHV-68 were about 5-fold lower than 
those observed for infection with MCMV. Infection of wild type FL-DC with MHV-68 led 
to the production of up to 20 ng/ml IFNα at an MOI of 2, but FL-DC derived from 
UNC93B-/- and 3d mice did not produce measurable amounts of IFNα upon infection 
with MHV-68 (Figure 14D). The role of TLR7 for the recognition of MHV-68 seemed to 
be more prominent than for the recognition of MCMV. Compared to wild type FL-DC, a 
2-fold reduction in amounts of secreted IFNα was observed for FL-DC derived from 
TLR7-/- mice infected with MHV-68 at MOI 0.5 or 2. However, this effect was not 
statistically significant. FL-DC derived from TLR9-/- mice showed a 3-fold reduction in 
the amounts of secreted IFNα compared to wild type FL-DC upon infection with 
MHV-68 at the two tested MOIs. The observation that TLR9 is important for the IFNα 
response upon infection of FL-DC with MHV-68 is consistent with previous findings96. A 
role for TLR7 for the recognition of MHV-68 has not been described so far. Thus, 
similar to the IFNα response upon MCMV infection, the IFNα response upon MHV-68 
infection of FL-DC was only completely abrogated when TLR7 and TLR9 were absent 
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and there was no difference in IFNα responses between FL-DC derived from 
UNC93B-/- or 3d mice. 
 
                    
 
Figure 14: Type I IFN responses of FL-DC upon MCMV or MHV-68 infection are dependent 
on UNC93B and intracellular TLRs. FL-DC from wild type (WT), UNC93B-/-, 3d, TLR7-/-, and 
TLR9-/- mice were transfected with Poly(U) (A), stimulated with CpG 2336 (B), or infected with 
MCMV-GFP (C) or MHV-68 (D) at indicated MOIs for 18 h. Levels of IFNα in supernatants were 
determined by ELISA. Results are shown as mean ± S.D. of 3 independent experiments for 
FL-DC from UNC93B-/- mice or 4 independent experiments for FL-DC derived from wild type, 
3d, TLR7-/-, and TLR9-/- mice. Statistical significance compared to wild type controls was 
determined by two-tailed, unpaired t test; *, p<0.05; **, p<0.01. 
 
To stimulate signaling pathways downstream of cytosolic DNA and RNA sensors in 
dendritic cells, FL-DC derived from wild type, UNC93B-/-, 3d, and TLR9-/- mice were 
transfected with interferon stimulatory DNA (ISD) or the RIG-I ligand 5`triphosphate 
double stranded RNA (5`ppp-dsRNA)211. ISD lacks any kind of CpG motif and is 
supposed to stimulate cytosolic DNA sensors in a TLR9-independent manner107. Two 
different kinds of ISD have been described, a 45-base pair (45bp) and a 85-base pair 
(85bp) ISD, and both were used to stimulate cytosolic DNA sensors in FL-DC107,141. 
As a control for FL-DC derived from TLR9-/- mice, cells were stimulated with the TLR9 
ligand CpG 2336. As observed earlier (Figure 14B), wild type FL-DC produced high 
amounts of IFNα upon stimulation with CpG 2336, whereas FL-DC derived from 
UNC93B-/-, 3d, and TLR9-/- mice did not respond to stimulation of TLR9 (Figure 15A).  
Transfection of FL-DC with the 85bp and the 45bp ISD led to the production of 5 and 
16 ng/ml of IFNα in wild type FL-DC, respectively (Figure 15, B and C). This suggests 
that the 45bp ISD is a more potent stimulator than the 85bp ISD. Surprisingly, FL-DC 
derived from UNC93B-/-, 3d, and TLR9-/- mice did not respond to stimulation with the 
45bp or 85bp ISD, indicating that the IFNα responses to both forms of ISD were 
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dependent on TLR9. However, a previous study showed that the IFNα response upon 
transfection of FL-DC with 45bp ISD is completely abrogated in STING-deficient mice, 
indicating that the ISD response is completely dependent on cytosolic DNA sensors 
and independent of TLR9117. 
 
                   
 
Figure 15: Sensing of ISD in FL-DC is dependent on TLR9. FL-DC derived from wild type 
(WT), UNC93B-/-, 3d, and TLR9-/- mice were stimulated with CpG 2336 (A) or transfected with 
45bp ISD (B), 85bp ISD (C), or 5`ppp-dsRNA (D) for 18 h. Levels of IFNα in supernatants were 
determined by ELISA. Results are shown as mean ± S.D. of 2 independent experiments for 
CpG 2336 and ISD 85bp or one representative experiment with duplicates for ISD 45bp and 
5`ppp-dsRNA. 
 
Stimulation of FL-DC with 5`ppp-dsRNA led to the production of IFNα in FL-DC derived 
from wild type and TLR9-/- mice as expected (Figure 15D). Surprisingly, this response 
was also dependent on intracellular TLRs, indicated by the complete absence of an 
IFNα response in FL-DC derived from UNC93B-/- and 3d mice. Since FL-DC derived 
from TLR9-/- mice produced IFNα levels comparable to those of wild type FL-DC, this 
response was most likely mediated by intracellular TLRs 3 or 7, which are dependent 
on UNC93B. Since 5`ppp-dsRNA is a double stranded RNA molecule, it could be 
sensed by TLR3. TLR3 is not expressed in pDC, whereas cDC which constitute up to 
60% of the cells in FL-DC cultures express TLR3 and are able to produce small 
amounts of IFNα 106,207,208. Since the amounts of IFNα secreted by FL-DC derived from 
wild type and TLR9-/- mice upon stimulation with 5`ppp-dsRNA were very low compared 
to stimulation with CpG 2336 or ISD (Figure 15, A-C), this response was very likely 
mediated by cDC in a TLR3-dependent manner. However, to clarify this, FL-DC 
derived from TLR3-/- and TLR7-/- mice should be included in further experiments. In 
addition, in order to find out which type of dendritic cells mediates the IFNα responses 
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to ISD and 5`ppp-dsRNA, these experiments should be repeated with pDC and cDC 
sorted from FL-DC cultures. 
 
Together, these data verify that the intracellular TLRs 7 and 9 are responsible for the 
type I IFN response upon infection of FL-DC with MCMV and that TLR9 plays a more 
important role for this process than TLR7. The importance of TLR9 for the IFNα 
response against MHV-68 in FL-DC was also confirmed. Additionally, TLR7 was shown 
to be involved in the recognition of MHV-68 in FL-DC. In agreement with these results, 
UNC93B is crucial for the recognition of MCMV and MHV-68 in FL-DC. A new role for 
UNC93B for the PRR response to cytosolic DNA or RNA could not be demonstrated. 
However, it was shown for the first time that the IFNα response upon stimulation of 
FL-DC with ISD was dependent on TLR9.  
As observed for BMDM (Figure 9 - Figure 12), we did not find differences in FL-DC 
derived from UNC93B-/- and 3d mice (Figure 14 and Figure 15). 
 
In summary, the experiments performed with BMDM and FL-DC derived from 
UNC93B-/- and 3d mice lead to the conclusion that upon stimulation of TLRs or 
cytosolic PRRs innate immune cells derived from UNC93B-/- and 3d mice exhibit the 
same phenotype. 
 
 
3.2. Identification of novel UNC93B interaction partners 
3.2.1. Identification of novel UNC93B interaction partners by large scale 
immunoprecipitation and mass spectrometry analysis 
UNC93B is crucial for the trafficking and signaling of intracellular TLRs. It delivers 
intracellular TLRs 3, 7, and 9 from the ER to the endolysosomal compartment where 
they can bind their ligands and initiate proinflammatory cytokine and type I IFN 
responses55. How trafficking of UNC93B-TLR complexes is regulated is not well 
understood. The identification and characterization of novel UNC93B interaction 
partners could give important insights into the regulation of UNC93B-TLR trafficking. 
 
RAW 264.7 macrophages stably expressing wild type UNC93B-Flag-TEV-HA WT or 
mutant UNC93B-myc-TEV-HA H412R were lysed with the mild detergent digitonin and 
subjected to an anti-HA immunoprecipitation. Proteins were released by digestion with 
TEV protease, separated by liquid chromatography, and analyzed by mass 
spectrometry (LC-MS/MS)54. TLRs 3, 7, 9, and 13 bound to wild type, but not mutant 
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UNC93B. Besides TLRs 3, 7, 9, and 13, mass spectrometry analysis revealed many 
proteins which interacted with both wild type and mutant UNC93B (Table 14, V 
Appendix). Several highly interesting candidates among these potential UNC93B 
interacting proteins were further analyzed in this study: the uncharacterized protein 
cleft lip and palate associated transmembrane protein (Clptm), the protein tyrosine 
phosphatase 1B (PTP1B) known to regulate endosomal receptor trafficking, and three 
prime repair exonuclease 1 (Trex1), which is involved in the innate immune response 
to cytosolic DNA (Figure 16A) (peptides found by large scale immunoprecipitation and 
mass spectrometry analysis, V Appendix). 
 
    
 
Figure 16: UNC93B and Clptm interaction partners in RAW 264.7 macrophages. RAW 
264.7 macrophages stably expressing tagged versions of wild type (UNC93B-Flag-TEV-HA WT) 
and mutant (UNC93B-myc-TEV-HA H412R) UNC93B (A) and Clptm (HA-Clptm) (B) were lysed 
with 1% digitonin and immunoprecipitated with an anti-HA antibody. Proteins were separated by 
liquid chromatography and analyzed by mass spectrometry (LC-MS/MS). Cleft lip and palate 
associated transmembrane protein (Clptm) was found to interact with wild type and mutant 
UNC93B-HA. Protein tyrosine phosphatase 1B (PTP1B) and three prime repair exonuclease 1 
(Trex1) were found to interact with wild type and mutant UNC93B-HA and HA-Clptm. Stimulator 
of interferon genes (STING) was found to interact with HA-Clptm. Peptides identified by mass 
spectrometry analysis are depicted in grey. Peptide coverage is shown in percent. 
 
Peptides for cleft lip and palate associated transmembrane protein (Clptm) were 
recovered in immunoprecipitations with wild type and mutant UNC93B (Figure 16A). 
Clptm was initially identified as HS9 Ag, a molecule involved in intrathymic T cell 
development, on thymic stromal cells212. Subsequently, the Clptm1 gene was found to 
be disrupted by translocation in a family that had a history of cleft lip and palate213. 
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However, a link between the Clptm1 gene and the etiology of cleft lip and palate has 
never been confirmed. Furthermore, mutations in the Clptm1 gene were found in 
prostate cancer cell lines214. Clptm is predicted to have 5 transmembrane domains with 
a large luminal N-terminus (aa 1-354) and a cytosolic C-terminus (aa 530-664) by the 
TMHMM 2.0 programme of the CBS prediction servers (Figure 17A). To gain insight 
into possible functions of Clptm, RAW 264.7 macrophages stably expressing 
HA-tagged Clptm were generated, lysed, and subjected to an anti-HA immuno-
precipitation. Proteins interacting with HA-Clptm were analyzed by LC-MS/MS 
(Table 15, V Appendix). Among the proteins listed in Table 15 PTP1B, Trex1, and 
stimulator of interferon genes (STING), which is a key regulator of the response to 
cytosolic DNA, were identified as binding partners of Clptm (Figure 16B) (peptides 
found by large scale immunoprecipitation and mass spectrometry analysis, 
V Appendix). 
 
 
Figure 17: Predicted topology of UNC93B and Clptm interaction partners. Clptm has five 
predicted transmembrane domains with a large luminal N-terminus (aa 1-354) and a cytosolic 
C-terminus (aa 530-664) (A). PTP1B and Trex1 are C-terminally anchored to the cytosolic side 
of the ER via a 35- or 79-residue domain, respectively (B, C). STING is reported to have four 
transmembrane domains with a short cytosolic N-terminus (aa 1-19) and a large cytosolic 
C-terminal domain (aa 137-378) (D). 
 
Protein tyrosine phosphatase 1B (PTP1B) was identified as an interacting partner of 
wild type and mutant UNC93B as well as Clptm (Figure 16). PTP1B is the best 
characterized tyrosine phosphatase (1.2). It is attached to the cytoplasmic face of the 
ER membrane via its hydrophobic C-terminal 35-residue domain (Figure 17B)154. 
Among other functions, PTP1B has been reported to regulate trafficking of receptor 
tyrosine kinases which made PTP1B a highly interesting candidate for this study158. 
The three prime repair exonuclease 1 (Trex1) interacted with wild type and mutant 
UNC93B and Clptm (Figure 16, A and B). Trex1 is the major 3`5` DNA exonuclease 
in mammals and has been described as a negative regulator of the cytosolic DNA 
response122. Trex1 has been reported to interact with the cytosolic side of the ER 
membrane via its 79-residue hydrophobic C-terminal domain (Figure 17C)141. 
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The membrane protein stimulator of interferon genes (STING) was only identified as an 
interaction partner of Clptm (Figure 16B). STING is an ER resident protein with four 
predicted transmembrane domains and a large C-terminal domain (aa 137-378) facing 
the cytosolic side of the ER (Figure 17D)215. STING is known to be a crucial player in 
the cytosolic DNA response216. 
The interaction between Trex1 and STING with UNC93B and Clptm has been 
extensively investigated in a separate study (Olga Trupp, bachelor thesis 2011: The 
DNA exonuclease Trex-1 interacts with Cleft lip and palate associated transmembrane 
protein (Clptm), a component of the UNC93B1/Toll-like receptor complex). 
 
 
3.3. Characterization of the role of Clptm and Trex1 for TLR- and 
UNC93B-mediated immune responses 
3.3.1. Clptm interacts with wild type and mutant UNC93B 
Clptm is a poorly characterized protein which is predicted to have five transmembrane 
domains (CBS prediction servers, TMHMM 2.0) (Figure 17A). To study the subcellular 
localization of Clptm and its interaction with UNC93B, Trex1, STING, and PTP1B, 
different expression constructs of Clptm were generated. Clptm was N-terminally as 
well as C-terminally tagged with the HA epitope tag or fused to GFP. RAW 264.7 
macrophage cell lines stably expressing HA-Clptm, Clptm-HA, GFP-Clptm, or 
Clptm-GFP were established by retroviral transduction. Expression of endogenous 
Clptm as well as HA-Clptm, Clptm-HA, GFP-Clptm, and Clptm-GFP in RAW 264.7 
macrophages was verified by immunoblotting with a polyclonal rabbit antibody raised 
against C-terminal peptides of Clptm (Figure 18, A and B).  
Clptm is predicted to have six putative N-linked glycosylation sites all of which are 
located within predicted luminal domains of Clptm (CBS prediction servers, NetNGlyc 
1.0) (Figure 18C). Potential glycosylation sites (consensus sequence NxS/T) are 
N28GS, N119AT, N161GS, N241IT, N295ES, and N413ET. In order to show whether Clptm is 
glycosylated, lysates of RAW 264.7 macrophages stably expressing Clptm-GFP were 
digested with PNGase F, a glycosidase which catalyzes the cleavage of N-linked 
oligosaccharides from glycoproteins. Immunoblot analysis revealed that endogenous 
Clptm as well as Clptm-GFP were glycosylated, since treatment of cell lysates with 
PNGase F resulted in a shift of both protein bands to bands of lower molecular weights 
(Figure 18D). This indicates that Clptm traffics through the Golgi apparatus where it is 
modified by glycosylation. Addition of the large GFP moiety does not influence Golgi 
trafficking of the GFP-Clptm fusion protein. Glycosylation of Clptm was also observed 
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in wild type RAW 264.7 macrophages and RAW 264.7 macrophages stably expressing 
GFP-Clptm (data not shown). 
 
 
 
Figure 18: HA-Clptm, Clptm-HA, GFP-Clptm, and Clptm-GFP are expressed and Clptm is 
glycosylated in macrophages. RAW 264.7 macrophages stably expressing HA-Clptm or 
Clptm-HA (A) and GFP-Clptm or Clptm-GFP (B) were lysed and expression of Clptm fusion 
proteins was analyzed by immunoblotting with the indicated antibodies. Predicted N-linked 
glycosylation sites of Clptm are indicated (*) (C). RAW 264.7 macrophages stably expressing 
Clptm-GFP were lysed with 1% NP-40. Lysates were left untreated or treated with PNGase F 
for 1 h at 37°C (D). 
 
To verify the interaction between UNC93B and Clptm identified by large scale 
immunoprecipitation and LC-MS/MS analysis (Figure 16A), individual co-
immunoprecipitations were performed with lysates of RAW 264.7 macrophages stably 
expressing wild type or mutant UNC93B-HA or HA-Clptm. Cells were lysed under mild 
conditions and subjected to immunoprecipitations with an anti-Clptm or anti-UNC93B 
antibody. Expression of wild type and mutant UNC93B-HA and HA-Clptm in input 
lysates was verified by anti-HA immunoblotting (Figure 19, A and B). Upon 
immunoprecipitation of endogenous Clptm, wild type and mutant (H412R) UNC93B-HA 
could be detected by anti-HA immunoblotting (Figure 19A). Vice versa, HA-Clptm co-
precipitated with endogenous UNC93B in RAW 264.7 macrophages stably expressing 
HA-Clptm (Figure 19B). These results confirm an interaction between UNC93B and 
Clptm as initially shown by large scale immunoprecipitation and LC-MS/MS. 
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Figure 19: Wild type and mutant UNC93B-HA interact with endogenous Clptm and 
HA-Clptm interacts with endogenous UNC93B in RAW 264.7 macrophages. RAW 264.7 
macrophages stably expressing wild type (WT) or mutant (H412R) UNC93B-HA (A) or 
HA-Clptm (B) were lysed with 1% digitonin and subjected to an immunoprecipitation with anti-
Clptm or anti-UNC93B, respectively. Rabbit serum was used as control. Immunoprecipitated 
UNC93B-HA or HA-Clptm were detected with an anti-HA antibody. 
 
3.3.2. Knockdown of Clptm in macrophages does not impair the TNF 
response upon TLR stimulation 
In order to find out whether Clptm plays a role for TLR signaling, a knockdown of Clptm 
was performed in RAW 264.7 macrophages using an shRNA approach. Knockdown of 
UNC93B was performed as a control. Two or three independent shRNAs were used for 
knockdown of Clptm and UNC93B, respectively. Additionally, control shRNAs targeting 
the human retinoblastoma protein (sh-control1) and Renilla luciferase (sh-control2) 
were included. Successful knockdown of Clptm and UNC93B in RAW 264.7 
macrophages was verified by immunoblotting with anti-Clptm and anti-UNC93B 
antibodies (Figure 20A). Expression of sh-UNC1, sh-UNC2, or sh-UNC3 efficiently 
downregulated protein levels of UNC93B compared to cells expressing the control 
shRNAs (sh-control1, sh-control2). sh-UNC2 mediated the strongest knockdown of 
UNC93B (Figure 20A). Compared to the control shRNAs, protein levels of Clptm were 
equally reduced upon expression of sh-Clptm1 and sh-Clptm2. Protein levels of Clptm 
were not affected by knockdown of UNC93B and vice versa (Figure 20A). 
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Figure 20: Knockdown of Clptm in RAW 264.7 macrophages does not have an effect on 
the TNF response upon TLR stimulation. RAW 264.7 macrophages stably expressing 
indicated shRNAs were lysed and protein levels of Clptm and UNC93B were analyzed by 
immunoblotting with anti-Clptm or anti-UNC93B antibodies (A). Loading of equal amounts of 
protein was confirmed by anti-tubulin immunoblots. Cells expressing indicated shRNAs were 
stimulated with 10 ng/ml of LPS (B) or 0.2 µM CpG 1826 (C) for 4 h. Levels of TNF in 
supernatants were determined by ELISA. Results are shown as mean ± S.D. of one 
representative experiment with duplicates. 
 
Next, the RAW 264.7 macrophage cell lines stably expressing UNC93B- or Clptm-
specific shRNAs or control shRNAs were stimulated with LPS or CpG 1826 and the 
amount of TNF in supernatants was determined by ELISA. Compared to the amounts 
of TNF secreted by cells expressing control shRNAs, knockdown of UNC93B led to an 
up to 2-fold reduction of the TNF response upon LPS stimulation of TLR4 (Figure 20B). 
Knockdown of Clptm with sh-Clptm1 and sh-Clptm2 did not impair the TNF production 
in response to LPS stimulation. As expected, upon stimulation of TLR9 with CpG 1826, 
knockdown of UNC93B with sh-UNC1 or sh-UNC2 led to a 3- or more than 6-fold 
reduction of the elicited TNF responses compared to responses of cells expressing 
control shRNAs, respectively (Figure 20C). Although the efficiency of the UNC93B 
knockdown with sh-UNC1 and sh-UNC3 seemed to be comparable by immunoblotting, 
knockdown of UNC93B with sh-UNC3 did not lead to a reduction of the TNF response 
upon stimulation of TLR9 to a degree as seen with sh-UNC1. TNF levels upon 
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stimulation with CpG 1826 were not affected by knockdown of Clptm with sh-Clptm1 or 
sh-Clptm2 (Figure 20C). 
This indicates that Clptm may not be involved in the proinflammatory cytokine response 
upon stimulation of cell surface TLR4 and intracellular TLR9 in macrophages. It is also 
possible that the shRNA-mediated knockdown of Clptm was not strong enough and 
that the remaining protein level of Clptm was sufficient to mediate a proinflammatory 
cytokine response. 
 
3.3.3. Clptm co-localizes with Trex1 in macrophages and interacts with the 
luminal domain of Trex1 
As described in 3.2.1, the DNA exonuclease Trex1 was found to interact with UNC93B 
and Clptm (Figure 16). Further interaction studies of UNC93B, Clptm, and Trex1 
revealed interactions between endogenous Clptm and UNC93B with endogenous 
Trex1 (Olga Trupp, bachelor thesis 2011). 
Trex1 was shown to co-localize with the ER-marker calnexin by immuno-
fluorescence141. In order to analyze localization of Trex1 and Clptm by live cell imaging, 
monomeric cherry (mcherry) was N-terminally fused to Trex1 and BMDM stably 
expressing GFP-Clptm and cherry-Trex1 were generated by retroviral transduction. Co-
localization of GFP-Clptm with cherry-Trex1 at the ER was demonstrated by live cell 
imaging (Figure 21A). 
Trex1 is composed of two different domains. The N-terminal domain (aa 1-235) 
mediates its exonuclease function and the hydrophobic C-terminal domain (aa 236-
314) attaches Trex1 to the cytoplasmic face of the ER membrane (Figure 17C). In 
order to find out which domain of Trex1 mediates interaction with Clptm, N- and 
C-terminally truncated versions of Trex1 were generated and N-terminally fused to 
mcherry. RAW 264.7 macrophage cell lines stably expressing GFP-Clptm and either 
full length or the N- or C-terminal truncated versions of cherry-Trex1 were established 
and expression of cherry-Trex1 constructs was verified by immunoblotting with an 
anti-RFP antibody which recognizes mcherry (Figure 21B). Upon anti-GFP immuno-
precipitation, full length as well as the C-terminally truncated version of Trex1, were 
detected by immunoblotting. The hydrophobic C-terminal domain of Trex1, which 
anchors the protein in the ER membrane, did not co-precipitate with GFP-Clptm.  
These results confirm the interaction between Clptm and Trex1 found by large scale 
immunoprecipitation and LC-MS/MS analysis and suggest that the luminal exonuclease 
domain of Trex1, but not the C-terminal domain, interacts with Clptm at the ER. 
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Figure 21: Clptm and Trex1 co-localize and Clptm interacts with the luminal domain of 
Trex1 in macrophages. BMDM stably expressing GFP-Clptm and cherry-Trex1 were analyzed 
by live cell imaging (A). Scale bar, 10 µm. RAW macrophages stably expressing GFP-Clptm 
and either full-length or truncated versions of cherry-Trex1 (cherry-Trex1 1-314, cherry-Trex1 
1-235, and cherry-Trex1 236-314) were lysed with 1% digitonin and subjected to an 
immunoprecipitation with an anti-GFP antibody. Rabbit serum was used as control. 
Immunoprecipitated cherry-Trex1 constructs were detected with an anti-RFP antibody (B). 
 
The immunoprecipitation experiments conducted with UNC93B, Clptm, and Trex1 
confirmed interactions between all these proteins (Figure 19, Figure 21, and Olga 
Trupp, bachelor thesis 2011). A role for Clptm for the TLR-dependent proinflammatory 
cytokine response could not be shown in initial experiments. However, Clptm could be 
important for the type I IFN response upon TLR stimulation. Unfortunately, Clptm 
knockout mice are not available which is why we could not study the role of Clptm for 
the TLR-dependent type I IFN response in pDC. 
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3.4. Characterization of the role of protein tyrosine phosphatase 
PTP1B for TLR and innate immune signaling 
3.4.1. PTP1B interacts with UNC93B, TLR9, TLR7, and Clptm 
Protein tyrosine phosphatase 1B (PTP1B) was identified as an interacting partner of 
UNC93B and Clptm in large scale immunoprecipitations (Figure 16). To confirm 
interaction of UNC93B and Clptm with PTP1B, individual co-immunoprecipitations were 
performed. 
Human embryonic kidney (HEK) 293T cells were co-transfected with HA-PTP1B and 
either wild type or mutant (H412R) UNC93B-GFP. Expression of HA-PTP1B in input 
lysates was verified by anti-HA immunoblotting (Figure 22, A and D) and expression of 
wild type and mutant UNC93B-GFP was verified by anti-GFP immunoblotting (data not 
shown and Figure 22D). Upon anti-GFP immunoprecipitation, HA-PTP1B was detected 
by immunoblotting when co-expressed with wild type or mutant UNC93B-GFP 
(Figure 22A). In the reverse experiment, wild type as well as mutant UNC93B-GFP was 
detected after anti-HA immunoprecipitation when co-expressed with HA-PTP1B 
(Figure 22D). 
In order to analyze whether Clptm interacts with PTP1B, HEK 293T cells were co-
transfected with HA-PTP1B and Clptm-GFP or empty vector. Expression of the 
transfected constructs in input lysates was verified by immunoblotting (Figure 22, B and 
E, and data not shown). HA-PTP1B co-precipitated with Clptm-GFP upon anti-GFP 
immunoprecipitation (Figure 22B). Vice versa, GFP-Clptm co-precipitated with 
HA-PTP1B upon anti-HA immunoprecipitation (Figure 22E). 
At this point it is not clear whether the interaction between UNC93B and PTP1B is 
direct or indirect. Since UNC93B has been shown to interact with TLR9 via its 
transmembrane domain54, it was also analyzed whether PTP1B interacts with TLR9. 
For this reason, anti-HA and anti-GFP immunoprecipitations were performed with HEK 
293T cells co-transfected with HA-PTP1B and TLR9-GFP. In both cases, HA-PTP1B or 
TLR9-GFP were detected by immunoblotting only when co-expressed with TLR9-GFP 
or HA-PTP1B, respectively (Figure 22, C and F). Expression of HA-PTP1B and TLR9-
GFP in input lysates was confirmed by immunoblotting (Figure 22, C and F, and data 
not shown). 
Together, the co-immunoprecipitation experiments performed with lysates of 
transfected HEK 293T cells indicate that PTP1B interacts with wild type and mutant 
(H412R) UNC93B, Clptm, and TLR9. 
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Figure 22: Wild type and mutant UNC93B-GFP, Clptm-GFP, and TLR9-GFP interact with 
HA-PTP1B in HEK 293T cells. HEK 293T cells were transfected with HA-PTP1B and empty 
vector (-) or together with wild type (WT) or mutant (H412R) UNC93B-GFP (A), Clptm-GFP (B), 
or TLR9-GFP (C). Expression of HA-PTP1B in input lysates was verified by anti-HA 
immunoblotting. Cells were lysed with 0.5% NP-40 and immunoprecipitation was performed with 
an anti-GFP antibody. HA-PTP1B was detected by immunoblotting with an anti-HA antibody 
(A-C). HEK 293T cells were transfected wild type (WT) or mutant (H412R) UNC93B-GFP (D), 
Clptm-GFP (E), or TLR9-GFP (F) together with empty vector (-) or with HA-PTP1B. Expression 
of the different constructs in input lysates was verified by anti-GFP and anti-HA immunoblotting. 
Immunoprecipitation was performed with an anti-HA antibody. GFP fusion proteins were 
detected by immunoblotting with an anti-GFP antibody. Co-immunoprecipitated HA-PTP1B was 
detected by anti-HA immunoblotting (D-F). 
 
HEK 293 cells do not express endogenous TLR9208. However, HEK 293 cells stably 
expressing human or murine TLR9 reporter constructs are commercially available 
(Invivogen) and functional, which indicates that UNC93B is expressed in HEK 293 
cells. In order to analyze the interactions between PTP1B, UNC93B, intracellular TLRs, 
and Clptm in a more relevant cell type, co-immunoprecipitation experiments were 
performed in murine BMDM. TLR9 is proteolytically cleaved in the endolysosome in 
order to generate a functional receptor71. In contrast to HEK 293T cells, BMDM express 
endogenous TLR9 and TLR9 as well as TLR9-GFP are processed in BMDM. In lysates 
of BMDM expressing TLR9-GFP, full-length as well as the C-terminal TLR9-GFP 
cleavage fragment can be detected by anti-GFP immunoblotting (Figure 23). 
Immortalized BMDM stably expressing TLR9-GFP and HA-PTP1B were lysed under 
mild conditions. For the analysis of the interaction between HA-PTP1B and TLR7, 
UNC93B, and Clptm, lysates were subjected to immunoprecipitations with antibodies 
against the respective proteins. To analyze whether HA-PTP1B interacts with 
TLR9-GFP, precipitations were performed with a GFP-binding protein coupled to 
agarose beads (GFP-Trap) or an anti-HA antibody. The expression of HA-PTP1B and 
TLR9-GFP in input lysates was confirmed by immunoblotting (Figure 23, A-C). 
HA-PTP1B co-precipitated with endogenous TLR7, UNC93B, and Clptm (Figure 23A). 
For the control immunoprecipitation rabbit serum was used instead of the antibodies 
against endogenous TLR7, UNC93B, and Clptm. This control only showed a very weak 
band upon anti-HA immunoblotting (Figure 23A). TLR7 and TLR9 both bind to 
UNC93B, which explains why detected signals for TLR9-GFP (full length and 
C-terminal cleavage fragment) were detected upon anti-TLR7 and anti-UNC93B 
immunoprecipitation and anti-GFP immunoblotting (Figure 23A). The signal detected 
for TLR9-GFP by anti-GFP immunoblotting upon anti-Clptm immunoprecipitation 
suggests a weak interaction of Clptm with TLR9-GFP. 
Because of the lack of an antibody able to detect endogenous TLR9, the GFP-Trap 
was used to precipitate TLR9-GFP in immortalized BMDM stably expressing 
TLR9-GFP and HA-PTP1B. HA-PTP1B was detected after precipitation of TLR9-GFP 
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with the GFP-Trap, but not with control beads (Figure 23B). Interaction between 
TLR9-GFP and HA-PTP1B was further verified by detection of full length TLR9 after 
anti-HA immunoprecipitation of HA-PTP1B in BMDM stably expressing TLR9-GFP and 
HA-PTP1B (Figure 23C). In the absence of HA-PTP1B, TLR9-GFP did not precipitate 
with anti-HA beads, verifying the specificity of the TLR9-PTP1B co-immunoprecipitation 
(Figure 23C). 
 
 
 
Figure 23: HA-PTP1B interacts with TLR7, UNC93B, Clptm, and TLR9-GFP in 
immortalized BMDM. BMDM stably expressing TLR9-GFP and HA-PTP1B were lysed with 1% 
digitonin. Immunoprecipitations for TLR7, UNC93B, and Clptm were performed with the 
indicated antibodies. Rabbit serum was used as control (A). TLR9-GFP was precipitated with 
GFP-Trap or control beads (B). Lysates of BMDM stably expressing TLR9-GFP alone or 
TLR9-GFP together with HA-PTP1B were subjected to an immunoprecipitation with an anti-HA 
antibody (C). HA-PTP1B was detected by immunoblotting with an anti-HA antibody. TLR9-GFP 
and its C-terminal cleavage fragment were detected with an anti-GFP antibody. 
 
Altogether, these data demonstrate that HA-tagged PTP1B interacts with endogenous 
UNC93B, Clptm, and TLR7, as well as with TLR9-GFP in BMDM. However, at this 
point we cannot draw any conclusions about the nature of these interactions. To 
address, for example, the question whether PTP1B directly interacts with TLR9 or, 
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rather likely, via UNC93B, co-immunoprecipitations would need to be performed in 
BMDM derived from UNC93B-/- or TLR9-/- mice. 
 
3.4.2. Ruby-PTP1B and TLR9-GFP partially co-localize in BMDM 
PTP1B is anchored to the cytosolic side of the ER membrane via a hydrophobic 
C-terminal 35-residue region. In order to analyze whether PTP1B co-localizes with 
TLR9 in the ER or endosomes by live cell imaging, the red fluorescent protein mRuby2 
was fused to HA-PTP1B. Immortalized BMDM stably expressing TLR9-GFP were 
retrovirally transduced with Ruby-PTP1B and cells were imaged unstimulated and upon 
stimulation with CpG DNA. As previously shown, TLR9-GFP localized to the ER as well 
as the endosomal compartment in unstimulated cells (Figure 24A)41,62,74. This is 
consistent with the observation that cleavage of TLR9 is present in unstimulated cells 
(Figure 23). Ruby-PTP1B was mainly located in the perinuclear region indicating ER 
localization. Occasionally, Ruby-PTP1B was also detected in endosomal structures 
(Figure 24A). The localization of TLR9-GFP and Ruby-PTP1B did not change upon 
CpG stimulation (Figure 24B). Stimulation of the cells with fluorescently labeled CpG 
1826 allowed the visualization of CpG DNA-containing endosomes. TLR9-GFP clearly 
localized to endosomes filled with CpG DNA (Figure 24C). In contrast, Ruby-PTP1B 
did not accumulate in endosomes. 
Live cell imaging of TLR9-GFP and Ruby-PTP1B indicates that both proteins partially 
co-localize in the ER. However, a large portion of TLR9-GFP localizes to the 
endosomal compartment and endosomal localization of Ruby-PTP1B was only 
observed occasionally. 
We previously observed that the localization of the UNC93B-GFP construct differs from 
the reported localization of UNC93B in macrophages (data not shown)52,55. Therefore, 
UNC93B was not included in the co-localization experiments with Ruby-PTP1B 
conducted by live cell imaging. 
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Figure 24: Ruby-PTP1B localizes to the ER where it partially co-localizes with TLR9-GFP 
in BMDM. Immortalized BMDM stably expressing TLR9-GFP were retrovirally transduced with 
Ruby-PTP1B and left unstimulated (A), stimulated with 1 µM CpG 1826 (B), or 1 µM CpG 1826-
Alexa647 (C) for 2 h and analyzed by confocal microscopy. Scale bar, 5 µm. 
 
3.4.3. The expression of PTP1B in BMDM is upregulated upon TLR 
stimulation  
Analysis of gene expression profiles for UNC93B and PTP1B (BioGPS) revealed 
similar expression patterns for both proteins. UNC93B and PTP1B are highly 
expressed in lymphoid organs and innate immune cells including B cells, dendritic 
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cells, and macrophages (Figure 25A). The fact that PTP1B is highly expressed in 
immune cells indicates a link between PTP1B and innate immunity. 
 
         
 
Figure 25: PTP1B protein levels are upregulated upon TLR stimulation in BMDM. Gene 
expression profiles for UNC93B and PTP1B were obtained from BioGPS (A). Primary BMDM 
were stimulated with LPS (100 ng/ml), CpG 1826 (1 µM), or R848 (1 µM) for 6, 12, and 24 h (B). 
Expression of PTP1B was analyzed by anti-PTP1B immunoblotting. BMDM derived from 
PTP1B-/- mice were used as a negative control. Loading of equal amounts of proteins was 
verified by anti-tubulin immunoblotting. 
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Furthermore, the gene expression profile for PTP1B suggested that gene expression of 
PTP1B is upregulated upon stimulation with the TLR ligand LPS (Figure 25A, red 
arrow). In order to analyze protein levels of PTP1B in unstimulated and TLR agonist 
stimulated BMDM, primary BMDM were stimulated with the TLR4 agonist LPS, the 
TLR9 agonist CpG 1826, and the TLR7 agonist R848 and lysed 6, 12, and 24 h post 
stimulation. Immunoblot analysis of PTP1B showed that protein levels of endogenous 
PTP1B were upregulated upon stimulation with all TLR agonists tested (Figure 25B). 
Primary BMDM derived from PTP1B-/- mice were used to verify the specificity of the 
PTP1B antibody. Upregulation of PTP1B expression upon TLR stimulation supports the 
idea that PTP1B may be involved in innate immune signaling. 
 
3.4.4. Knockout of PTP1B does not impair proinflammatory cytokine 
responses upon TLR stimulation in BMDM 
To investigate the role of PTP1B for signaling of intracellular TLRs in macrophages, 
primary BMDM derived from wild type, PTP1B-/-, and TLR9-/- mice were stimulated with 
TLR agonists and amounts of the proinflammatory cytokines TNF and IL-6 in 
supernatants were measured by ELISA. 
 
 
 
Figure 26: TNF responses in primary BMDM derived from PTP1B
-/-
 mice are not impaired 
upon TLR stimulation. Primary BMDM derived from wild type (WT), PTP1B-/-, and TLR9-/- mice 
were stimulated with indicated concentrations of TLR agonists for 18 h (A-F). TNF levels in 
supernatants were determined by ELISA. Shown is one representative experiment with 
duplicates as mean ± S.D. out of 3 independent experiments. 
 
Stimulation of cell surface TLRs 1/2, 2/6, and 4 with Pam3CSK4, FSL-1, and LPS, 
respectively, did not reveal considerable differences in TNF or IL-6 responses between 
BMDM derived from wild type, PTP1B-/-, and TLR9-/- mice (Figure 26, A-C and 
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Figure 27, A-C). Upon stimulation of intracellular TLRs 3, 7, and 9 with Poly(I:C), R848, 
and CpG 1826, the amounts of produced TNF and IL-6 did not differ between BMDM 
derived from wild type and PTP1B-/- mice (Figure 26, D-F and Figure 27, D-F). As 
expected, BMDM derived from TLR9-/- mice did not secrete TNF or IL-6 in response to 
stimulation of TLR9 with CpG 1826. Upon stimulation of TLR3 with Poly(I:C) or TLR7 
with R848, BMDM derived from TLR9-/- mice secreted amounts of TNF and IL-6 
comparable to wild type and PTP1B-/- mice. 
 
 
 
Figure 27: IL-6 responses in primary BMDM derived from PTP1B
-/-
 mice are not impaired 
upon TLR stimulation. Primary BMDM derived from wild type (WT), PTP1B-/-, and TLR9-/- mice 
were stimulated with indicated concentrations of TLR agonists for 18 h (A-F). IL-6 levels in 
supernatants were determined by ELISA. Shown is one representative experiment with 
duplicates as mean ± S.D. out of 3 independent experiments. 
 
To further study TLR responses of BMDM derived from wild type, PTP1B-/-, and TLR9-/- 
mice, production of the proinflammatory cytokine IL-12p40 upon stimulation of cell 
surface and intracellular TLRs was analyzed by ELISA. Stimulation of TLR1/2 with 
Pam3CSK4 and TLR2/6 with FSL-1 only led to the production of extremely low amounts 
of IL-12p40 in primary BMDM, which did not allow any conclusion from this data set 
(not shown). Upon stimulation of TLR4 and intracellular TLRs 3, 7, and 9 with LPS, 
Poly(I:C), R848, and CpG 1826, respectively, no prominent differences in IL-12p40 
levels were observed between BMDM derived from wild type and PTP1B-/- mice 
(Figure 28, A-D). BMDM derived from TLR9-/- mice responded like BMDM derived from 
wild type and PTP1B-/- mice upon stimulation of TLR4, TLR3, and TLR7, but, as 
expected, did not secrete IL-12p40 in response to stimulation of TLR9 with CpG 1826. 
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Figure 28: IL-12p40 responses in primary BMDM derived from PTP1B
-/-
 mice are not 
impaired upon TLR stimulation. Primary BMDM derived from wild type (WT), PTP1B-/-, and 
TLR9-/- mice were stimulated with indicated concentrations of TLR agonists for 18 h (A-D). 
IL-12p40 levels in supernatants were determined by ELISA. Shown is one representative 
experiment with duplicates as mean ± S.D. out of 3 independent experiments. 
 
In summary, we found no difference in proinflammatory cytokine levels of TNF, IL-6, 
and IL-12p40 between BMDM derived from wild type and PTP1B-/- mice. Therefore, we 
conclude that PTP1B does not play a role for the proinflammatory cytokine response 
upon stimulation of cell surface or intracellular TLRs in macrophages. 
 
3.4.5. PTP1B regulates the type I IFN response upon MCMV infection of 
BMDM 
To investigate the role of PTP1B for the type I IFN response in macrophages in the 
context of viral infection, BMDM derived from wild type, PTP1B-/-, 3d, and TLR9-/- mice 
were infected with MCMV and amounts of TNF, IFNα, and IFNβ in supernatants were 
determined by ELISA. Consistent with the data shown for UNC93B-/- mice (Figure 11, A 
and B), the TNF response upon infection with MCMV was only slightly reduced in 
BMDM derived from TLR9-/- or 3d mice (Figure 29A). The TNF response upon MCMV 
infection of BMDM derived from PTP1B-/- mice was not impaired compared to wild type 
BMDM. In contrast, the IFNα response upon MCMV infection was almost completely 
abolished in PTP1B-/- BMDM (Figure 29B). Since the IFNα response in BMDM derived 
from TLR9-/- and 3d mice was intact, we conclude that the phenotype observed in 
BMDM derived from PTP1B-/- mice is not linked to the TLR9 response in BMDM. A 
similar picture as for IFNα was observed for the IFNβ response, but less pronounced. 
Upon infection with MCMV, BMDM derived from TLR9-/- and 3d mice produced 
amounts of IFNβ comparable to wild type BMDM, whereas BMDM derived from 
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PTP1B-/- mice secreted a significantly lower amount of IFNβ than wild type BMDM 
(Figure 29C). 
 
  
 
Figure 29: Type I IFN responses upon MCMV infection are impaired in primary BMDM 
derived from PTP1B
-/-
 mice. Primary BMDM from wild type (WT), PTP1B-/-, TLR9-/-, and 3d 
mice were infected with MCMV-GFP at MOI 0.5, 1, or 2 for 18 h. Levels of TNF (A), IFNα (B), 
and IFNβ (C) in supernatants were determined by ELISA. Results are shown as mean ± S.D. of 
3 independent experiments. Statistical significance compared to wild type controls was 
determined by two-tailed, unpaired t test; *, p<0.05; **, p<0.01. 
 
These data show that PTP1B regulates the IFNα and IFNβ response upon MCMV 
infection in BMDM. However, since TLR9 does not play a role for the type I IFN 
response upon MCMV infection of BMDM, we conclude that this effect is independent 
of intracellular TLRs. This suggests a role for PTP1B in the regulation of cytosolic 
PRRs or a general role in the regulation of type I IFN responses. Consistent with the 
hypothesis that PTP1B is important for the regulation of cytosolic DNA sensors, BMDM 
derived from STING-deficient mice do not produce IFNα or IFNβ in response to MCMV 
infection (Baca Chan, unpublished results). Since STING is the key regulator for the 
cytosolic DNA response216, this suggests that in BMDM MCMV is detected by cytosolic 
DNA sensors upstream of STING. 
 
3.4.6. Knockout of PTP1B does not have an effect on the TLR9-dependent 
IFNα response in BMDM 
The IFNα response upon MCMV infection of primary BMDM was significantly impaired 
in the absence of PTP1B, but not in the absence of TLR9 (Figure 29B). This indicates 
that PTP1B regulates the IFNα response upon MCMV infection of BMDM in a TLR9-
independent manner. In addition to intracellular TLRs 3, 7, and 9, MCMV also activates 
other PRRs90. The production of type I IFN in response to MCMV infection is partially 
dependent on TLR2 in murine bone marrow cells36 and in the absence of STING, 
BMDM do not produce type I IFN upon MCMV infection (Baca Chan, unpublished 
results). Upon TLR9 stimulation with CpG ODN, BMDM only produce very low amounts 
of type I IFN which cannot be detected by ELISA. To study whether PTP1B has a role 
for the TLR9-dependent type I IFN response in BMDM, qPCR analysis upon MCMV 
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infection or stimulation with two different kinds of CpG A was carried out with IFNα4-
specific primers. Macrophages produce small amounts of type I IFN upon transfection 
with CpG A in a TLR9-dependent manner. In contrast, CpG B, which has a different 
backbone, does not induce a type I IFN response, but activates TLR9-dependent 
NF-κB signaling, leading to the production of proinflammatory cytokines78. 
To confirm the result that PTP1B, but not TLR9, is required for the IFNα response by 
primary BMDM upon MCMV infection described in 3.4.5, primary BMDM derived from 
wild type, PTP1B-/-, and TLR9-/- mice were first infected with MCMV and the expression 
of IFNα4 2 h and 6 h post infection was analyzed by qPCR. Compared to wild type 
BMDM, the relative induction of IFNα4 in BMDM derived from PTP1B-/- mice was 
impaired 2 h as well as 6 h after MCMV infection (Figure 30, A and B). The relative 
IFNα4 mRNA expression in BMDM derived from TLR9-/- mice 2 h and 6 h post infection 
was comparable to BMDM derived from wild type mice. Thus, qPCR analysis of the 
IFNα4 response in primary BMDM confirmed the ELISA results shown in Figure 29B 
that PTP1B, but not TLR9, regulates the IFNα response upon MCMV infection. 
 
               
 
Figure 30: The IFNα4 response upon MCMV infection is impaired in the absence of 
PTP1B in primary BMDM. Primary BMDM were generated from wild type (WT), PTP1B-/-, and 
TLR9-/- mice. Cells were spin infected with MCMV-GFP at MOI 0.5 for 2 h (A) or 6 h (B). qPCR 
was carried out with 200 ng RNA and IFNα4-specific primers. Data were normalized to Rpl8 and 
fold induction was calculated relative to uninfected cells. Results are shown as mean ± S.D. of 
one experiment in duplicates. 
 
To find out whether PTP1B regulates the TLR9-dependent IFNα response in BMDM, 
primary BMDM derived from wild type, PTP1B-/-, and 3d mice were transfected with the 
A type CpG ODN 2336 and 1585 and the expression of IFNα4 6 h post transfection 
was analyzed by qPCR. Since experiments were performed with different amounts of 
RNA, results of two independent experiments are shown in separate graphs 
(Figure 31). Transfection of BMDM with CpG 2336 or CpG 1585 induced a potent 
IFNα4 response in wild type BMDM (Figure 31, A-D). However, the relative induction of 
IFNα4 mRNA expression upon stimulation with CpG 2336 or 1585 did not differ 
between BMDM derived from wild type and from PTP1B-/- mice. Stimulation of BMDM 
derived from 3d mice, which lack functional TLR9, with CpG 2336 or CpG 1585 only 
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marginally induced IFNα4 mRNA expression as expected. In accordance with previous 
studies83, transfection of BMDM with CpG 1826, a B type CpG ODN, did not elicit a 
potent IFNα4 response in BMDM (data not shown). 
 
    
 
Figure 31: PTP1B does not regulate the TLR9-dependent IFNα4 response in primary 
BMDM. Primary BMDM were generated from wild type (WT), PTP1B-/-, and 3d mice. Cells were 
transfected with CpG 2336 (A, B) or CpG 1585 (C, D) for 6 h. qPCR was carried out with 150 ng 
(A, C) or 100 ng (B, D) RNA and IFNα4-specific primers. Data were normalized to Rpl8 and fold 
induction was calculated relative to untransfected cells. Results are shown as mean ± S.D. of 2 
independent experiments in duplicates, respectively. 
 
Together with the results described in 3.4.5, these data suggest that PTP1B is 
important for the type I IFN response upon MCMV infection, but is not involved in the 
TLR9-dependent IFNα response in primary BMDM. 
 
3.4.7. Knockout of PTP1B affects differentiation of bone marrow cells into 
FL-DC 
Plasmacytoid dendritic cells (pDC) produce high amounts of type I IFN in response to 
stimulation of TLR7, TLR9, and upon viral infection. Up to 40% of pDC can be 
generated by culturing bone marrow cells for 8 days in the presence of Flt3 ligand209. 
The Flt3 ligand is a growth factor which stimulates differentiation of bone marrow cells 
into dendritic cells. The majority of cells in Flt3 cultures that do not display the 
phenotype of pDC are conventional dendritic cells (cDC). cDC can only produce very 
small amounts of type I IFN upon TLR stimulation or viral infection. Because of their 
ability to produce high amounts of type I IFN, FL-DC were the cells of choice to further 
study the impact of PTP1B on the type I IFN response upon TLR stimulation and 
MCMV infection. 
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FL-DC were generated from bone marrow of wild type and PTP1B-/- mice by culturing 
with Flt3 ligand for 8 days. The absence of PTP1B in FL-DC derived from PTP1B-/- 
mice was verified by immunoblotting with a PTP1B-specific antibody (Figure 32A). 
Surprisingly, the total number of FL-DC differed substantially between cells derived 
from wild type and PTP1B-/- mice. Cell numbers of wild type and PTP1B-/- cells were 
determined on day 0, directly after preparation of the bone marrow, and on day 8, when 
they were used for experiments. On day 0, around 6 x 107 cells per mouse were 
obtained from the bone marrow preparation of wild type and PTP1B-/- mice. On day 8 
however, more than twice as many cells were counted in PTP1B-/- cultures compared 
to wild type cultures (Figure 32B).  
 
                     
 
Figure 32: Cell numbers of cells derived from PTP1B
-/-
 mice are higher than cell numbers 
of cells derived from wild type mice after 8 days of culture with Flt3 ligand. Immunoblot 
analysis of PTP1B protein expression in FL-DC generated from wild type (WT) and PTP1B-/- 
mice (A). PTP1B was detected using an antibody against endogenous PTP1B. Loading of equal 
amounts of protein was verified by anti-tubulin immunoblot. Bone marrow was prepared from 
wild type (WT) and PTP1B-/- mice (B). Cell numbers were determined directly after bone marrow 
preparation (day 0) and after 8 days of culture with Flt3 ligand. Data are shown as mean ± S.D. 
of 24 mice, respectively. 
 
The Flt3 receptor is a receptor tyrosine kinase (RTK) and a number of RTKs are 
regulated by PTP1B158,217. Therefore, the difference in FL-DC cell numbers obtained 
from wild type and PTP1B-/- mice most likely results from the fact that the Flt3 receptor 
is not functioning normally in the absence of PTP1B. 
When identical numbers of FL-DC from wild type and PTP1B-/- mice were seeded and 
stimulated with TLR agonists or ligands for intracellular DNA or RNA sensors, cells 
derived from PTP1B-/- mice consistently showed higher IFNα responses than wild type 
FL-DC (Figure 35). For this reason, FL-DC derived from wild type and PTP1B-/- mice 
were analyzed by flow cytometry using antibodies against CD11c, CD11b, B220, and 
Siglec-H and percentages of pDC and cDC populations were determined. pDC and 
cDC are positive for CD11c, which is a marker for dendritic cells. cDC are positive for 
CD11b and negative for B220. Vice versa, pDC are negative for CD11b and positive for 
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B220. Furthermore, cells were stained with an antibody against Siglec-H, a specific 
marker for murine pDC. Flow cytometry analysis of wild type and PTP1B-/- FL-DC 
revealed higher amounts of pDC in PTP1B-/- samples (Figure 33, A and B). FL-DC 
cultures from wild type mice contained about 30% of pDC (CD11b-
B220+CD11c+Siglec-H+), whereas FL-DC cultures from PTP1B-/- mice contained about 
40% of pDC and less cDC (CD11b+B220-CD11c+Siglec-H-). 
 
                   
 
Figure 33: FL-DC derived from PTP1B
-/-
 mice contain higher numbers of pDC than FL-DC 
from wild type mice. In vitro generated FL-DC from wild type (WT) and PTP1B-/- mice were 
stained with antibodies against CD11b, B220, CD11c, and Siglec-H and analyzed by flow 
cytometry. Representative dot plots are shown for FL-DC from WT and PTP1B-/- mice (A). 
Portions of cDC (CD11b+B220-CD11c+Siglec-H-) and pDC (CD11b-B220+CD11c+Siglec-H+) 
were calculated relative to the amount of living cells (B). Results are shown as mean ± S.D. of 2 
independent experiments. 
 
It seems very likely that the increased IFNα responses seen in FL-DC from PTP1B-/- 
mice were caused by the elevated numbers of pDC. Therefore, pDC were sorted from 
wild type and PTP1B-/- FL-DC by magnetic-activated cell sorting (MACS) and 
fluorescence-activated cell sorting (FACS). For MACS, FL-DC were incubated with a 
mix of antibodies against non-pDC and cells were sorted based on negative selection. 
For FACS, FL-DC were sorted using Siglec-H as a specific marker for pDC. Sorted 
pDC were stimulated with TLR agonists or ligands for intracellular DNA or RNA 
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sensors. However, even after sorting, cells from PTP1B-/- mice secreted higher 
amounts of IFNα and also TNF and IL-6 than wild type cells in response to all stimuli 
(data not shown). 
 
In conclusion, the data obtained for the IFNα response by FL-DC suggest that 
compared to wild type FL-DC, FL-DC from PTP1B-/- mice produce higher amounts of 
IFNα in response to TLR stimulation or MCMV infection. This stands in conflict with the 
observation that the type I IFN response upon MCMV infection in BMDM is impaired in 
the absence of PTP1B (Figure 29 and Figure 30). However, since the Flt3 receptor is 
regulated by PTP1B, we conclude that FL-DC generated from PTP1B-/- mice do not 
behave normally and therefore cannot be used to study the role of PTP1B for type I 
IFN responses. For this reason we were looking for other options or cell types to 
evaluate the role of PTP1B for TLR-dependent type I IFN responses. 
 
3.4.8. Inhibition of PTP1B with a specific inhibitor reduces the TLR-
dependent IFNα response in a PTP1B-independent manner 
Due to the fact that PTP1B regulates trafficking of the Flt3 receptor, FL-DC were not an 
ideal system to study the role of PTP1B for the type I IFN response. Therefore, FL-DC 
derived from wild type mice were treated with PTP1B inhibitors. Many different PTP1B 
inhibitors are commercially available. Two different inhibitors were used in this study to 
inhibit PTP1B in wild type FL-DC, MSI-1436 (trodusquemine) and PTP Inhibitor XXII. 
MSI-1436 and PTP Inhibitor XXII are selective, allosteric, and noncompetitive inhibitors 
of PTP1B with an IC50 of approximately 1 µM and 4 µM, respectively. MSI-1436 has 
been successfully used for the treatment of obesity and type 2 diabetes in mice218. 
Recently, a phase I clinical trial for MSI-1436 has been completed. 
Upon pretreatment of wild type FL-DC with 10 µM MSI-1436 for 4 h and subsequent 
TLR stimulation for 6 h in presence of the inhibitor, there was no effect on the IFNα 
response compared to FL-DC which had been treated with DMSO. However, flow 
cytometry analysis upon staining of MSI-1436-treated FL-DC with the DNA intercalator 
propidium iodide, which stains the DNA of dead cells, revealed that a dose of 20 µM 
MSI-1436 resulted in cell death (data not shown). 
We therefore first tested whether PTP inhibitor XXII induced apoptosis or cell death. 
Cells were treated with 50 or 150 µM of PTP Inhibitor XXII, z-FA-fmk, or DMSO as 
control, stained with 7-Aminoactinomycin (7-AAD) and Annexin V, and analyzed by 
flow cytometry. 7-AAD is a DNA intercalator and Annexin V binds to phosphatidylserine 
exposed on the cell surface of apoptotic cells. Staining of DMSO-treated FL-DC with 
7-AAD and Annexin V revealed a large population of about 62-68% of dead cells 
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positive for 7-AAD and Annexin V (Figure 34). Around 30% of living cells, which were 
negative for 7-AAD and Annexin V, were found in DMSO-treated FL-DC cultures. Upon 
treatment of wild type FL-DC with 50 or 150 µM of PTP Inhibitor XXII, the amount of 
dead cells was only slightly increased to around 70%. The amount of dead cells in 
FL-DC cultures, which had been treated with z-FA-fmk, was around 66%. Apoptotic 
cells should appear negative for 7-AAD and positive for Annexin V. However, 
populations of apoptotic cells were not identified in this experiment. Thus, PTP Inhibitor 
XXII did not induce apoptosis and did also not induce extensive cell death and was 
therefore used for functional experiments in wild type FL-DC. 
 
                    
 
Figure 34: Treatment of FL-DC with PTP Inhibitor XXII does not induce apoptosis. FL-DC 
from wild type mice were treated with indicated concentrations of PTP Inhibitor XXII, z-FA-fmk, 
or DMSO as control for 10 h. Cells were stained with 7-AAD and Annexin V and analyzed by 
flow cytometry. Percentages of living cells are depicted in lower left quadrants and percentages 
of dead cells are depicted in upper right quadrants. 
 
To study the role of PTP1B for the TLR-dependent IFNα response in pDC, FL-DC were 
pretreated with PTP Inhibitor XXII for 4 h and subsequently stimulated with the TLR9 
ligand CpG 2336 or transfected with the TLR7 ligand Poly(U) to initiate the production 
of IFNα. Amounts of IFNα in supernatants were measured by ELISA. Treatment of 
FL-DC with 10 µM PTP Inhibitor XXII did not affect IFNα responses upon TLR 
stimulation (data not shown). Upon treatment of FL-DC with 50 µM or 150 µM PTP 
Inhibitor XXII, the IFNα responses upon stimulation of TLR9 or TLR7 were reduced 
(Figure 35, A-D). Treatment of FL-DC with z-FA-fmk, an inhibitor of TLR9 and TLR7 
endosomal processing, confirmed that the IFNα responses upon stimulation with CpG 
2336 and Poly(U) were dependent on TLR9 and TLR7, respectively (Figure 35, E and 
F). 
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To ensure that the observed inhibitory effect was PTP1B-specific, PTP1B-/- FL-DC 
were included in the experiment. As described in 3.4.7, FL-DC derived from PTP1B-/- 
mice generally showed higher IFNα responses compared to wild type cells (Figure 35, 
A-F). However, similar to wild type FL-DC, they also showed reduced IFNα responses 
upon TLR stimulation in the presence of PTP inhibitor XXII (Figure 35, A-D). 
This leads to the conclusion that the inhibitory effect of PTP Inhibitor XXII on the IFNα 
response in wild type FL-DC was unspecific. In summary, the two tested PTP1B 
inhibitors were not suitable to study the type I IFN response upon TLR stimulation in 
primary cells. 
 
   
 
Figure 35: Treatment of wild type FL-DC with a PTP1B inhibitor leads to unspecific 
downregulation of the IFNα response upon TLR stimulation in FL-DC. FL-DC derived from 
wildtype (WT) or PTP1B-/- mice were incubated with 50 µM (A, B) or 150 µM (C, D) of PTP 
Inhibitor XXII or 1 µM z-FA-fmk (E, F) for 4 h. Subsequently, cells were stimulated with 1 µM 
CpG 2336 (A, C, E) or transfected with 1 µg/ml of Poly(U) (B, D, F) for additional 6 h in 
presence of the inhibitor. Levels of IFNα in supernatants were determined by ELISA. Results 
are shown as mean ± S.D. of one representative experiment in duplicates. 
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3.4.9. IFNα responses of total BM cells from PTP1B-/- mice are impaired 
upon TLR stimulation or infection with MCMV 
FL-DC from PTP1B-/- mice could not be used to study type I IFN responses, and 
treatment of wild type FL-DC with PTP1B inhibitors either induced cell death or was not 
specific. We therefore chose different sources of primary pDC. pDC are the main 
source of type I IFN. In mice, pDC are present in lymphoid organs including the spleen 
and bone marrow. Hence, pDC were isolated from spleens of wild type and PTP1B-/- 
mice with a negative selection approach using MACS. Unfortunately, cell numbers of 
splenic pDC after isolation were extremely low (less than 0.5% of total splenocytes) 
which made this approach inapplicable to study type I IFN responses in PTP1B-/- cells. 
 
Next, total bone marrow (BM) cells from wild type, PTP1B-/-, TLR9-/-, and 3d mice were 
stimulated with agonists for TLR9 or TLR7 or were infected with MCMV, and amounts 
of secreted IFNα in supernatants were measured by ELISA. Upon stimulation of TLR9 
with CpG 2336 or TLR7 with Poly(U), IFNα responses in cells from PTP1B-/- mice were 
decreased compared to cells from wild type mice (Figure 36, A and B). As expected, 
total BM cells from TLR9-/- mice did not respond to stimulation of TLR9, but produced 
amounts of IFNα similar to those produced by total BM cells from wild type mice upon 
stimulation of TLR7, and total BM cells from 3d mice did not respond to stimulation of 
TLR9 or TLR7 (Figure 36, A and B). However, due to the high variability of the 
measured IFNα responses, especially by the control cells from wild type mice, none of 
these effects was statistically significant. 
 
 
 
Figure 36: The IFNα response by total BM cells from PTP1B
-/-
 mice is impaired upon TLR 
stimulation or MCMV infection. Total BM cells were prepared from wild type (WT) (n=3), 
PTP1B-/- (n=3), TLR9-/- (n=2), and 3d (n=2) mice. Cells were stimulated with CpG 2336 (A), 
transfected with Poly(U) (B), or infected with MCMV-GFP (C) for 22 h. Levels of IFNα in 
supernatants were determined by ELISA. Results are shown as mean ± S.D. of n (as specified) 
independent experiments. Statistical significance compared to wild type controls was 
determined by two-tailed, unpaired t test; *, p<0.05. 
 
Upon MCMV infection, total BM cells from PTP1B-/- mice produced significantly lower 
amounts of IFNα than total BM cells from wild type mice (Figure 36C). Total BM cells 
from TLR9-/- and 3d mice did not respond to infections with MCMV indicating that the 
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recognition of MCMV by pDC in total BM cells is completely dependent on TLR9 
(Figure 36C). 
 
We next analyzed the proinflammatory cytokine responses in total BM cells from wild 
type, PTP1B-/-, TLR9-/-, and 3d mice. TNF and IL-6 levels in supernatants of total BM 
cells upon stimulation with the TLR9 ligand CpG 2336 or the TLR7 ligand Poly(U) or 
upon infection with MCMV were determined by ELISA. Compared to total BM cells from 
wild type mice, TNF as well as IL-6 responses were not decreased in total BM cells 
from PTP1B-/- mice upon stimulation of TLR7 or TLR9 or upon MCMV infection 
(Figure 37, A-F). Total BM cells from TLR9-/- and 3d mice did not produce TNF or IL-6 
in response to stimulation of TLR7 or 9 and secreted only very low amounts of TNF 
and IL-6 upon infection with MCMV. 
 
 
 
Figure 37: TNF and IL-6 responses upon TLR stimulation or MCMV infection are not 
impaired in total BM cells from PTP1B
-/-
 mice. Total BM cells were prepared from wild type 
(WT), PTP1B-/-, TLR9-/-, and 3d mice. Cells were stimulated with CpG 2336 (A, D), transfected 
with Poly(U) (B, E) or infected with MCMV (C, F) for 22 h. Levels of TNF (A-C) and IL-6 (D-F) in 
supernatants were determined by ELISA. Results are shown as mean ± S.D. of 2 independent 
experiments. Statistical significance compared to wild type controls was determined by two-
tailed, unpaired t test; *, p<0.05; **, p<0.01. 
 
In contrast to BMDM (Figure 29A), proinflammatory cytokine responses upon MCMV 
infection were almost completely dependent on TLR9 in total BM cells. This suggests 
that intracellular PRRs do not play an important role for viral infection with MCMV in 
total BM cells.  
Thus, PTP1B regulates the IFNα response, but not the proinflammatory cytokine 
response, upon stimulation of TLR7 and 9 and upon the TLR9-dependent recognition 
of MCMV in total BM cells. 
3. Results 90 
3.4.10. MEF express low amounts of PTP1B, but do not express TLR9 
Although mouse embryonic fibroblasts (MEF) do not produce high amounts of IFN, 
they can be used to study type I IFN responses. Especially the IFNβ response upon 
stimulation of cytosolic DNA or RNA sensors is often analyzed in MEF. The use of MEF 
has some advantages in comparison to the use of other kinds of primary cells. First, 
large numbers of cells can be obtained from one single embryo and MEF can be 
passaged several times before they stop proliferating. Second, MEF can easily be 
immortalized and, in contrast to primary BMDM or FL-DC, they can efficiently be 
transduced with retroviruses for the generation of stable cell lines. These 
characteristics should allow analysis of the role of the enzymatic function of PTP1B for 
its effect on type I IFN responses by transduction of immortalized PTP1B-/- MEF with a 
catalytically inactive mutant (D181A) of PTP1B. However, we first had to verify whether 
MEF express PTP1B and TLR9. 
MEF were prepared from embryos of wild type and PTP1B-/- mice 13.5 days post 
coitum (d.p.c.). To verify mRNA expression of PTP1B in MEF, qPCR analysis was 
carried out with PTP1B-specific primers on RNA from wild type and PTP1B-/- MEF and 
BMDM. qPCR analysis of PTP1B mRNA expression confirmed expression of 
endogenous PTP1B in wild type MEF (Figure 38A). The PTP1B mRNA expression in 
primary BMDM was 2.6-fold higher than in MEF. The specificity of the chosen 
primer/probe combination was validated with MEF and BMDM from PTP1B-/- mice. 
To analyze protein expression of PTP1B in MEF, immunoblotting using a PTP1B-
specific antibody was performed with lysates of wild type MEF, PTP1B-/- MEF, and 
PTP1B-/- MEF stably expressing empty vector or wild type or mutant (D181A) 
HA-PTP1B. Protein expression of endogenous PTP1B in MEF from wild type mice was 
not detected by anti-PTP1B immunoblotting (Figure 38B). In contrast, using the 
PTP1B-specific antibody, endogenous PTP1B was detected in BMDM by 
immunoblotting (Figure 25B). In MEF, PTP1B was only detected by immunoblotting in 
MEF stably expressing wild type HA-PTP1B or the catalytically inactive HA-PTP1B 
D181A (Figure 38B). Together, these data indicate that PTP1B is only weakly 
expressed in MEF and cannot be detected by immunoblotting with the available PTP1B 
antibody. 
 
To find out whether the TLR9-dependent type I IFN response to CpG DNA can be 
studied in MEF, total RNA from wild type MEF and MEF from PTP1B-/- mice was 
analyzed for expression of TLR9 by qPCR. No signal for TLR9 mRNA expression was 
detected in MEF from wild type or PTP1B-/- mice by qPCR using TLR9-specific primers 
(data not shown). In contrast, mRNA expression of TLR9 in BMDM was detected as 
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expected. For this reason MEF were not used to investigate the role of PTP1B for the 
TLR-dependent type I IFN response. 
 
       
 
Figure 38: Expression of endogenous PTP1B in MEF can be detected by qPCR, but not 
by immunoblotting. Primary MEF (n=1) and BMDM (n=2) were generated from wild type (WT) 
and PTP1B-/- mice. qPCR was carried out with 100 ng RNA and PTP1B-specific primers. Data 
were normalized to Rpl8 and fold induction was calculated relative to wild type MEF (A). Shown 
are mean ± S.D. of n (as specified) independent experiments. n.d., not detected. PTP1B-/- MEF 
were left untransduced (-) or transduced with empty vector (e.v.), wild type HA-PTP1B, or 
catalytically inactive HA-PTP1B D181A (B). Cells were lysed and an anti-PTP1B antibody was 
used for immunoblotting. Loading of equal amounts of protein was verified by anti-tubulin 
immunoblotting. 
 
3.4.11. PTP1B plays an important role for the TLR9-dependent IFNα and 
IL-12p40 response in vivo 
In vivo, injection of CpG DNA in mice leads to the production of IFNα. This response 
has been described to be exclusively mediated by pDC219,220. To study the role of 
PTP1B for the TLR9-dependent type I IFN and proinflammatory cytokine response in 
vivo, wild type and PTP1B-/- mice were challenged with CpG DNA and serum levels of 
IFNα, IL-12p40, TNF, and IL-6 2 or 6 h post injection were measured by ELISA. Upon 
intravenous injection (i.v.) of CpG A 2216, PTP1B-/- mice showed significantly reduced 
serum levels of IFNα and IL-12p40 compared to wild type mice (Figure 39, A and B). 
As expected, CpG A challenge of TLR9-/- mice did not lead to the production of relevant 
amounts of IFNα or IL-12p40. The control oligonucleotide GpC 2216 contains two GpC 
dinucleotides instead of CpG motifs and was used as a negative control. As expected, 
GpC 2216 did not elicit an IFNα or IL-12p40 response. 
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Figure 39: IFNα and IL-12p40 responses are impaired in PTP1B
-/-
 mice upon in vivo 
administration of CpG 2216. Wild type (WT), PTP1B-/-, and TLR9-/- mice were intravenously 
injected with 10 µg CpG 2216 or GpC 2216 control complexed with 30 µl DOTAP in PBS. 
Serum levels of IFNα (A) and IL-12p40 (B) 6 h post injection were determined by ELISA. 
Results are from 3 independent experiments with each point representing an individual mouse. 
**, p<0.01 by two-tailed, unpaired t test. 
 
Additionally, mice were challenged intraperitoneally (i.p.) with CpG B to analyze TNF 
and IL-6 responses upon stimulation of TLR9. Serum levels of TNF were comparable 
between wild type and PTP1B-/- mice (Figure 40A). However, serum levels of IL-6 were 
significantly elevated in PTP1B-/- mice compared to wild type mice (Figure 40B). The 
TNF and IL-6 responses to CpG B were strictly TLR9-dependent, as TLR9-/- mice did 
not produce TNF or IL-6 upon challenge with CpG B. 
 
                               
 
Figure 40: TNF and IL-6 responses are not reduced in PTP1B
-/-
 mice upon in vivo 
administration of CpG 1826. Wild type (WT), PTP1B-/-, and TLR9-/- mice were intraperitoneally 
injected with 60 µg CpG 1826 in PBS. Serum levels of TNF (A) and IL-6 (B) 2 h post injection 
were determined by ELISA. Results are from 3 independent experiments with each point 
representing an individual mouse. *, p<0.05 by two-tailed, unpaired t test; n.s., not significant. 
 
To make sure that the differences in immune responses upon CpG challenge in vivo 
did not arise from differences in the amount of immune cells between wild type and 
PTP1B-/- mice, immune cell populations in lymphoid organs were analyzed by flow 
cytometry. Single cell suspensions were prepared from spleen, lymph nodes, and bone 
marrow of wild type and PTP1B-/- mice and cells were stained with antibodies to identify 
B cell, T cell, cDC, and pDC populations (Figure 41). In the spleen pDC only made up 
around 0.25% of total cells (Figure 41B), which explains the low yield of pDC that was 
obtained upon splenic pDC isolation by MACS (3.4.9). It has been reported that 
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PTP1B-/- mice show significantly increased numbers of B cells in lymph nodes and 
bone marrow compared to wild type mice221. In the spleens of PTP1B-/- mice, the 
authors of this study detected a slight but not significant decrease of B cells compared 
to wild type mice221. In accordance with these findings, we detected a significant 
increase in the proportion of B cells (CD3-CD19+) in lymph nodes from PTP1B-/- mice 
compared to wild type mice (Figure 41A). In contrast, the proportion of B cells in the 
spleens from PTP1B-/- mice was significantly decreased compared to wild type mice. 
The proportions of CD4+ T cells (CD3+CD19-CD4+CD8α-) in spleen and lymph nodes 
were equal between wild type and PTP1B-/- mice, but there was a slight but significant 
increase in the proportion of CD8+ T cells (CD3+CD19-CD4-CD8α+) in the spleens of 
PTP1B-/- mice compared to wild type mice (Figure 41A). The proportions of CD8+ T 
cells in lymph nodes did not show significant differences between wild type and 
PTP1B-/- mice. The proportions of cDC (CD11c+CD11b+B220-) and pDC 
(CD11c+Siglec-H+mPDCA+) in bone marrow, spleen, and lymph nodes did not 
significantly differ between wild type and PTP1B-/- mice (Figure 41B). 
 
Together, the in vivo experiments performed with PTP1B-/- mice suggest an important 
role of PTP1B for the TLR9-dependent IFNα and IL-12p40 responses in vivo. Flow 
cytometry analysis of cell populations in lymphoid organs showed that there are small 
differences in B cell and T cell populations in spleen and lymph nodes between wild 
type and PTP1B-/- mice. However, since pDC are the main source for IFNα it is very 
unlikely that the observed effects can be attributed to abnormalities of immune cell 
populations in PTP1B-/- mice. 
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Figure 41: Knockout of PTP1B does not have an effect on cDC and pDC populations in 
mice. Single cell suspensions from spleen and inguinal lymph nodes of wild type (WT) and 
PTP1B-/- mice were stained with antibodies against CD3, CD19, CD4, and CD8α and analyzed 
by flow cytometry (A). Portions of B cells (CD3-CD19+) were calculated relative to the amount of 
living cells. Portions of CD4+ T cells (CD3+CD19-CD4+CD8α-) and CD8+ T cells (CD3+CD19-
CD4-CD8α+) were calculated relative to the amount T cells (CD3+CD19-). Single cell 
suspensions from bone marrow, spleen, and inguinal lymph nodes of WT and PTP1B-/- mice 
were stained with antibodies against CD11c, CD11b, B220, Siglec-H, and mPDCA and 
analyzed by flow cytometry (B). Portions of cDC (CD11c+CD11b+B220-) and pDC 
(CD11c+Siglec-H+mPDCA+) were calculated relative to the amount of living cells. Results are 
shown as mean ± S.D. of organs from 3 different mice, respectively. *, p<0.05; **, p<0.01 by 
two-tailed, unpaired t test; n.s., not significant. 
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3.4.12. Trafficking and processing of TLR9 and its interaction with UNC93B 
are not dependent on PTP1B 
TLR9 traffics from the ER to the endolysosomal compartment where it is proteolytically 
cleaved and initiates the production of proinflammatory cytokines and type I IFN upon 
binding of DNA. PTP1B could regulate TLR responses in different ways: it could, for 
example, mediate binding between UNC93B and TLR9, regulate endolysosomal 
trafficking of TLR9, or facilitate proteolytic processing of TLR9. Trafficking of TLR9 can 
be analyzed with TLR9-GFP, a fluorescent version of TLR974. Cleavage of TLR9-GFP 
can easily be analyzed by the detection of full-length TLR9-GFP and the C-terminal 
TLR9-GFP cleavage fragment upon anti-GFP immunoblotting. To gain insight into how 
PTP1B regulates TLR responses, TLR9-GFP mice were crossed with PTP1B-/- mice. 
These mice were used to study trafficking and processing of TLR9 in the absence of 
PTP1B. 
TLR9 binds UNC93B in the ER and traffics together with UNC93B from the ER to the 
endolysosome. If binding to UNC93B is disrupted, TLR9 cannot leave the ER55. To test 
whether UNC93B and TLR9 still interact in the absence of PTP1B, interaction between 
these two proteins was assessed by co-immunoprecipitation in primary BMDM derived 
from TLR9-GFP/PTP1B-/- and TLR9-GFP/WT mice. Endogenous UNC93B and PTP1B 
in input lysates were detected by immunoblotting with an UNC93B- or PTP1B-specific 
antibody, respectively (Figure 42A). UNC93B was recovered after an anti-GFP 
immunoprecipitation of TLR9-GFP in BMDM derived from TLR9-GFP/WT as well as 
TLR9-GFP/PTP1B-/- mice, indicating that UNC93B interacts with TLR9-GFP 
independently of PTP1B. 
To analyze whether trafficking of TLR9-GFP is still intact in the absence of PTP1B, 
primary BMDM from TLR9-GFP/WT and TLR9-GFP/PTP1B-/- mice were analyzed by 
live cell imaging. Unstimulated cells were incubated with lysotracker, a dye that labels 
acidic organelles like lysosomes in living cells. A large portion of TLR9-GFP was found 
in the ER and in lysotracker-positive compartments in BMDM from TLR9-GFP/WT as 
well as TLR9-GFP/PTP1B-/- mice (Figure 42B). To promote trafficking of TLR9-GFP to 
the endolysosomal compartment, cells were incubated with fluorescently labeled CpG 
DNA. Upon TLR9 stimulation, TLR9-GFP almost exclusively localized to CpG DNA-
positive endolysosomes (Figure 42C). Again, BMDM derived from TLR9-GFP/WT and 
TLR9-GFP/PTP1B-/- mice showed a similar subcellular distribution, indicating that 
endosomal trafficking of TLR9-GFP is intact in the absence of PTP1B. 
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Figure 42: Interaction with UNC93B and trafficking of TLR9-GFP are intact in primary 
BMDM from TLR9-GFP/PTP1B
-/-
 mice. Primary BMDM derived from TLR9-GFP/WT and 
TLR9-GFP/PTP1B-/- mice were lysed in 0.5% NP-40 and subjected to an anti-GFP immuno-
precipitation. Beads without addition of antibody were used as control. Endogenous UNC93B 
was detected by anti-UNC93B immunoblotting (A). Knockout of PTP1B was verified by anti-
PTP1B immunoblotting. Cells were incubated with lysotracker and left unstimulated (B) or 
stimulated with 1 µM CpG-Alexa647 (C) for 3.5 h and analyzed by confocal microscopy. Scale 
bar, 5 µm. 
 
TLR9 needs to be proteolytically cleaved by cathepsins in the endolysosomal 
compartment in order to initiate signal transduction. To find out whether cleavage of 
TLR9 occurs in the absence of PTP1B, primary BMDM derived from TLR9-GFP/WT 
and TLR9-GFP/PTP1B-/- mice were treated with the cathepsin inhibitor z-FA-fmk or 
DMSO and lysates were analyzed by anti-GFP immunoblotting. The C-terminal 
cleavage fragment of TLR9-GFP was detected in TLR9-GFP/WT as well as in 
TLR9-GFP/PTP1B-/- cells (Figure 43A). Inhibition of TLR9 cleavage with z-FA-fmk led 
to the accumulation of a high molecular weight form of TLR9 which has been described 
in earlier studies71,72. However, the C-terminal TLR9-GFP cleavage fragment was still 
present after treatment of the cells with z-FA-fmk for 15 h indicating that it is very stable 
and has a long half-life.  
Cleavage of TLR9-GFP was also assessed in pDC and cDC sorted from FL-DC 
derived from TLR9-GFP/WT, TLR9-GFP/UNC93B-/-, and TLR9-GFP/PTP1B-/- mice. 
Full length TLR9-GFP and the C-terminal TLR9-GFP cleavage fragment were detected 
in lysates of pDC and cDC from TLR9-GFP/WT and TLR9-GFP/PTP1B-/- FL-DC upon 
anti-GFP immunoblotting (Figure 43B). As expected, the C-terminal TLR9-GFP 
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cleavage fragment was not detected in pDC and cDC sorted from TLR9-GFP/ 
UNC93B-/- FL-DC. 
Collectively, these data suggest that trafficking and processing of TLR9 are 
independent of PTP1B. 
 
               
 
Figure 43: Processing of TLR9-GFP in primary BMDM, pDC, and cDC is independent of 
PTP1B. Primary BMDM from TLR9-GFP/WT and TLR9-GFP/PTP1B-/- mice were incubated with 
10 µM z-FA-fmk or DMSO for 15 h (A). cDC (B220-CD11b+) and pDC (B220+CD11b-) were 
sorted from TLR9-GFP/WT, TLR9-GFP/UNC93B-/-, and TLR9-GFP/PTP1B-/- FL-DC by FACS 
(B). TLR9-GFP and its C-terminal cleavage fragment were detected by anti-GFP immuno-
blotting. Knockouts of UNC93B and PTP1B were verified by anti-UNC93B and anti-PTP1B 
immunoblotting, respectively. 
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3.4.13. UNC93B, TLR9, and Clptm could be potential substrates of PTP1B 
PTP1B regulates trafficking of RTKs by dephosphorylation of tyrosine residues. TLR9 
has been shown to be tyrosine phosphorylated in response to stimulation with CpG 
DNA222,223. Where exactly TLR9 is phosphorylated is not clear. A tyrosine-based motif 
in the cytoplasmic tail of TLR9 (Y888NEL) was shown to be required for the TNF 
response, but not for the type I IFN response, upon TLR9 stimulation with CpG DNA in 
macrophages223. Although Y888 was not phosphorylated itself, TLR9 could not be 
phosphorylated and induce a TNF response upon stimulation with CpG DNA when Y888 
was substituted with alanine. This indicates that the structure of the Y888NEL motif is 
important for phosphorylation of TLR9 and its ability to induce the production of TNF. 
To identify potentially phosphorylated tyrosine residues in UNC93B and TLR9, 
UNC93B and TLR9 peptide sequences were screened for potential tyrosine 
phosphorylation sites. Seven putative tyrosine phosphorylation sites in UNC93B were 
found by bioinformatic analysis (CBS prediction servers, NetPhos 2.0). Potential 
tyrosine phosphorylation sites in UNC93B are: Y8, Y52, Y94, Y99, Y159, Y182, and Y191, 
with high scores for Y94 and Y99 (Figure 44A). For TLR9, three potential phosphorylation 
sites were found by bioinformatic analysis: Y180, Y321, and Y980 (Figure 44B). However, 
Y180 and Y321 are part of the luminal TLR9 ectodomain which makes it very unlikely that 
these two tyrosine residues are dephosphorylated by PTP1B, because the catalytic 
domain of PTP1B faces the cytoplasm. Y980 is part of the cytoplasmic domain of TLR9 
which makes it accessible for PTP1B.  
Clptm, which binds to UNC93B, PTP1B, and possibly TLR9, could be another potential 
substrate of PTP1B (Figure 19, Figure 22, and Figure 23). Bioinformatic analysis of the 
Clptm peptide sequence revealed eleven potential tyrosine phosphorylation sites: Y146, 
Y165, Y229, Y265, Y276, Y284, Y292, Y335, Y463, Y471, and Y546 (CBS prediction servers, 
NetPhos 2.0) (Figure 44C). Eight of these predicted phosphorylation sites are located 
within the large predicted luminal N-terminus of Clptm which makes them inaccessible 
for PTP1B. The residual three predicted tyrosine phosphorylation sites are located in 
predicted cytosolic domains of Clptm where they would be accessible for PTP1B. 
It has been described that PTP1B has a high affinity for tandem phosphotyrosine 
(pTyr)-containing peptides224. Analysis of the UNC93B peptide sequence revealed 
three tandem pTyr motifs: Y52Y, Y158Y, and Y190Y. All of the three tandem pTyr motifs 
include one tyrosine residue which had also been identified as putative phosphorylation 
site by bioinformatic analysis. Based on the predicted membrane topology of UNC93B, 
Y52Y and Y190Y would be accessible for PTP1B (Figure 44A). Analysis of the TLR9 
peptide sequence revealed only one tandem pTyr motif (Y179Y) which is one of the 
potential phosphorylation sites located in the ectodomain of TLR9 (Figure 44B). Clptm 
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contains two tandem pTyr motifs (YY276, YY292) which are located in the N-terminal 
domain of Clptm facing the luminal side of the ER (Figure 44C). It has further been 
shown that an acidic and a basic residue, flanking the tandem pTyr motif on the N- and 
the C-terminal side, respectively, contribute to the high affinity of PTP1B for tandem 
pTyr motifs and that (E/D)-pY-pY-(R/K) is a consensus substrate recognition motif for 
PTP1B187,224. However, none of the tandem pTyr motifs identified in UNC93B (RY52YR, 
RY158YT, and KY190YE), TLR9 (CY179YK), and Clptm (DYY276P, DYY292P) completely 
matches these criteria. 
 
        
 
Figure 44: UNC93B, TLR9, and Clptm have several potential tyrosine phosphorylation 
sites. Potential tyrosine phosphorylation sites in UNC93B (A), TLR9 (B), and Clptm (C) 
identified by bioinformatic analysis (CBS prediction servers, NetPhos 2.0) are highlighted in red. 
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In order to find out whether UNC93B, Clptm, or TLR9 are phosphorylated, we tried to 
detect phosphorylation of endogenous UNC93B, endogenous Clptm, UNC93B-GFP, 
and TLR9-GFP in immortalized and primary BMDM upon immunoprecipitation with 
anti-UNC93B, anti-Clptm, or anti-GFP antibodies by immunoblotting using an antibody 
against pTyr. Unfortunately, we were not successful in showing phosphorylation of 
UNC93B, Clptm, or TLR9 in preliminary experiments. 
 
In summary, UNC93B, TLR9, and Clptm could be potential substrates of PTP1B. 
However, in preliminary experiments we could not yet show whether UNC93B, Clptm, 
or TLR9 are phosphorylated and are indeed substrates of PTP1B. 
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4. Discussion 
4.1. Characterization of innate immune signaling by UNC93B 
knockout mice 
TLRs are located on the cell surface or intracellularly and recognize structurally 
conserved microbial features. Upon ligand binding, activated TLRs induce a potent 
innate immune response which leads to the elimination of infected cells and the 
activation of a specific adaptive immune response. The recognition of nucleic acids by 
intracellular TLRs in the endolysosome has been well documented21-24,41,43, but how 
exactly the trafficking of intracellular TLRs from the ER to the endolysosome is 
regulated is not completely understood. The polytopic ER resident membrane protein 
UNC93B binds to the transmembrane domains of nucleic acid-sensing TLRs 3, 7, and 
9 and delivers them from the ER to the endolysosomal compartment where they can 
bind their ligands and initiate the production of proinflammatory cytokines and type I 
IFN54,55. A single histidine-to-arginine point mutation in UNC93B (H412R) causes 
defective signaling of nucleic acid-sensing TLRs52. Mice carrying the H412R point 
mutation were termed “triple defect” (3d) mice because they fail to respond to agonist 
stimulation of TLRs 3, 7, and 952. The H412R mutation disrupts binding of UNC93B to 
intracellular TLRs and UNC93B as well as TLR7 and TLR9 fail to leave the ER54,55. 3d 
mice have exclusively been used to study the role of UNC93B for the trafficking of 
intracellular TLRs. However, since mutated UNC93B is still present in the ER of cells 
derived from 3d mice, it could still fulfill yet unknown functions besides the regulation of 
intracellular TLR trafficking. Additionally, ENU mutagenesis usually induces various 
point mutations which further complicates the characterization of UNC93B in cells 
derived from 3d mice. UNC93B knockout (UNC93B-/-) mice were only recently made 
publicly available which offers the possibility to further study the function of UNC93B. In 
this study, innate immune responses were compared between innate immune cells 
derived from UNC93B-/- and 3d mice. Proinflammatory cytokine and type I IFN 
responses were analyzed upon stimulation of TLRs and cytosolic PRRs with synthetic 
ligands and upon herpesviral infections in primary macrophages and dendritic cells 
derived from wild type, UNC93B-/-, and 3d mice. 
An antibody raised against C-terminal peptides of UNC93B specifically detected 
endogenous UNC93B in BMDM and FL-DC and confirmed the absence of UNC93B in 
BMDM and FL-DC derived from UNC93B-/- mice (Figure 8). Upon stimulation of TLRs 
with synthetic agonists, BMDM derived from UNC93B-/- mice responded exactly as 
BMDM derived from 3d mice. Like BMDM derived from wild type and 3d mice, BMDM 
from UNC93B-/- mice secreted the proinflammatory cytokines TNF and IL-6 in response 
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to stimulation of cell surface TLRs. In contrast, BMDM derived from UNC93B-/- and 3d 
mice did not respond to stimulation of intracellular TLRs, whereas wild type BMDM 
induced the production of TNF and IL-6 in response to stimulation of TLRs 3, 7, and 9 
(Figure 9 and Figure 10). Cells derived from heterozygous UNC93B+/- mice expressed 
similar protein levels of UNC93B as wild type cells (Figure 8) and did not show 
differences to wild type BMDM upon stimulation of TLRs with synthetic agonists of cell 
surface and intracellular TLRs (Figure 9 and Figure 10). The UNC93B+/- data lead to 
the conclusion that only a complete loss of UNC93B leads to the 3d phenotype. 
 
To assess the role of UNC93B in the context of viral infections, primary BMDM and 
FL-DC were infected with the murine herpesviruses mouse cytomegalovirus (MCMV) 
and murine herpesvirus 68 (MHV-68) followed by the analysis of proinflammatory 
cytokine and type I IFN responses. Previous studies showed that intracellular TLRs 3, 
7, and 9 are involved in the recognition of MCMV93,94. MCMV infection induced the 
production of comparable amounts of TNF, IL-6, IFNα, and IFNβ by BMDM derived 
from UNC93B-/- and 3d mice (Figure 11 and Figure 12). There were no significant 
differences in TNF, IL-6, IFNα, and IFNβ responses between BMDM derived from 
UNC93B-/- and 3d mice compared to BMDM from wild type and TLR9-/- mice. However, 
upon MCMV infection, BMDM derived from UNC93B-/- and 3d mice produced 30-55% 
less TNF and IL-6 than wild type BMDM (Figure 11, A and B). This suggests that type I 
IFN response in BMDM upon MCMV infection is completely independent of intracellular 
TLRs, whereas the production of proinflammatory cytokines depends on intracellular 
TLRs to a limited extend. Studies which reported the involvement of intracellular TLRs 
in proinflammatory cytokine and type I IFN responses upon MCMV infection mainly 
focus on pDC and in vivo studies93,94. The impairment of TNF and IL-6 responses upon 
MCMV infection of BMDM from UNC93B-/- and 3d mice indicates that intracellular TLRs 
are at least partially involved in the proinflammatory cytokine response against MCMV 
in BMDM, although the absence of TLR9 alone did not have an effect on TNF and IL-6 
levels. To clarify the role of intracellular TLRs 3, 7, and 9 for proinflammatory cytokine 
responses upon MCMV infection of BMDM, BMDM derived from TLR3-/- and TLR7-/- 
mice should be included in further experiments.  
Herpesviral DNA is recognized by intracellular TLRs in the endolysosome or by PRRs 
in the cytosol90. The first cytosolic DNA sensor which was identified to recognize 
MCMV is AIM2130. However, the activation of AIM2 leads to inflammasome formation, 
which results in the secretion of IL-1β and IL-18, and does not contribute to TNF, IL-6, 
or type I IFN responses. MDA5, RNA Polymerase III, RIG-I, DAI, IFI16, and DHX9 and 
DHX36 have been linked to the innate immune recognition of herpes simplex virus 
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(HSV) and human cytomegalovirus (HCMV)90. Therefore, it is likely that at least some 
of the cytosolic PRRs, which have been described to detect HSV or HCMV, are also 
involved in the detection of MCMV. Preliminary data suggest that the production of 
TNF, IL-6, IL-12p40, IFNα, and IFNβ upon MCMV infection of BMDM is impaired in the 
absence of STING (Baca Chan, unpublished results). STING is a key regulator of the 
cytosolic DNA response and acts downstream of cytosolic DNA sensors including 
cGAS, DAI, IFI16, DDX41, MRE11, and DNA-PK. In order to show that pro-
inflammatory cytokine and type I IFN responses upon MCMV infection of BMDM are 
dependent on cytosolic PRRs, BMDM derived from STING-deficient mice could be 
included in further experiments. The observation that intracellular TLRs do not play an 
important role for the proinflammatory cytokine and no role for the type I IFN response 
upon MCMV infection of BMDM was further supported by a microarray experiment that 
was conducted with MCMV infected BMDM from wild type and UNC93B-/- mice 2 and 
6 h post infection (Figure 13). However, the microarray experiment was only performed 
once and should be confirmed by at least one more experiment. Furthermore, BMDM 
derived from 3d mice should be included in the experiment in order to compare the 
induction of genes involved in the innate immune response between BMDM derived 
from UNC93B-/- and 3d mice. 
In contrast to MCMV, BMDM which had been infected with MHV-68 produced very low 
amounts of TNF and IL-6 even at high MOIs (Figure 11) and no IFNα production was 
detected upon MHV-68 infection of BMDM (data not shown). Based on this 
observation, we recently showed that BMDM infected with MHV-68 do not secrete TNF 
or IL-6 upon TLR stimulation (Bussey et al., submitted)201. This demonstrates that 
MHV-68 can manipulate proinflammatory cytokine responses to evade recognition by 
the innate immune system. 
 
pDC secrete high amounts of IFNα upon activation of TLRs 7 or 9, but they do not 
express TLR3106,206,207. TLR7 and TLR9 contribute to the innate immune response 
against MCMV in pDC92,94. In this study, MCMV infection induced the secretion of high 
amounts of IFNα in FL-DC derived from wild type or TLR7-/- mice, but the IFNα 
response was significantly impaired in FL-DC from TLR9-/- mice (Figure 14C). In FL-DC 
from UNC93B-/- and 3d mice, the IFNα response was reduced to the background level. 
This result confirms the observation of an earlier study which showed that pDC from 
TLR9-/-, but not from TLR7-/- mice, produce significantly lower amounts of type l IFN 
than wild type pDC, whereas the type I IFN response is completely abolished in pDC 
from mice deficient of TLR9 and TLR794. The authors concluded that TLR7 can partially 
compensate the TLR9 deficiency, which most likely also applies to the observations 
4. Discussion 104 
described here. Only upon MCMV infection of FL-DC from UNC93B-/- or 3d mice, when 
TLR7 and TLR9 were not functional, the IFNα response was completely abrogated 
(Figure 14C). How exactly TLR7, which is a sensor for single-stranded RNA, senses 
MCMV in the endolysosome is not clear. HCMV, another betaherpesvirus, has been 
reported to deliver viral mRNAs, which are packaged within the infectious virions, to the 
host cell225. Therefore, TLR7 most likely senses virion- or replication-associated viral 
RNA upon MCMV infection90. Overlapping functions of TLR7 and TLR9 were also 
shown for TNF and IL-12p40 responses in MCMV infected pDC94. Analyses of 
proinflammatory cytokine levels upon MCMV infection of FL-DC were not included in 
this study. However, to see whether intracellular TLRs and UNC93B in addition to the 
type I IFN response also mediate proinflammatory cytokine responses, it would be 
interesting to analyze TNF, IL-6, and IL-12p40 levels in supernatants of MCMV infected 
FL-DC. 
The amounts of secreted IFNα upon infection of FL-DC with MHV-68 were lower than 
the IFNα amounts secreted upon MCMV infection, but the response pattern was 
similar. MHV-68 induced the production of IFNα in wild type FL-DC, whereas it did not 
induce an IFNα response in FL-DC from UNC93B-/- or 3d mice (Figure 14D). A role for 
TLR9 has previously been implicated in the recognition of MHV-68 in FL-DC96. We also 
observed a significantly impaired but measurable IFNα response upon MHV-68 
infection of FL-DC derived from TLR9-/- mice (Figure 14D). Since MHV-68 infection did 
not induce an IFNα response in FL-DC from UNC93B-/- and 3d mice, at least one more 
UNC93B-dependent sensor must be involved in the recognition of MHV-68 in FL-DC. 
This role could be fulfilled by TLR7. Upon infection with MHV-68, the amount of 
secreted IFNα by FL-DC from TLR7-/- mice was 2-fold lower than the amount of IFNα 
secreted by wild type FL-DC (Figure 14D). To our knowledge TLR7 has not been 
implicated in the recognition of MHV-68 so far. This result suggests that, in addition to 
TLR9, TLR7 is involved in the type I IFN response upon MHV-68 infection of FL-DC 
and that similar to the recognition of MCMV, TLR7 and TLR9 have overlapping 
functions in the recognition of MHV-68. IL-6 and IL-12 proinflammatory cytokine 
responses upon MHV-68 infection are also dependent on TLR9 in FL-DC96. To 
investigate the role of TLR7 for proinflammatory cytokine responses upon MHV-68 
infection of FL-DC, TNF, IL-6, and IL-12 levels in supernatants of infected FL-DC 
should be determined. 
 
In addition to TLRs, cytosolic DNA and RNA sensors were also stimulated in FL-DC. 
Surprisingly, IFNα responses in FL-DC upon transfection with ISD or 5`ppp-dsRNA 
were dependent on UNC93B and the response upon ISD stimulation was also 
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dependent on TLR9 (Figure 15). ISD is described to be recognized by cytosolic DNA 
sensors in a TLR-independent manner in FL-DC and BMDM107. A previous study 
showed that the IFNα response in FL-DC upon transfection with ISD was completely 
dependent on STING117. 5`ppp-dsRNA is a ligand for the cytosolic RNA sensor 
RIG-I211. Why IFNα responses upon stimulation of FL-DC with ISD and 5`ppp-dsRNA 
were dependent on UNC93B is not clear. The interpretation of these results is 
complicated by the fact that FL-DC are not a homogenous cell population. FL-DC are a 
mix of about 40% pDC and 60% cDC, but the proportions can vary between different 
preparations. pDC are the main producers of IFNα in FL-DC cultures, but cDC also 
produce small amounts of type I IFN upon stimulation210. Therefore, the possibility that 
especially the low IFNα response, which was observed upon stimulation of FL-DC with 
5`ppp-dsRNA, was mediated by cDC and not by pDC cannot be excluded. If the 
response to 5`ppp-dsRNA was mediated by cDC, it could be dependent on TLR3, 
which is expressed in cDC, but not in pDC. Analysis of the proteome of cDC and pDC 
confirmed expression of STING in cDC as well as in pDC106. To study the role of 
intracellular TLRs and UNC93B for the type I IFN response upon stimulation with ISD 
or 5`ppp-dsRNA in pDC or cDC, the experiment should be repeated with pDC and cDC 
sorted from FL-DC cultures including cells derived from TLR3-, TLR7-, and STING-
deficient mice.  
 
In summary, we conclude that at least in the experiments described here, the 
phenotype of innate immune cells from UNC93B-/- mice does not differ from the 
phenotype observed for cells derived from 3d mice. Additionally, we suggest a 
previously undescribed role for TLR7 for the recognition of the gammaherpesvirus 
MHV-68 in FL-DC and overlapping functions of TLR7 and TLR9 in the recognition of 
MHV-68 in FL-DC. 
 
 
4.2. Characterization of the role of Clptm and Trex1 for TLR- and 
UNC93B-mediated immune responses 
To improve our understanding of the regulation of UNC93B-TLR complexes, novel 
UNC93B interaction partners were identified and characterized in this study. Clptm is 
an uncharacterized protein which was found to interact with wild type and mutant 
(H412R) UNC93B by large scale immunoprecipitation and mass spectrometry analysis 
(Figure 16A). The interaction between Clptm and wild type as well as mutant UNC93B 
in macrophages was confirmed by co-immunoprecipitation experiments (Figure 19). A 
recent study, which systemically investigated the human innate immune signaling 
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network regulating the production of type I IFN, also found Clptm as UNC93B 
interaction partner226. In this study, 58 proteins with known functions in the regulation of 
type I IFN production, including UNC93B, were used as baits to get insight into the 
human innate immunity interactome for type I IFN. The interaction between human 
UNC93B and Clptm was verified by co-immunoprecipitation in HEK 293T cells226. This 
study supports our finding that Clptm interacts with UNC93B and indicates that human 
UNC93B and human Clptm also interact. 
Since, to our knowledge, Clptm knockout mice do not exist, a stable shRNA-mediated 
knockdown of Clptm was performed in macrophages in order to find out whether Clptm 
regulates the TLR-dependent proinflammatory cytokine response. Protein expression 
of Clptm was efficiently reduced upon expression of two different shRNAs targeting 
Clptm (Figure 20A). Besides control shRNAs targeting unrelated proteins, three 
shRNAs targeting UNC93B, which is known to be crucial for innate immune responses 
mediated by intracellular TLRs 3, 7, and 9, were included as positive controls. The 
shRNA-mediated knockdown of UNC93B was also successful (Figure 20A). As 
expected, compared to macrophages stably expressing control shRNAs, the TNF 
response in macrophages stably expressing sh-UNC1 and sh-UNC2 was impaired 
upon stimulation of TLR9 (Figure 20C). Surprisingly, in comparison to macrophages 
expressing control shRNAs, the TLR4-dependent TNF response was also impaired in 
BMDM stably expressing shRNAs targeting UNC93B, but to a lesser extent than upon 
TLR9 stimulation (Figure 20B). This stands in contrast to the data obtained with BMDM 
derived from UNC93B-/- or 3d mice (Figure 9C). Why the shRNA knockdown of 
UNC93B affected TNF levels upon stimulation of TLR4 in macrophages is not clear. 
Before macrophages were stimulated with TLR agonists, they were counted and 
identical cell numbers were seeded. Usually, the seeding of equal amounts of cells was 
verified by lysis and the determination of protein amounts in these lysates. However, 
seven different stable shRNA-expressing macrophage cell lines were generated here, 
and not all of them always showed exactly the same growth behavior. These 
differences in the growth rates could be the cause for the observed differences in the 
proinflammatory cytokine responses upon TLR stimulation. The possibility of off-target 
effects, which are a major disadvantage using shRNAs, can also not be excluded. 
However, since at least a slight downregulatory effect on the TLR4-dependent TNF 
response upon expression of all three UNC93B-targeting shRNAs was observed, it is 
not very likely that this downregulation was mediated by off-target effects. In this study, 
only one representative experiment is shown and especially upon stimulation of TLR4, 
the standard deviations were quite high for some of the samples. However, a slight 
downregulatory effect on the TLR4-dependent TNF response upon expression of 
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UNC93B-targeting shRNAs was observed in other experiments as well. To find out 
whether this is a significant effect, more experiments should be conducted in order to 
reduce standard deviations and to perform statistical analysis. TLR4- and TLR9-
dependent TNF responses upon stimulation with the specific agonists LPS and 
CpG 1826 did not differ between macrophages expressing Clptm-targeting shRNAs 
and control shRNA (Figure 20, B and C). Thus, a regulatory function of Clptm for cell 
surface TLR4 and intracellular TLR9 signaling could not be shown. To find out whether 
proinflammatory cytokine responses of other TLRs besides TLR4 and TLR9 are 
regulated by Clptm, additional TLR agonists for the stimulation of TLR3 and TLR7 
should be included in further experiments. Furthermore, other proinflammatory 
cytokines could be tested and the cells could be infected with MCMV to investigate 
whether Clptm has a role for proinflammatory cytokine responses upon viral infection of 
macrophages. However, protein knockdowns are never complete and thus there is 
always the possibility that the remaining protein level of Clptm is sufficient to regulate 
innate immune responses. Another disadvantage of the shRNAs is the variability in the 
efficiency of the knockdown. To circumvent this problem, stable cell lines expressing 
the different shRNA constructs were generated in this study. However, although the 
cells were always kept under antibiotic selection, the efficiency of the protein 
knockdowns decreased after a few passages. 
Unfortunately, Clptm knockout mice are not available and primary cells such as FL-DC 
cannot efficiently be transduced with retroviruses. For this reason the role of Clptm for 
TLR-dependent type I IFN responses in FL-DC or pDC could not be studied. However, 
the role of Clptm for the TLR-dependent type I IFN response could be studied in 
macrophage reporter cell lines stably expressing Clptm-targeting shRNAs. To study the 
IFNα response, RAW macrophages stably expressing an IFNα4-turboGFP reporter 
construct could be used. The IFNβ response could be studied in immortalized BMDM 
generated from IFNβ+/∆β-luc reporter mice which express luciferase under transcriptional 
control of the IFNβ promoter195. Alternatively to an shRNA knockdown of Clptm, the 
use of the recently described clustered regularly interspaced short palindromic repeat 
(CRISPR)-Cas knockout system might be more effective to stably disrupt gene 
expression of Clptm227. 
In summary, apart from the observation that Clptm interacts with UNC93B, a role for 
Clptm for TLR-dependent innate immune signaling could not be shown in this study. 
 
The exonuclease Trex1 was found to interact with HA-tagged wild type and mutant 
UNC93B and Clptm by large scale immunoprecipitation and mass spectrometry 
analysis (Figure 16). Trex1 has been reported to interact with the cytosolic side of the 
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ER membrane141. Trex1 co-localized with Clptm at the ER (Figure 21A). Interactions 
between Trex1 and Clptm as well as UNC93B were verified by co-immunoprecipitation 
in macrophages (Olga Trupp, bachelor thesis 2011). Using N- and C-terminally 
truncated versions of Trex1, it was further shown that Clptm interacts with the luminal 
exonuclease domain of Trex1, but not with the hydrophobic membrane anchor domain 
(Figure 21B). This was unexpected, since the C-terminally truncated version of Trex1 
(aa 1-235) has been reported to localize diffusely throughout the cell because of its 
missing ER anchor, whereas the N-terminally truncated version of Trex1 (aa 236-314) 
as well as full-length Trex1 localize to the ER141. However, in this report, the 
localization of the C- and N-terminally truncated versions of Trex1 has only been 
analyzed in transfected HeLa cells141. Therefore, the localization of the truncated 
versions of Trex1, which were generated in this study, should be verified by co-
localization experiments in macrophages using an ER marker. Co-localization of the 
truncated versions of Trex1 with Clptm should also be analyzed. 
Trex1 digests cytosolic DNA and is a negative regulator of the ISD response. If 
UNC93B or Clptm are important for the function of Trex1, the type I IFN response upon 
ISD stimulation should be upregulated in macrophage reporter cell lines (RAW IFNα4-
turboGFP or immortalized BMDM generated from IFNβ+/∆β-luc reporter mice) stably 
expressing shRNAs targeting UNC93B or Clptm. To study the role of UNC93B or Clptm 
for the function of Trex1, type I IFN response upon ISD stimulation could alternatively 
be analyzed by qPCR in MEF or BMDM derived from UNC93B-/- mice or upon 
CRISPR-Cas knockout of Clptm. 
 
The ER resident protein STING is a key regulator of the response to cytosolic DNA and 
was found to interact with Clptm (Figure 16B). The interaction between STING and 
Clptm was verified by co-immunoprecipitation in macrophages, an interaction between 
STING and wild type UNC93B was not detected (Olga Trupp, bachelor thesis 2011). 
Since Clptm interacts with STING, Clptm could play a role in sensing cytosolic DNA. 
The IFNβ response upon stimulation of cytosolic PRRs is often analyzed in MEF which 
can easily be transduced with retroviruses. In order to investigate the role of Clptm for 
the STING-dependent type I IFN response, wild type MEF transduced with shRNAs 
targeting Clptm could be used to study the role of Clptm for the localization and 
trafficking of STING and for the type I IFN response upon stimulation of cytosolic 
PRRs. 
 
In all co-immunoprecipitation experiments for the investigation of interactions between 
the ER proteins UNC93B, Clptm, Trex1, and STING in macrophages, cells were lysed 
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with the mild detergent digitonin in order to preserve weak protein interactions. These 
co-immunoprecipitation experiments should be repeated with a stronger detergent, for 
example NP-40, to ensure complete solubilization of the ER membrane. 
In order to investigate whether UNC93B is important for the localization of Clptm, 
Trex1, or STING, localization studies could be performed in cells derived from 
UNC93B-/- mice. 
 
In summary, in this study, interactions between wild type and mutant (H412R) UNC93B 
and Clptm, between Trex1 and Clptm as well as wild type UNC93B, and between 
Clptm and STING in macrophages were shown by co-immunoprecipitation. This 
indicates that all these proteins form a large complex in the ER membrane. The 
relevance of these interactions for the innate immune response needs to be elucidated 
in further studies. 
 
 
4.3. Characterization of the role of protein tyrosine phosphatase 
PTP1B for TLR and innate immune signaling 
Protein tyrosine phosphatase PTP1B was identified as an interaction partner of wild 
type and mutant (H412R) UNC93B and Clptm (Figure 16). PTP1B terminates signaling 
of receptor tyrosine kinases (RTKs) by dephosphorylation and thereby regulates 
endocytosis and endosomal trafficking of RTKs158.  
The interactions of HA-PTP1B with wild type and mutant UNC93B, Clptm, TLR7, and 
TLR9-GFP were confirmed by co-immunoprecipitations in transfected HEK 293T cells 
and immortalized macrophages (Figure 22 and Figure 23). So far, it is not clear which 
of the demonstrated interactions are direct interactions and which interactions are 
indirect interactions mediated by another protein. In order to get an idea of how PTP1B 
could regulate innate immune signaling, it would be helpful to find out whether PTP1B 
directly interacts with UNC93B or with TLR9. HEK 293 cells do not express 
endogenous TLR9208. The fact that an interaction between UNC93B-GFP and 
HA-PTP1B was observed in transfected HEK 293T cells therefore indicates that 
UNC93B and PTP1B interact in the absence of TLR9. This suggests an indirect 
interaction between TLR9 and PTP1B via UNC93B. However, we cannot draw this 
conclusion yet since it is not clear whether HEK 293T cells express endogenous 
UNC93B. The fact that HEK 293 cells stably expressing human or murine TLR9 
reporter constructs are commercially available and functional indicates that UNC93B is 
expressed in HEK 293 cells and that human UNC93B, which has 90% amino acid 
identity with murine UNC93B54, can mediate trafficking of murine TLR9. On the other 
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hand, we did not detect cleavage of TLR9 in HEK 293T cells transfected with 
TLR9-GFP. This suggests that signaling of at least murine TLR9 in HEK 293T cells 
differs from TLR9 signaling in murine immune cells. Proteolytic cleavage of TLR9 is 
required for TLR9 signaling in murine cells, but cleavage of TLR9 may not be 
necessary to induce downstream signaling in HEK 293T cells71,72. It was shown that 
UNC93B acquires Endo H resistance when it is transiently expressed in HEK 293T 
cells indicating that Golgi trafficking of murine UNC93B is intact in HEK 293T cells78. To 
find out whether PTP1B directly interacts with TLR9-GFP or with UNC93B, co-
immunoprecipitations can be performed with lysates of BMDM derived from 
TLR9-GFP/UNC93B-/- or TLR9-/- mice, respectively. Cells derived from UNC93B-/- mice 
can also be used to analyze whether Clptm still interacts with PTP1B in the absence of 
UNC93B. Unfortunately, the antibody for detection of endogenous PTP1B is not very 
sensitive and did not precipitate or detect precipitated PTP1B in first preliminary co-
immunoprecipitation experiments using lysates of BMDM from UNC93B-/- or TLR9-/- 
mice. Nevertheless, given that TLR9 has no functional relevance in HEK 293T cells, 
further interaction studies should focus on the co-immunoprecipitation experiments with 
BMDM from UNC93B-/- and TLR9-/- mice. In BMDM derived from TLR9-GFP/PTP1B-/- 
mice the interaction between UNC93B and TLR9-GFP was intact, indicating that 
PTP1B is not required for their interaction (Figure 42). 
Full-length, but not the C-terminal cleavage fragment of TLR9-GFP co-precipitated with 
HA-PTP1B in BMDM (Figure 23C). Co-precipitation of HA-PTP1B with TLR9-GFP was 
observed in multiple experiments, whereas the reverse experiment was only performed 
once. After a long exposure (data not shown) the C-terminal TLR9-GFP cleavage 
fragment was detected upon precipitation of HA-PTP1B in BMDM stably expressing 
TLR9-GFP and HA-PTP1B, but also in the control experiment using BMDM stably 
expressing TLR9-GFP only. If PTP1B interacts with full-length, but not the C-terminal 
cleavage fragment of TLR9, this could indicate that PTP1B, unlike the UNC93B-TLR9 
complex, does not traffic to the endolysosome where TLR9 is proteolytically cleaved. 
Further co-immunoprecipitation experiments using PTP1B as a bait need to be 
performed to convincingly show that PTP1B only interacts with full-length TLR9 and not 
with the TLR9 C-terminal cleavage fragment and whether this interaction is mediated 
by UNC93B. A truncated version of TLR9-GFP, which comprises only the C-terminal 
cleavage fragment of TLR9, could be used for co-immunoprecipitation experiments in 
transfected HEK 293T cells or upon retroviral transduction of immortalized TLR9-
deficient BMDM. Furthermore, the interaction of PTP1B with UNC93B, TLR9, and 
Clptm should also be studied in FL-DC or sorted pDC. The question whether PTP1B 
traffics to the endolysosome was addressed by co-localization experiments with 
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TLR9-GFP and Ruby-PTP1B. Analysis of BMDM expressing TLR9-GFP and 
Ruby-PTP1B by live cell imaging revealed that PTP1B, as previously described, 
localizes to the ER and only occasionally localizes to endosomes (Figure 24). Co-
staining with an ER marker and a marker for endosomes could clarify if PTP1B actually 
localizes to endosomal structures in BMDM. Unfortunately, ER markers for live cell 
imaging and the visualization of endosomes upon fixation of BMDM do not work well, 
which makes it difficult to visualize both structures in the same experiment. Together, 
these data do not indicate that PTP1B traffics to the endolysosomal compartment. 
However, direct sites of membrane contact between the ER and endosomes facilitate 
the dephosphorylation of endosomally localized RTKs by PTP1B179. Therefore, PTP1B 
could regulate endosomally localized TLRs although it does not traffic to endosomes 
itself. 
 
The expression of PTP1B in BMDM was upregulated upon TLR stimulation, indicating 
that PTP1B is involved in innate immune signaling (Figure 25). To test whether PTP1B 
is upregulated specifically upon TLR stimulation or upon activation of innate immune 
responses in general, expression levels of PTP1B in BMDM could also be analyzed 
upon stimulation with agonists for cytosolic PRRs or upon viral infection. 
 
Using BMDM derived from PTP1B-/- mice, it was clearly demonstrated that PTP1B 
does not play a role for proinflammatory cytokine responses upon stimulation of cell 
surface or intracellular TLRs or upon MCMV infection (Figure 26 - Figure 29). In 
contrast, compared to wild type BMDM, type I IFN responses were downregulated 
upon MCMV infection of BMDM derived from PTP1B-/- mice (Figure 29). The 
production of IFNα in BMDM derived from PTP1B-/- mice was almost completely 
abrogated, whereas the IFNβ response was only slightly but significantly reduced 
compared to wild type BMDM. Why the impairment of the IFNα response in the 
absence of PTP1B was stronger than the impairment of the IFNβ response is not clear. 
A role of PTP1B for the IFNα response upon MCMV infection of BMDM was confirmed 
by qPCR (Figure 30). In order to clarify the role of PTP1B for the IFNβ response upon 
MCMV infection of BMDM, the mRNA induction of IFNβ in the presence and absence 
of PTP1B should be analyzed as well. Because the effect on the type I IFN response 
observed in the absence of PTP1B was independent of TLRs, we conclude that PTP1B 
regulates the type I IFN response upon stimulation of cytosolic DNA sensors or has a 
general role for the regulation of type I IFN responses. In order to find out which PRRs 
are involved in the recognition of MCMV in BMDM, we started to test proinflammatory 
cytokine and type I IFN responses upon MCMV infection in BMDM derived from mice 
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which are deficient of adaptor proteins used by one or more PRRs. These experiments 
are still ongoing and will be helpful to understand how exactly MCMV is sensed in 
BMDM. In order to analyze innate immune responses upon MCMV infection of BMDM 
in the absence of STING, the Goldenticket mouse can be used. The Goldenticket 
mouse carries a single point mutation in Sting resulting in a non-functional (null) allele 
that fails to produce detectable protein228. Using BMDM generated from mice deficient 
of MyD88 (all TLRs except TLR3), TRIF (TLR3/TLR4), MAVS (RLRs), MyD88/TRIF (all 
TLRs), and MyD88/TRIF/MAVS (all TLRs and RLRs), or from Goldenticket mice 
(cytosolic DNA sensors), preliminary data suggest that especially STING is crucial for 
INFα and IFNβ responses against MCMV in BMDM (Baca Chan, unpublished results). 
This supports the hypothesis that PTP1B regulates type I IFN signaling downstream of 
cytosolic DNA sensors. In addition, results obtained from BMDM derived from MAVS-/- 
mice suggest that RLRs such as RIG-I and MDA5 also play an important role at least 
for the IFNα response upon MCMV infection in macrophages (Baca Chan, unpublished 
results). The data presented in this study show that MCMV infection does not affect the 
TNF response in BMDM derived from PTP1B-/- mice (Figure 29A). However, we 
observed that TNF, IL-6, and IL-12p40 responses were impaired in BMDM derived 
from Goldenticket mice compared to wild type BMDM (Baca Chan, unpublished 
results), which is in contrast with our hypothesis that PTP1B only regulates type I IFN 
responses upon stimulation of cytosolic DNA sensors. Upon activation, STING 
translocates from the ER to a perinuclear compartment117. The analysis of STING 
trafficking in BMDM derived from PTP1B-/- mice could therefore be helpful to find out 
whether PTP1B plays a role for the regulation of STING and co-immunoprecipitation 
experiments with macrophages could reveal if PTP1B and STING interact. 
Furthermore, the role of PTP1B for cytosolic PRRs should be studied in BMDM or MEF 
derived from PTP1B-/- mice upon agonist stimulation of cytosolic DNA or RNA sensors, 
for example with ISD. 
The recognition of MCMV is not dependent on TLRs in BMDM. Analysis of the TLR9-
dependent IFNα4 response by qPCR indicates that PTP1B does not play a role for the 
TLR9-dependent IFNα response in BMDM (Figure 31). Following experiments should 
also include the analysis of IFNβ mRNA induction. To further address the question 
whether PTP1B is involved in the TLR9-dependent type I IFN response, PTP1B-/- mice 
were crossed with IFNβ∆β-luc mice which express luciferase under transcriptional control 
of the IFNβ promoter195. This luciferase reporter system is very sensitive and in 
contrast to ELISA experiments facilitates the detection of low amounts of IFNβ195. Cells 
generated from IFNβ+/∆β-luc/PTP1B-/- mice will allow us to easily study whether PTP1B 
plays a role for the IFNβ response upon TLR9-specific stimulation of BMDM. 
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Since the Flt3 receptor is a RTK which is dependent on PTP1B, FL-DC derived from 
PTP1B-/- mice could not be used to study the role of PTP1B for the TLR-dependent 
type I IFN response in FL-DC. Therefore, wild type FL-DC were treated with PTP1B 
inhibitors. Because PTP1B is regarded as a novel therapeutic target for the treatment 
of type 2 diabetes and obesity, a variety of PTP1B inhibitors are commercially 
available. Unfortunately, the downregulation of the IFNα response that was observed 
upon stimulation of TLRs 7 and 9 in FL-DC which had been treated with a PTP1B 
inhibitor was not specific, since IFNα responses were also downregulated in FL-DC 
derived from PTP1B-/- mice (Figure 35). The possibility that the treatment of FL-DC with 
PTP inhibitor XXII induces cell death was ruled out by flow cytometry analysis 
(Figure 34). PTP1B is closely related to TC-PTP and the catalytic sites of both 
phosphatases are highly conserved which makes the design of specific inhibitors with a 
high selectivity for PTP1B over TC-PTP difficult. In order to see a downregulation of 
IFNα responses upon TLR stimulation, FL-DC were treated with relatively high doses 
of PTP inhibitor XXII (12.5- to 37.5-fold of the IC50). Therefore, in addition to PTP1B, 
the treatment of FL-DC with PTP inhibitor XXII might have inhibited other PTPs, 
especially TC-PTP, as well. In future experiments, further PTP1B inhibitors could be 
tested in order to inhibit PTP1B in FL-DC. These inhibitors should be carefully titrated 
to ensure that potentially observed effects are not caused by the induction of cell death 
or are unspecific side effects. Alternatively to flow cytometry analysis, the colorimetric 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay could be 
used to easily test the cell viability upon treatment of the cells with different doses of 
inhibitors229. 
Since FL-DC could not be used, the role of PTP1B for the type I IFN response upon 
stimulation of TLR7 and TLR9 was investigated in total BM cells. TLR-dependent IFNα, 
but not proinflammatory cytokine responses, were impaired in total BM cells from 
PTP1B-/- mice compared to BM cells from wild type mice (Figure 36 and Figure 37). 
Since pDC are the main source for IFNα, this suggests a role of PTP1B for the TLR7- 
and TLR9-dependent IFNα response in pDC. In accordance with these results, the 
TLR9-dependent IFNα response, but not TNF or IL-6 responses, was significantly 
impaired in the absence of PTP1B in vivo (Figure 39A and Figure 40). These 
experiments convincingly demonstrate that PTP1B regulates the IFNα response upon 
stimulation of TLR7 or TLR9 in pDC. In addition to IFNα, decreased TLR9-dependent 
IL-12p40 levels were observed in the sera of PTP1B-/- mice compared to sera from wild 
type mice (Figure 39B). Whether this effect was mediated by pDC is not clear, since 
IL-12 is also secreted by other types of antigen presenting cells (APC) in response to 
stimulation of TLR9. However, upon MCMV infection in vivo, pDC are the main source 
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for IL-12230. In order to find out whether PTP1B is important for IL-12 responses upon 
TLR stimulation in general, levels of IL-12p40 should also be determined in 
supernatants of total BM cells upon stimulation of TLR7 or TLR9. The fact that the 
IFNα response upon injection of CpG DNA was not completely abrogated in PTP1B-/- 
mice supports the idea that PTP1B regulates TLR9 signaling in pDC, but not in other 
types of APC which also produce small amounts of type I IFN upon stimulation of 
TLR9. TNF responses upon i.p. injection of CpG DNA did not differ between wild type 
and PTP1B-/- mice and IL-6 levels in sera from PTP1B-/- mice were slightly elevated 
compared to sera from wild type mice (Figure 40). TNF and IL-6 in response to 
stimulation of TLR9 are mainly secreted by macrophages and B cells and not by pDC. 
Therefore, the increased number of B cells that was observed in lymph nodes of 
PTP1B-/- mice compared to wild type mice in accordance with previous studies 
(Figure 41A) could explain why the IL-6 levels in sera from PTP1B-/- mice were 
elevated compared to wild type mice upon TLR9-specific stimulation. The numbers of 
cDC and pDC, which are the main source of IFNα and probably IL-12 upon TLR9-
specific stimulation with CpG DNA in vivo, did not differ between wild type and PTP1B-/- 
mice231. Together, the experiments with total BM cells and the in vivo experiments 
strongly indicate that PTP1B regulates signaling of intracellular TLRs in pDC. To test 
whether the absence of PTP1B also affects IFNα and IL12-p40 responses upon TLR7-
specific stimulation in vivo, mice could be injected with the TLR7 ligands R848 or 
Poly(U). Additionally, we currently investigate the role of PTP1B for type I IFN and 
proinflammatory cytokine responses upon MCMV infection of wild type and PTP1B-/- 
mice in vivo. So far, this study focused on the IFNα response upon in vivo stimulation 
of TLR9. In future experiments, analysis of the IFNβ response in vivo upon TLR 
stimulation or viral infection can easily be studied in the IFNβ+/∆β-luc/PTP1B-/- reporter 
mouse line. This mouse line was generated during this study by crossing PTP1B-/- mice 
with IFNβ∆β-luc mice that expresses luciferase under transcriptional control of the IFNβ 
promoter195. Using these mice, the luciferase activity can be visualized with an in vivo 
imaging system (IVIS) upon injection of luciferin as well as in vitro with cells extracted 
from these mice. 
 
There are different hypotheses that could explain the regulation of intracellular TLR 
signaling in pDC and the type I IFN response against MCMV in BMDM by PTP1B 
(Figure 45). First, PTP1B could act differently in pDC and BMDM and directly regulate 
TLRs and cytosolic PRRs or STING by distinct mechanisms. Second, PTP1B could 
regulate common features in the downstream signaling cascades of intracellular TLRs 
and cytosolic PRRs. Third, PTP1B could generally affect type I IFN responses by 
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regulating the type I IFN receptor complex or molecules downstream of type I IFN 
signaling. 
 
 
Figure 45: Possible mechanisms of regulation of type I IFN responses by PTP1B. PTP1B 
could directly regulate TLRs and cytosolic PRRs or STING, act on downstream signaling 
cascades of intracellular TLRs and cytosolic PRRs, or regulate the type I IFN receptor complex 
or molecules downstream of type I IFN signaling. 
 
In order to investigate whether PTP1B directly affects trafficking of TLR9, mice 
expressing TLR9-GFP were crossed with PTP1B-/- mice. Using BMDM derived from 
these mice, it was shown that PTP1B does not regulate trafficking of TLR9 from the ER 
to the endolysosome in BMDM (Figure 42). Unfortunately, imaging of pDC, which are 
non-adherent cells, is very challenging and it is almost impossible to clearly visualize 
endosomal structures in these relatively small and round cells. Therefore, the 
possibility that PTP1B regulates trafficking of intracellular TLR9 in pDC cannot be 
excluded at this point. 
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The adaptor proteins AP-2 and AP-3 mediate trafficking of TLR9. TLR9 is thought to 
traffic to the endolysosome via the cell surface. At the cell surface, UNC93B recruits 
AP-2 which mediates the internalization of TLR978. Upon internalization, TLR9 traffics 
to the endosomal compartment where it initiates the production of proinflammatory 
cytokines by recruitment of MyD88. To induce a type I IFN response, TLR9 traffics from 
the endosomal to a lysosomal compartment where it activates IRF7. This trafficking 
process is mediated by AP-388. PTP1B could facilitate the recruitment of AP-2 or AP-3 
by the UNC93B-TLR9 complex. Binding of AP-2 and AP-3A to RTKs has been reported 
to be inhibited by serine phosphorylation of AP-2 and AP-3A binding sites which 
prevents receptor endocytosis and late endolysosomal trafficking of RTKs232,233. 
Furthermore, AP-2-mediated endocytosis of the IFNα/β receptor chain 1 (IFNAR1) is 
regulated by PTP1B through dephosphorylation of Y466 which is part of the AP-2 
binding motif in the cytosolic domain of human IFNAR1234. Since murine IFNAR1 lacks 
an analogous tyrosine-based motif, PTP1B does not regulate receptor endocytosis of 
IFNAR1 in murine cells234. These studies suggest that the recruitment of AP-2 and 
AP-3 to UNC93B-TLR9 complexes could be inhibited by tyrosine phosphorylation of 
UNC93B and TLR9 and that dephosphorylation by PTP1B could mediate binding of 
AP-2 or AP-3 and thereby positively regulates TLR9 signaling. However, proteolytic 
cleavage of TLR9 was intact in BMDM, cDC, and pDC derived from PTP1B-/- mice 
indicating that TLR9 at least reaches the endosomal compartment in these cell types 
also in the absence of PTP1B (Figure 43). Additionally, in the absence of PTP1B, the 
IFNα response in total BM cells was impaired upon stimulation of TLR7 (Figure 36), 
which uses a different route to traffic to the endolysosomal compartment than TLR9. 
TLR7 does not traffic via the cell surface, but directly recruits AP-4 which mediates its 
trafficking from the ER to the endolysosome78. These two observations do not support 
the hypothesis that PTP1B mediates the recruitment of AP-2 by UNC93B. AP-3 was 
not only reported to be required for TLR9, but also for TLR7 signaling88. However, 
AP-3-deficient mice still produced the proinflammatory cytokine IL-12p40 in response 
to injection of CpG DNA in vivo88, but IL-12p40 levels in sera of PTP1B-/- mice were 
impaired compared to sera from wild type mice (Figure 39B). Therefore, it also seems 
unlikely that PTP1B regulates the recruitment of AP-3 by TLR7 or TLR9. In this regard, 
it would be interesting to test whether the adaptor protein MyD88 still interacts with 
TLR9 in the absence of PTP1B in FL-DC or sorted pDC. Altogether, PTP1B does not 
seem to regulate trafficking of intracellular TLRs. 
 
We showed that UNC93B, TLR9, and Clptm could be potential substrates of PTP1B 
(Figure 44). Tyrosine phosphorylation of TLR9 has already been reported222,223. 
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Unfortunately, tyrosine phosphorylation of TLR9, UNC93B, or Clptm by anti-pTyr 
immunoblotting could not be detected in this study. In order to enhance the amount of 
tyrosine phosphorylated proteins, cells could be treated with pervanadate, an 
irreversible inhibitor of tyrosine phosphatases235, prior to cell lysis. 
Whether the enzymatic activity of PTP1B is important for the regulation of the IFNα 
response in pDC is not clear. The protein tyrosine phosphatase non-receptor type 22 
(Ptpn22) was recently reported to positively regulate the TLR-dependent type I IFN 
response in myeloid cells by promoting K63-linked ubiquitination of TRAF3236. This 
process is completely independent of the enzymatic phosphatase activity of Ptpn22, 
suggesting that PTP1B could also act downstream of TLR signaling and independently 
of its phosphatase activity. In order to study the requirement of the enzymatic function 
of PTP1B for the regulation of signaling of intracellular TLRs and cytosolic PRRs, an 
enzymatically inactive point mutant (D181A) of PTP1B can be used. However, primary 
BMDM or FL-DC derived from PTP1B-/- mice cannot be efficiently transduced with 
mutant (D181A) PTP1B and MEF derived from PTP1B-/- mice, which can be passaged 
several times and were effectively transduced with mutant PTP1B (Figure 38), do not 
express TLR9. Therefore, BMDM derived from PTP1B-/- mice are currently 
immortalized which should enable retroviral transduction of these cells (T. May, HZI). 
PTP1B inhibitors could also be used to study the role of PTP1B enzymatic activity for 
innate immune signaling, however, the use of PTP1B inhibitors in FL-DC was 
problematic due to cytotoxicity and unspecific side effects of the inhibitors (3.4.8). 
 
Intracellular TLRs and cytosolic PRRs activate distinct downstream signaling cascades 
which involve different sets of proteins upon ligand binding. PTP1B-mediated 
regulation of proteins involved in signaling pathways downstream of TLR-dependent 
type I IFN signaling as well as cytosolic PRRs could explain how PTP1B regulates the 
TLR-independent IFNα response upon MCMV infection in BMDM as well as the TLR7- 
and TLR9-dependent IFNα response in pDC. TRAF3 is required for the activation of 
IRF7 downstream of TLR7 and TLR9 signaling in pDC. TRAF3 is also crucial for the 
signaling cascade downstream of MAVS. MAVS is activated upon interaction with the 
cytosolic RNA sensors RIG-I or MDA5 and induces the activation of IRF3 and IRF7 via 
STING237. An interaction between STING and TRAF3 has been shown in transfected 
HEK 293T cells113. A direct role for TRAF3 for STING-mediated signaling downstream 
of cytosolic DNA sensors or for RIG-I and MDA5 in sensing of MCMV has not been 
described so far. However, preliminary results with BMDM derived from MAVS-/- mice 
suggest that RLRs such as RIG-I or MDA5 are involved in the IFNα response upon 
MCMV infection (Baca Chan, unpublished results). Therefore, regulation of TRAF3 by 
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PTP1B, for example through a mechanism similar to the one that has been described 
for the phosphatase Ptpn22, could possibly explain the impairment of the IFNα 
response observed upon MCMV infection of PTP1B-deficient BMDM. 
In order to systematically investigate whether PTP1B acts downstream of TLRs or 
cytosolic PRRs, the phosphorylation and translocation of IRF3 and IRF7 upon 
stimulation of TLRs or cytosolic PRRs should be analyzed in wild type and PTP1B-
deficient cells. Unfortunately, the available antibodies against IRF7 or phospho-IRF7 
are not very sensitive which makes the analysis of endogenous IRF7 difficult. IRF3 and 
IRF7 are activated by TBK1 which becomes serine phosphorylated upon activation238. 
Furthermore, IRF7 has been reported to interact with and to be ubiquitinated by 
TRAF6239,240. Therefore, the phosphorylation of TBK1, the interaction between IRF7 
and TRAF6, and the ubiquitination of IRF7 could be analyzed in presence and absence 
of PTP1B. 
Recently, it was shown that the spleen tyrosine kinase (Syk) differentially regulates 
TLR4-dependent signaling pathways through TRAF6 and TRAF3241. Syk negatively 
regulated the TRAF6- and TAK1-dependent proinflammatory cytokine pathway upon 
TLR4 stimulation on the cell surface, whereas it positively regulated TRAF3- and 
TBK1-dependent type I IFN production upon internalization of TLR4. It was shown that 
Syk interactes with TRAF3, TRAF6, TAK1, and TBK1 and inhibites K63-linked 
polyubiquitination of TRAF6. In contrast, Syk increased K63-specific autopoly-
ubiquitination of TRAF3 and thereby stimulated the activation of TBK1-IRF3 signaling 
and the production of type I IFN. The authors of this study suggest that Syk could 
generally be involved in the regulation of TLR signaling since it associated with TLR3, 
TLR4, and TLR9 and because TRAF3, TRAF6, TAK1, and TBK1 are common 
molecules involved in TLR signaling241. Furthermore, cytosolic PRRs also signal via 
TBK1 which indicates that Syk could also regulate signaling pathways initiated by 
cytosolic DNA or RNA sensors. Upon activation, Syk becomes phosphorylated. PTP1B 
could either counteract the mechanism by which Syk positively regulates type I IFN 
signaling and negatively regulates the production of proinflammatory cytokines or it 
could regulate Syk itself by dephosphorylation. In order to find out whether PTP1B 
affects Syk activation or Syk mediated regulation of TLR signaling, the phosphorylation 
status of Syk and K63-linked polyubiquitination of TRAF3 and TRAF6 in the presence 
and absence of PTP1B could be analyzed. 
 
Upon secretion, type I IFN binds to the IFN receptor complex which consists of IFNAR1 
and IFNAR2 and thereby further activates the production of type I IFN in an autocrine 
and paracrine manner. The IFN receptor complex recruits Janus kinase 1 (JAK1) and 
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tyrosine kinase 2 (TYK2). JAK1 and TYK2 phosphorylate signal transducer and 
activator of transcription 1 (STAT1) and STAT2 leading to the formation of IFN-
stimulated gene factor 3 complexes (ISGF3) with IRF9 which translocate into the 
nucleus and initiate gene transcription via IFN-stimulated response elements (ISRE)242. 
It has been shown that 6 h after i.v. injection of CpG DNA, mice deficient of IFNAR 
show severely impaired serum levels of type I IFN compared to wild type mice243. 
Therefore, PTP1B could directly regulate IFNAR or regulate signaling molecules 
downstream of IFNAR. As mentioned earlier, it is known that PTP1B positively 
regulates AP-2-mediated endocytosis of IFNAR1 by dephosphorylation of the AP-2 
binding motif in human, but not in murine cells234. However, a similar mechanism in 
murine cells, for example on IFNAR2, would lead to increased IFNAR signaling and 
type I IFN production in the absence of PTP1B, because IFNAR could not be 
internalized to terminate its signaling. A conserved tyrosine motif in the cytoplasmic 
domain of IFNAR2 has been identified to mediate the recruitment of STAT1 and STAT2 
and therefore plays a critical role for the response to type I IFN244. However, targeting 
of this tyrosine motif by PTP1B would decrease binding of STATs to IFNAR2 
and would therefore also lead to increased type I IFN production in the absence of 
PTP1B. 
TYK2, which is required for IFNAR signaling, is a known substrate of PTP1B187. TYK2 
is also activated upon induction of the IL-12 signaling pathway245. However, 
dephosphorylation of TYK2 negatively regulates the production of type I IFN and IL-12. 
Therefore, the effect of PTP1B on TYK2 cannot explain the observations that IFNα and 
IL-12 responses are impaired in the absence of PTP1B which have been reported 
here. Nevertheless, the regulation of IFNAR or of components of the IFNAR signaling 
pathway could explain the effects on the TLR-independent type I IFN response upon 
MCMV infection of BMDM and the TLR7- and the TLR9-depdendent IFNα response in 
pDC observed in the absence of PTP1B. In addition to PTP1B, several molecules 
which negatively regulate type I IFN signaling have been described246-249. Inhibition of 
one of these negative regulators by PTP1B could counteract their downregulatory 
effects. In order to find out whether signaling of IFNAR is intact in the absence of 
PTP1B, the phosphorylation status of STAT1 and STAT2 in lysates of BMDM derived 
from PTP1B-/- mice could be analyzed upon stimulation of IFNAR with IFNα or IFNβ. 
 
The identification of PTP1B interaction partners might help to find proteins involved in 
innate immune signaling which are targeted by PTP1B and could therefore give 
important insights into the mechanism by which PTP1B regulates type I IFN responses. 
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In order to identify binding partners of PTP1B, mass spectrometry analysis with BMDM 
stably expressing HA-PTP1B could be performed. 
 
In this study it was demonstrated that PTP1B interacts with UNC93B, TLR9, TLR7, and 
Clptm in macrophages and that the expression of PTP1B is upregulated upon TLR 
stimulation. The type I IFN, but not proinflammatory cytokine responses, upon MCMV 
infection of primary BMDM were significantly impaired in the absence of PTP1B. In 
addition, compared to wild type controls, the IFNα response in PTP1B-deficient bone 
marrow cells was impaired upon stimulation of TLR7 or TLR9 and IFNα and IL-12p40 
responses in PTP1B-deficient mice were impaired upon stimulation of TLR9 in vivo. In 
summary, these data show that PTP1B is a critical regulator of the TLR-independent 
type I IFN response upon MCMV infection of BMDM and the TLR7- and TLR9-
depdendent IFNα response in pDC. The exact mechanism by which PTP1B 
differentially regulates the type I IFN response in these two cell types will be 
investigated in further studies. 
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5. Abstract 
Toll-like receptors (TLRs) are key players of the innate immune system. Localized at 
the cell surface or intracellularly, they trigger immune responses upon recognition of 
pathogenic patterns. After their synthesis in the endoplasmic reticulum (ER), 
intracellular TLRs 3, 7, and 9 need to move to the endolysosome to meet their ligands. 
On their way they are escorted by the polytopic membrane protein UNC93B. UNC93B 
interacts with TLRs 3, 7, and 9 and delivers them from the ER to the endolysosome 
where they initiate the expression of proinflammatory cytokines and type I interferon 
(IFN) upon encounter of nucleic acids. In 3d mice, which express a missense mutant of 
UNC93B (H412R), binding of UNC93B to TLRs is disrupted and UNC93B H412R as 
well as intracellular TLRs fail to leave the ER. How function and trafficking of UNC93B-
TLR complexes is regulated is not entirely understood. A comparison of innate immune 
cells derived from UNC93B knockout and 3d mice showed that the phenotype of cells 
from UNC93B knockout mice does not differ from the 3d phenotype. In a proteomics 
approach, cleft lip and palate transmembrane protein (Clptm), three prime repair 
exonuclease 1 (Trex1), and the protein tyrosine phosphatase 1B (PTP1B) have been 
identified as novel binding partners of UNC93B in macrophages. Co-immuno-
precipitation experiments verified interactions between UNC93B, the previously 
uncharacterized protein Clptm, as well as the negative regulator of cytosolic DNA 
responses Trex1. PTP1B is known to be crucial for intracellular trafficking of receptor 
tyrosine kinases, but had not been linked to regulation of TLR signaling. Interaction of 
PTP1B with UNC93B, Clptm, TLR7, and TLR9 was verified by co-immunoprecipitation. 
The TLR-independent type I IFN response upon infection of bone marrow-derived 
macrophages with mouse cytomegalovirus, as well as the TLR7- and TLR9-dependent 
IFNα responses in plasmacytoid dendritic cells (pDC) were impaired in cells derived 
from PTP1B knockout mice compared to wild type cells. Furthermore, PTP1B knockout 
mice showed significantly reduced IFNα and interleukin (IL)-12p40 responses 
compared to wildtype mice upon stimulation of TLR9 by intravenous administration of 
CpG oligonucleotides in vivo. This suggests that PTP1B is a critical regulator of the 
TLR7- and TLR9-dependent IFNα response in pDC as well as the TLR-independent 
type I IFN response in macrophages. 
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5`ppp-dsRNA 5`triphosphate double stranded RNA 
7-AAD 7-Aminoactinomycin 
aa amino acid 
AIM2 absent in melanoma 2 
AMPK adenosine monophosphate-activated protein kinase 
AP adaptor protein 
AP-1 activator protein 1 
AP-2/AP-3/AP-4 adaptor protein 2/adaptor protein 3/adaptor protein 4 
APC antigen presenting cells 
APS ammonium persulfate 
ASC apoptosis-associated speck-like protein containing a CARD domain 
ATCC American Type Culture Collection 
BM bone marrow 
BMDM bone marrow-derived macrophages 
bp base pair 
BSA bovine serum albumin 
CARD caspase recruitment domain 
CD cluster of differentiation 
cDC conventional dendritic cells 
CDN cyclic dinucleotides 
cGAMP cyclic guanosine monophosphate-adenosine monophosphate 
cGAS cGAMP synthase 
Clptm cleft lip and palate associated transmembrane protein 
CLR C-type lectin receptor 
CRISPR clustered regularly interspaced short palindromic repeat 
C-terminus carboxy-terminus 
DAI DNA-dependent activator of IFN-regulatory factors 
DAMP damage- or danger-associated molecular pattern 
DC dendritic cells 
DDX DEAD box helicase 
DHX DExD/H-box helicase 
DNA deoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase 
dsDNA double-stranded DNA 
dsRNA double-stranded RNA 
EGFR epidermal growth factor receptor 
ELISA enzyme-linked immunosorbent assay 
Endo H Endoglycosidase H 
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ENU N-ethyl-N-nitrosourea 
ER endoplasmic reticulum 
ESCRT endosomal sorting complex required for transport 
FACS fluorescence-activated cell sorting 
FCS fetal calf serum 
FELASA Federation of European Laboratory Animal Science Associations 
FL-DC Flt3 ligand-induced dendritic cells 
Flt3 Fms-like tyrosine kinase 3 
FRET fluorescence resonance energy transfer 
GFP green fluorescent protein 
GRP94 (gp96) glucose-regulated protein of 94 kDa 
HA hemagglutinin 
HBS HEPES-buffered saline 
HCMV human cytomegalovirus 
HEK human embryonic kidney 
HRP horseradish peroxidase 
HRS hepatocyte growth factor-regulated tyrosine kinase substrate 
HSV herpes simplex virus 
IC50 half maximal inhibitory concentration 
IFI16 IFNγ-inducible protein 16 
IFN interferon 
IFNAR IFNα/β receptor 
IKK IκB kinase 
IL interleukin 
IRAK IL-1 receptor-associated kinase 
IRF interferon regulatory factor 
ISD interferon stimulatory DNA 
ISG interferon-stimulated gene 
ISGF3 IFN-stimulated gene factor 3 complexes 
ISRE IFN-stimulated response elements 
JAK1/JAK2 Janus kinase 1/Janus kinase 2 
kDa kilodalton 
KSHV Kaposi`s sarcoma-associated herpesvirus 
LBP LPS-binding protein 
LC-MS/MS liquid chromatography and mass spectrometry 
LGP2 laboratory of genetics and physiology 2 
LPS lipopolysaccharide 
LRO lysosome-related organelle 
LRR leucine-rich repeat 
LRRFIP1 leucine-rich repeat flightless-interacting protein 1 
LTA lipotechoic acid 
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MACS magnetic-activated cell sorting 
MAPK mitogen-activated protein kinase 
MAVS mitochondrial antiviral signaling protein 
MCMV mouse cytomegalovirus 
MCSF (CSF-1) macrophage colony-stimulating factor (colony-stimulating factor 1) 
MD-2 myeloid differentiation factor 2 
MDA5 melanoma differentiation-associated gene-5 
MEF mouse embryonic fibroblasts 
MGC Mammalian Gene Collection 
MHV-68 murine herpesvirus 68 
miR-30 microRNA-30 
MOI multiplicity of infection 
MRE11 meiotic recombination 11 
mRNA messenger RNA 
MSCV murine stem cell virus 
MVB multivesicular body 
MyD88 myeloid differentiation primary response gene 88 
NAP1 NAK-associated protein 1 
NEAA non-essential amino acids 
NEMO NF-κB essential modulator 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NK cell natural killer cell 
NLR NOD-like receptor 
NOD nucleotide-binding oligomerization domain 
N-terminus amino-terminus 
ODN oligonucleotide 
P/S penicillin/streptomycin 
PAGE polyacrylamide gel electrophoresis 
PAMP pathogen-associated molecular pattern 
PBS Phosphate-buffered saline 
PCR polymerase chain reaction 
pDC plasmacytoid dendritic cell 
PNGase F Peptide-N-Glycosidase F 
Poly(I:C) polyinosinic-polycytidylic acid 
Poly(U) polyuridylic acid 
PRAT4A protein associated with TLR4 
PRR pattern recognition receptor 
PTP protein tyrosine phosphatase 
PTP1B protein tyrosine phosphatase 1B 
Ptpn22 protein tyrosine phosphatase non-receptor type 22 
pTyr phosphotyrosine 
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PYHIN pyrin and HIN domain-containing protein 
qPCR real-time quantitative PCR 
R848 resiquimod 
RIG-I retinoic acid-inducible gene-I 
RIP1 receptor-interacting protein 1 
RLR RIG-I-like receptor 
RNA ribonucleic acid 
RNA Pol III RNA Polymerase III 
Rpl8 murine ribosomal protein L8 
rpm rounds per minute 
RT room temperature 
RTK receptor tyrosine kinase 
shRNA small hairpin RNA 
ssRNA single-stranded RNA 
STAM2 signal transducing adaptor molecule 2 
STAT signal transducer and activator of transcription 
STING stimulator of interferon genes 
Syk spleen tyrosine kinase 
TAB TAK1-binding protein 
TAK1 transforming growth factor β-activated kinase 1 
TANK TNFR-associated factor family member-associated NF-κB activator 
TBK1 TANK-binding kinase 1 
TBS Tris-buffered saline 
TBS-T TBS/0.1% Tween 20 
TC-PTP T cell PTP 
TEV tobacco etch virus 
TIR domain Toll-interleukin-1 receptor domain 
TIRAP TIR domain-containing adaptor protein 
TLR Toll-like receptor 
TMB 3,3’,5,5’-Tetramethylbenzidine 
TNF tumor necrosis factor 
TRADD TNF receptor type 1-associated Death domain protein 
TRAF tumor necrosis factor receptor-associated factor 
TRAM TRIF-related adaptor molecule 
Trex1 three prime repair exonuclease 1 
TRIF TIR domain-containing adaptor inducing IFNβ 
TYK2 tyrosine kinase 2 
ULK1 UNC-51-like kinase 1 
WT wild type 
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Table 14: List of potential interaction partners of wild type (WT) and mutant (H412R) 
UNC93B. 
Protein Description Interaction with 
UNC93B 
Protein 
Accession 
    
5'-3' exoribonuclease 2  H412R gi|117606214 
78 kDa glucose-regulated protein WT H412R gi|2506545 
A disintegrin and metalloprotease domain 17  H412R gi|110347485 
AAA-ATPase TOB3  H412R gi|30725845 
ADP-ribosylation factor-like 10C WT H412R gi|13385518 
ADP-ribosylation factor-like 8A WT H412R gi|23956194 
AGP7  H412R gi|22550098 
AHNAK nucleoprotein isoform 1  H412R gi|61743961 
ARP3 actin-related protein 3 homolog WT H412R gi|23956222 
ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit WT H412R gi|31980648 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d  H412R gi|21313679 
ATP-binding cassette, sub-family F (GCN20), member 2  H412R gi|23956078 
ATP-binding cassette, subfamily E, member 1  H412R gi|114205431 
ATP-dependent glucokinase WT H412R gi|21312406 
ATPase type 13A1 WT H412R gi|18875382 
ATPase, Ca++ transporting, slow twitch 2 isoform a WT H412R gi|158635979 
ATPase, H+ transporting, lysosomal V1 subunit A WT H412R gi|31560731 
Abhydrolase domain containing 6 WT H412R gi|31560264 
Achalasia, adrenocortical insufficiency, alacrimia WT H412R gi|23510311 
Actin related protein 2/3 complex, subunit 1B  H412R gi|160837788 
Actin, beta-like 2  H412R gi|30425250 
Actin-like 6A  H412R gi|189181668 
Actinin alpha 4  H412R gi|11230802 
Actinin, alpha 1  H412R gi|61097906 
Acyl-CoA synthetase long-chain family member 3 isoform b  H412R gi|209977076 
Acyl-CoA synthetase long-chain family member 5 WT H412R gi|58218988 
Acyl-CoA thioesterase 9  H412R gi|31980998 
Adaptor protein complex AP-1, beta 1 subunit WT H412R gi|88853578 
Adaptor protein complex AP-1, gamma 1 subunit WT H412R gi|56744242 
Adaptor protein complex AP-2, alpha 1 subunit isoform b  H412R gi|116256510 
Adaptor protein complex AP-2, alpha 2 subunit WT H412R gi|163644277 
Adaptor protein complex AP-2, mu1 WT H412R gi|6753074 
Adenylosuccinate lyase WT H412R gi|29788764 
Adenylosuccinate synthetase 1  H412R gi|6671519 
Adenylosuccinate synthetase, non muscle  H412R gi|31560737 
Alanyl-tRNA synthetase  H412R gi|34610207 
Aldehyde dehydrogenase family 3, subfamily A2 WT H412R gi|75677435 
Aldo-keto reductase family 1, member B3 (aldose reductase) WT H412R gi|160707894 
All-trans-13,14-dihydroretinol saturase WT H412R gi|52627143 
Alpha glucosidase 2 alpha neutral subunit WT H412R gi|6679891 
Alpha isoform of regulatory subunit B55, protein phosphatase 2 WT H412R gi|110625886 
Alpha-N-acetylglucosaminidase WT  gi|7305299 
Amplified in osteosarcoma WT H412R gi|29243990 
Ankycorbin  H412R gi|13507620 
Ankyrin repeat and FYVE domain containing 1  H412R gi|85702366 
Ankyrin repeat domain 39 WT H412R gi|58037099 
Annexin A5 WT H412R gi|6753060 
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Arachidonate 5-lipoxygenase WT H412R gi|62526037 
Arsenate resistance protein 2 isoform 3  H412R gi|158186674 
Arylacetamide deacetylase-like 1  H412R gi|30520239 
Asparaginyl-tRNA synthetase  H412R gi|29789191 
Aspartyl beta-hydroxylase isoform 1 WT H412R gi|125628659 
Aspartyl-tRNA synthetase isoform 1 WT H412R gi|211065507 
Ataxia telangiectasia mutated homolog  H412R gi|163838660 
Atlastin GTPase 3 WT H412R gi|31559920 
B Chain B, Porcine E-Trypsin (E.C.3.4.21.4) WT H412R gi|999627 
B aggressive lymphoma  H412R gi|13384918 
B-cell receptor-associated protein 29 WT H412R gi|6671620 
BCL2-associated athanogene 5 WT  gi|58037205 
BRCA1/BRCA2-containing complex, subunit 3  H412R gi|22165366 
Bcl2-associated X protein  H412R gi|6680770 
Branched chain aminotransferase 1, cytosolic isoform 2  H412R gi|161016828 
Bri3 binding protein WT H412R gi|58037467 
C-src tyrosine kinase WT H412R gi|31560712 
CCR4-NOT transcription complex, subunit 1 isoform 2  H412R gi|189458844 
CDK5 regulatory subunit associated protein 3  H412R gi|13384788 
CDNA sequence BC022641  H412R gi|31712002 
CDP-diacylglycerol--inositol 3-phosphatidyltransferase (phosphatidylinositol 
synthase) 
WT H412R gi|28076897 
CNDP dipeptidase 2 WT H412R gi|31981273 
Calcium/calmodulin-dependent protein kinase II, delta isoform 1 WT H412R gi|70906479 
Calreticulin WT H412R gi|6680836 
Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and 
dihydroorotase 
 H412R gi|51093867 
Casein kinase 1, alpha 1  H412R gi|22165382 
Cathepsin A isoform a WT H412R gi|84042525 
Cathepsin S preproprotein WT  gi|160707996 
Cathepsin Z preproprotein WT H412R gi|11968166 
Cell division cycle 37 homolog  H412R gi|7949018 
Cell division cycle 5-like  H412R gi|22779899 
Centromere/kinetochore protein zw10  H412R gi|22165349 
Chaperonin containing Tcp1, subunit 5 (epsilon)  H412R gi|6671702 
Chaperonin containing Tcp1, subunit 7 (eta)  H412R gi|31982472 
Chaperonin subunit 2 (beta) WT H412R gi|126521835 
Checkpoint kinase 1 homolog WT H412R gi|31542385 
Chloride channel CLIC-like 1  H412R gi|21704070 
Chondroitin sulfate proteoglycan 6  H412R gi|36031035 
Chromodomain helicase DNA binding protein 4  H412R gi|39204553 
Chromosome segregation 1-like  H412R gi|12963737 
Cleft lip and palate associated transmembrane protein 1 WT H412R gi|103472025 
Coatomer protein complex subunit alpha  H412R gi|31981828 
Coatomer protein complex, subunit beta 1  H412R gi|15426055 
Coatomer protein complex, subunit beta 2 (beta prime) WT H412R gi|29789080 
Coatomer protein complex, subunit gamma 2  H412R gi|8567340 
Coatomer protein complex, subunit gamma isoform 1  H412R gi|8567338 
Coiled-coil domain containing 115  H412R gi|58037169 
Coiled-coil domain containing 47 WT H412R gi|125628650 
Cold shock domain protein A long isoform  H412R gi|47059495 
Coronin, actin binding protein 1B  H412R gi|6753494 
Coronin, actin binding protein 1C WT H412R gi|31542413 
Crystallin, zeta (quinone reductase)-like 1  H412R gi|21617847 
Cullin 3  H412R gi|7710014 
Cullin 4A WT H412R gi|167466258 
Cyclin H WT H412R gi|12963599 
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Cytidine 5'-triphosphate synthase  H412R gi|172072613 
Cytochrome P450 reductase WT H412R gi|6679421 
Cytochrome P450, family 51 WT H412R gi|71061451 
Cytochrome b5 type B precursor WT H412R gi|31542438 
Cytoplasmic FMR1 interacting protein 1 WT H412R gi|164698474 
Cytoskeleton-associated protein 4 WT H412R gi|62526118 
D6Wsu176e protein WT H412R gi|42734496 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1  H412R gi|19527256 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 39  H412R gi|38372907 
DEAH (Asp-Glu-Ala-His) box polypeptide 8  H412R gi|56699440 
DEK oncogene (DNA binding)  H412R gi|29789160 
DENN/MADD domain containing 2A  H412R gi|27369652 
DH and coiled-coil domain-containing protein ENSP00000381780 homolog WT  gi|123792451 
Dedicator of cyto-kinesis 2 WT H412R gi|117553625 
Dehydrogenase/reductase (SDR family) member 1 WT H412R gi|31980844 
Dehydrogenase/reductase (SDR family) member 8 WT H412R gi|16716597 
Deltex 3-like  H412R gi|133930784 
Deoxyuridine triphosphatase  H412R gi|21281687 
Desmin  H412R gi|33563250 
Diaphorase 1 WT  gi|19745150 
Dihydrolipoamide branched chain transacylase E2 WT H412R gi|170172520 
Dihydrolipoamide dehydrogenase  H412R gi|31982856 
DnaJ (Hsp40) homolog, subfamily A, member 1  H412R gi|6680297 
DnaJ (Hsp40) homolog, subfamily A, member 2  H412R gi|9789937 
DnaJ (Hsp40) homolog, subfamily B, member 11 WT H412R gi|110625998 
DnaJ (Hsp40) homolog, subfamily B, member 12 WT H412R gi|31982701 
DnaJ (Hsp40) homolog, subfamily C, member 10  H412R gi|119508443 
DnaJ (Hsp40) homolog, subfamily C, member 11  H412R gi|164565394 
Dynactin 1  H412R gi|118601017 
Dynactin 2  H412R gi|28076935 
Dynein cytoplasmic 1 intermediate chain 2  H412R gi|6753658 
Dynein cytoplasmic 1 light intermediate chain 1  H412R gi|22122795 
EF hand domain containing 2  H412R gi|31981086 
ER lipid raft associated 1 WT H412R gi|31981799 
Elongation factor Tu GTP binding domain containing 2 isoform b WT H412R gi|158508674 
Enolase 2, gamma neuronal WT H412R gi|7305027 
Epidermal growth factor receptor pathway substrate 8  H412R gi|75677397 
ErbB3-binding protein 1  H412R gi|6755100 
Eukaryotic translation elongation factor 1 delta isoform b WT H412R gi|54287684 
Eukaryotic translation initiation factor 2, subunit 1 alpha WT  gi|13385624 
Eukaryotic translation initiation factor 3 subunit 6 interacting protein WT H412R gi|51093840 
Eukaryotic translation initiation factor 3, subunit 10 (theta)  H412R gi|146219837 
Eukaryotic translation initiation factor 3, subunit 9 WT H412R gi|29789343 
Eukaryotic translation initiation factor 3, subunit C  H412R gi|22203755 
Eukaryotic translation initiation factor 3, subunit F WT H412R gi|21313620 
Eukaryotic translation initiation factor 3, subunit G  H412R gi|31980808 
Eukaryotic translation initiation factor 4A, isoform 3  H412R gi|20149756 
Eukaryotic translation initiation factor 5B WT H412R gi|84043961 
Excision repair cross-complementing rodent repair deficiency, complementation 
group 2 
 H412R gi|31542614 
Exportin 1, CRM1 homolog WT H412R gi|78190507 
Exportin 5  H412R gi|24429570 
F-box protein 22  H412R gi|139948465 
FK506 binding protein 11 WT H412R gi|15277331 
Fatty acyl CoA reductase 1  H412R gi|74096448 
Ferredoxin reductase WT H412R gi|6679767 
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Fibronectin type III domain containing 3a WT  gi|83745139 
Filamin, alpha WT H412R gi|125347376 
Flightless I homolog  H412R gi|11528490 
Formin-like 1 isoform 1  H412R gi|118136290 
Fucokinase isoform 2  H412R gi|41281971 
GPI anchor attachment protein 1 WT H412R gi|6754046 
GTP binding protein 7 (putative)  H412R gi|188528646 
Gelsolin  H412R gi|28916693 
Gem (nuclear organelle) associated protein 5  H412R gi|27369782 
Glucosamine-6-phosphate deaminase 1 WT H412R gi|188219582 
Glucose phosphate isomerase 1 WT H412R gi|6680067 
Glucosidase 1 WT H412R gi|31981106 
Glutamic pyruvate transaminase (alanine aminotransferase) 2  H412R gi|27805389 
Glutaminyl-tRNA synthetase WT H412R gi|55741703 
Glutamyl-prolyl-tRNA synthetase WT H412R gi|82617575 
Glutaredoxin 3 WT  gi|31981269 
Glyceraldehyde-3-phosphate dehydrogenase WT H412R gi|6679937 
Glycerol phosphate dehydrogenase 2, mitochondrial  H412R gi|31981769 
Glycyl-tRNA synthetase  H412R gi|93102417 
GrpE-like 2, mitochondrial WT H412R gi|29789124 
Guanine monphosphate synthetase WT H412R gi|85861218 
Guanine nucleotide binding protein, alpha 13 WT  gi|89001109 
Guanine nucleotide binding protein, alpha q polypeptide WT  gi|84662745 
Guanine nucleotide-binding protein, beta-1 subunit WT  gi|6680045 
Guanine nucleotide-binding protein, beta-2 subunit WT H412R gi|13937391 
HECT domain containing 1  H412R gi|205277432 
HIV TAT specific factor 1 WT H412R gi|23956212 
Heat shock protein 105 WT H412R gi|114145505 
Heat shock protein 4 WT H412R gi|112293266 
Hect domain and RLD 4  H412R gi|32451488 
Hematopoietic cell specific Lyn substrate 1  H412R gi|6680187 
Heme oxygenase (decycling) 2 WT H412R gi|209862939 
Heterogeneous nuclear ribonucleoprotein A1 isoform b  H412R gi|85060507 
Heterogeneous nuclear ribonucleoprotein A2/B1 isoform 1  H412R gi|109134362 
Heterogeneous nuclear ribonucleoprotein C  H412R gi|8393544 
Heterogeneous nuclear ribonucleoprotein F  H412R gi|19527048 
Heterogeneous nuclear ribonucleoprotein H1  H412R gi|10946928 
Heterogeneous nuclear ribonucleoprotein K WT H412R gi|13384620 
Heterogeneous nuclear ribonucleoprotein L  H412R gi|183980004 
Heterogeneous nuclear ribonucleoprotein L-like  H412R gi|110347535 
Heterogeneous nuclear ribonucleoprotein M isoform b  H412R gi|158186704 
Heterogeneous nuclear ribonucleoprotein R  H412R gi|33859724 
Heterogeneous nuclear ribonucleoprotein U  H412R gi|160333923 
Hexokinase 1  H412R gi|6754206 
Hexokinase 2  H412R gi|7305143 
Hexokinase 3 WT H412R gi|84370288 
High density lipoprotein binding protein  H412R gi|19527028 
Histocompatibility 13 WT H412R gi|18034682 
Histone deacetylase 1  H412R gi|6680193 
Hydrogen/potassium-exchanging ATPase 12A  H412R gi|157168326 
Hydroxymethylglutaryl-CoA synthase 1 WT H412R gi|31981842 
Hydroxysteroid (17-beta) dehydrogenase 4 WT H412R gi|31982273 
Hypothetical protein LOC217370 WT H412R gi|21450219 
Hypothetical protein LOC223665 WT H412R gi|21735489 
Hypothetical protein LOC224171  H412R gi|125858491 
Hypothetical protein LOC230866 isoform 1 WT H412R gi|31542273 
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Hypothetical protein LOC230866 isoform 2 WT H412R gi|85861260 
Hypothetical protein LOC28088  H412R gi|21703842 
Hypothetical protein LOC67490  H412R gi|21312946 
Hypothetical protein LOC73694 WT  gi|158937256 
Hypoxia up-regulated 1  H412R gi|157951706 
IlvB (bacterial acetolactate synthase)-like WT H412R gi|30424591 
Implantation-associated protein WT  gi|148747202 
Importin 11 WT H412R gi|31541898 
Importin 5 WT H412R gi|29789199 
Importin 9  H412R gi|112734861 
Influenza virus NS1A binding protein isoform 3  H412R gi|87239996 
Inhibitor of kappa light polypeptide enhancer in B-cells, kinase complex-associated 
protein 
 H412R gi|158937298 
Inner membrane protein, mitochondrial  H412R gi|70608131 
Inorganic pyrophosphatase 2  H412R gi|22203753 
Inosine 5'-phosphate dehydrogenase 2  H412R gi|31981382 
Inositol 1,4,5-triphosphate receptor 1  H412R gi|146198792 
Integrin linked kinase  H412R gi|6754342 
Interferon-induced protein 44-like  H412R gi|190359774 
Intergral membrane protein 1 WT H412R gi|148747128 
Interleukin 16  H412R gi|52138550 
Isocitrate dehydrogenase 3, beta subunit WT H412R gi|18700024 
Isoleucyl-tRNA synthetase  H412R gi|29789383 
Junction-mediating and regulatory protein  H412R gi|61098108 
KH-type splicing regulatory protein (FUSE binding protein 2)  H412R gi|163954948 
Karyopherin (importin) alpha 2  H412R gi|6754474 
Kelch domain containing 5  H412R gi|124486991 
Kelch-like 25  H412R gi|170671742 
Keratin complex 1, acidic, gene 10 WT H412R gi|112983636 
Kinectin 1  H412R gi|144922638 
Kinesin family member 21B  H412R gi|86990454 
Kinesin family member 2C  H412R gi|31981665 
Kinesin family member 5A  H412R gi|84781727 
Lamin B receptor WT H412R gi|19527034 
Lanosterol synthase WT H412R gi|22122469 
Lectin, mannose-binding 2 WT H412R gi|34328278 
Lectin, mannose-binding 2-like WT  gi|61656186 
Lectin, mannose-binding, 1 WT H412R gi|21312570 
Leucine aminopeptidase 3  H412R gi|31981147 
Leucine carboxyl methyltransferase 2  H412R gi|198278410 
Leucine rich repeat (in FLII) interacting protein 1 isoform 1  H412R gi|162417949 
Leucine rich repeat (in FLII) interacting protein 2  H412R gi|110625827 
Leucine rich repeat containing 47  H412R gi|41152116 
Leucine rich repeat containing 59 WT H412R gi|19527026 
Leucine rich repeat containing 8D  H412R gi|170650657 
Leucine rich repeat protein 4, neuronal  H412R gi|22122701 
Leucine zipper protein 5  H412R gi|91208439 
Leucyl-tRNA synthetase  H412R gi|120537241 
Ligase I, DNA, ATP-dependent  H412R gi|133892807 
Lymphocyte specific 1 isoform 2  H412R gi|11225264 
Lymphoid-restricted membrane protein  H412R gi|162287383 
Lysophosphatidylcholine acyltransferase 2 WT H412R gi|27370522 
Lysophosphatidylcholine acyltransferase 3 WT H412R gi|21699058 
Lysophosphatidylcholine acyltransferase 4  H412R gi|46402175 
Lysyl-tRNA synthetase isoform 1 WT H412R gi|195963321 
MCG129058  H412R gi|148679865 
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MCG13955  H412R gi|148704913 
MMS19 (MET18 S. cerevisiae)  H412R gi|15100156 
Major facilitator superfamily domain containing 10 WT H412R gi|13386144 
Mannose-6-phosphate receptor, cation dependent  H412R gi|14916479 
Mannosidase, alpha, class 2C, member 1 WT H412R gi|30794150 
Membrane bound C2 domain containing protein  H412R gi|33859650 
Methionine-tRNA synthetase  H412R gi|51491852 
Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like WT H412R gi|31559887 
Methylenetetrahydrofolate dehydrogenase 1  H412R gi|20270275 
Minichromosome maintenance complex component 7  H412R gi|10242373 
Minichromosome maintenance deficient 3  H412R gi|33859484 
Minichromosome maintenance deficient 5, cell division cycle 46  H412R gi|112293273 
Mitochondrial trifunctional protein, beta subunit WT H412R gi|21704100 
MutS homolog 6  H412R gi|6754744 
Myo-inositol 1-phosphate synthase A1  H412R gi|12963757 
Myosin IC isoform b  H412R gi|124494244 
Myosin IE  H412R gi|68299824 
Myosin IG  H412R gi|30410767 
Myosin XVIIIa  H412R gi|22094119 
Myosin, heavy polypeptide 9, non-muscle isoform 1  H412R gi|114326446 
N-acetyltransferase 10  H412R gi|23346561 
N-ethylmaleimide sensitive fusion protein  H412R gi|31543349 
N-ethylmaleimide sensitive fusion protein attachment protein alpha WT H412R gi|13385392 
NAD(P) dependent steroid dehydrogenase-like WT  gi|31982437 
NADH dehydrogenase (ubiquinone) flavoprotein 1  H412R gi|19526814 
NOD9 protein  H412R gi|30410746 
Nardilysin  H412R gi|31559918 
Neuroplastin WT  gi|153945724 
Nicalin homolog WT H412R gi|33469043 
Nodal modulator 1 WT H412R gi|27151748 
Non-SMC condensin I complex, subunit D2  H412R gi|22165392 
Non-metastatic cells 6, protein expressed in (nucleoside-diphosphate kinase)  H412R gi|9055290 
Nuclear VCP-like  H412R gi|33468981 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100  H412R gi|9506921 
Nuclear matrix protein SNEV  H412R gi|19527358 
Nuclease sensitive element binding protein 1  H412R gi|113205059 
Nucleophosmin 1 WT  gi|6679108 
Nucleoporin 160  H412R gi|10946932 
Nucleoporin 85  H412R gi|108773813 
Nucleoporin 93  H412R gi|27369533 
Nucleoporin 98 WT  gi|39930413 
Nudix (nucleoside diphosphate linked moiety X)-type motif 5  H412R gi|8393853 
O-linked N-acetylglucosamine transferase WT H412R gi|46909607 
On-SMC condensin I complex, subunit G  H412R gi|169234780 
PAP associated domain containing 1  H412R gi|21312970 
PREDICTED: hypothetical protein WT H412R gi|149273161 
PREDICTED: similar to 2310014H01Rik protein  H412R gi|149269292 
PREDICTED: similar to 2310022K01Rik protein  H412R gi|149256963 
PREDICTED: similar to Rab3 GTPase-activating protein non-catalytic subunit 
(Rab3 GTPase-activating protein 150 kDa subunit) (Ra 
 H412R gi|94364680 
PREDICTED: similar to Small subunit processome component 20 homolog 
(Down-regulated in metastasis protein) isoform 4 
 H412R gi|149261463 
PREDICTED: similar to Tripartite motif protein 21 isoform 2 WT  gi|149257887 
Paraoxonase 3 WT H412R gi|27370510 
Pentatricopeptide repeat domain 3  H412R gi|33469980 
Peptidase (mitochondrial processing) alpha WT H412R gi|27502349 
Peptidylprolyl isomerase B WT  gi|71774133 
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Phosphatidylinositol 3-kinase catalytic delta polypeptide WT H412R gi|71067116 
Phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 isoform 2 WT H412R gi|117320524 
Phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta)  H412R gi|6679321 
Phosphatidylinositol glycan, class T  H412R gi|120587021 
Phosphofructokinase, liver, B-type  H412R gi|31560653 
Phosphofructokinase, platelet  H412R gi|9790051 
Phosphogluconate dehydrogenase WT H412R gi|124486895 
Phosphoglycerate dehydrogenase like 1  H412R gi|90568036 
Phospholipase A2, activating protein  H412R gi|114431250 
Phospholipase C, gamma 2  H412R gi|26986603 
Phosphoribosylglycinamide formyltransferase WT H412R gi|93102415 
Phosphorylase kinase beta  H412R gi|40789096 
Pitrilysin metallepetidase 1 WT  gi|21699068 
Plastin 1 (I-isoform) WT H412R gi|85986577 
Platelet-activating factor acetylhydrolase, isoform 1b, beta1 subunit WT H412R gi|7305363 
Poly (ADP-ribose) polymerase family, member 1 WT H412R gi|20806109 
Poly-U binding splicing factor 60 isoform b  H412R gi|76677895 
Polymerase (DNA directed), delta 2, regulatory subunit  H412R gi|6679413 
Polypyrimidine tract binding protein 1 isoform 2  H412R gi|116517303 
Prenylcysteine oxidase 1 like WT H412R gi|27370248 
Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 
1 polypeptide 
 H412R gi|33859596 
Progesterone receptor membrane component WT H412R gi|31980806 
Proteasome (prosome, macropain) 26S subunit, ATPase 2  H412R gi|33859604 
Proteasome (prosome, macropain) 26S subunit, ATPase 3  H412R gi|6679503 
Proteasome (prosome, macropain) subunit, beta type 2 WT H412R gi|31981327 
Proteasome 26S  ATPase subunit 4 WT H412R gi|124248577 
Proteasome 26S ATPase subunit 6  H412R gi|27754103 
Proteasome 26S non-ATPase subunit 1 WT H412R gi|74315975 
Proteasome 26S non-ATPase subunit 12  H412R gi|13385384 
Proteasome 26S non-ATPase subunit 13 WT H412R gi|6755210 
Proteasome 26S non-ATPase subunit 2 WT H412R gi|19882201 
Proteasome 26S non-ATPase subunit 3  H412R gi|19705424 
Protein kinase C substrate 80K-H WT  gi|6679465 
Protein kinase, cAMP dependent regulatory, type I, alpha  H412R gi|30794476 
Protein phosphatase 1, catalytic subunit, alpha WT H412R gi|13994195 
Protein phosphatase 1, regulatory (inhibitor) subunit 12A  H412R gi|95772123 
Protein phosphatase 1, regulatory subunit 12C  H412R gi|124249341 
Protein phosphatase 1, regulatory subunit 9B  H412R gi|50053703 
Protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform 
isoform b 
 H412R gi|77539776 
Protein phosphatase 2a, catalytic subunit, alpha isoform WT H412R gi|9506983 
Protein tyrosine phosphatase, non-receptor type 1 WT H412R gi|133505845 
Protein tyrosine phosphatase, non-receptor type 6 isoform b  H412R gi|118130785 
Purine rich element binding protein A WT H412R gi|6679573 
Putative membrane protein WT H412R gi|87116677 
Pyruvate dehydrogenase complex, component X  H412R gi|28201978 
RAB1, member RAS oncogene family WT H412R gi|6679587 
RAB11a, member RAS oncogene family WT H412R gi|31980840 
RAB1B, member RAS oncogene family WT H412R gi|21313162 
RAB21, member RAS oncogene family WT  gi|33859751 
RAB2B protein WT  gi|30525051 
RAB6B, member RAS oncogene family WT H412R gi|30424655 
RAB7, member RAS oncogene family WT H412R gi|148747526 
RAD50 homolog  H412R gi|153945822 
RANBP4  H412R gi|19745156 
RAP1, GTP-GDP dissociation stimulator 1 isoform a WT  gi|100818161 
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RAP2B, member of RAS oncogene family WT  gi|13386338 
RIKEN cDNA 2310001A20 WT  gi|21313668 
RIKEN cDNA 2310044H10 WT  gi|37574074 
Ras homolog gene family, member A  H412R gi|31542143 
Ras-GTPase-activating protein SH3-domain  binding protein  H412R gi|7305075 
Regulator of nonsense transcripts 1 isoform a  H412R gi|170784813 
Required for meiotic nuclear division 1 homolog  H412R gi|86198296 
Reticulocalbin 2 WT H412R gi|114205428 
Reticulon 4 isoform A  H412R gi|34610235 
Retinol dehydrogenase 11 WT  gi|19482172 
Rho GTPase activating protein 9  H412R gi|90093351 
Rho guanine nucleotide exchange factor (GEF) 11  H412R gi|51491850 
Rho-associated coiled-coil forming kinase 2  H412R gi|134949013 
Rho/rac guanine nucleotide exchange factor (GEF) 2  H412R gi|170650647 
Ribonucleotide reductase M1  H412R gi|31982026 
Ribosomal RNA processing 12 homolog  H412R gi|40789092 
Ribosomal protein 10  H412R gi|16418339 
Ribosomal protein L12  H412R gi|160333553 
Ribosomal protein L13 WT  gi|33186863 
Ribosomal protein L21 WT  gi|31560385 
Ribosomal protein L23a  H412R gi|46430508 
Ribosomal protein L24  H412R gi|18250296 
Ribosomal protein L26 WT H412R gi|6677777 
Ribosomal protein L3  H412R gi|7305441 
Ribosomal protein S6 WT H412R gi|6677809 
Ribosome binding protein 1 isoform a WT H412R gi|124486712 
RuvB-like protein 1 WT H412R gi|9790083 
RuvB-like protein 2 WT H412R gi|6755382 
SEC22 vesicle trafficking protein-like 1 WT H412R gi|6755448 
SERPINE1 mRNA binding protein 1 isoform 2  H412R gi|165932377 
SMC1 structural maintenance of chromosomes 1-like 1  H412R gi|9790237 
SPECC1-like  H412R gi|49274627 
STIP1 homology and U-box containing protein 1 WT H412R gi|9789907 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily d, member 2 isoform 1 
 H412R gi|194328773 
Saccharomyces cerevisiae Nip7p homolog  H412R gi|13928674 
Sel1 (suppressor of lin-12) 1 homolog isoform a WT H412R gi|84875513 
Serine (or cysteine) proteinase inhibitor, clade B, member 6a  H412R gi|6678097 
Serine palmitoyltransferase subunit 1 WT H412R gi|29244577 
Serine palmitoyltransferase, long chain base subunit 2 WT H412R gi|6755656 
Seryl-aminoacyl-tRNA synthetase 2 WT H412R gi|12963765 
Signal recognition particle receptor  H412R gi|27229036 
Signal sequence receptor, alpha WT H412R gi|165377206 
Signal sequence receptor, delta WT  gi|6678145 
Signal transducer and activator of transcription 1  H412R gi|114326482 
Signal transducer and activator of transcription 5A  H412R gi|6755672 
Signal-induced proliferation associated gene 1  H412R gi|61556720 
Signaling molecule ATTP WT H412R gi|104294890 
Silencer-associated factor WT  gi|110626163 
Sjogren syndrome antigen B  H412R gi|158636012 
Smooth muscle cell associated protein-1  H412R gi|19527172 
Solute carrier family 33 (acetyl-CoA transporter), member 1 WT H412R gi|31543730 
Solute carrier family 39, member 7  H412R gi|118150670 
Sorting and assembly machinery component 50 homolog WT H412R gi|30519943 
Sorting nexin 5  H412R gi|18034769 
Source of immunodominant MHC-associated peptides WT H412R gi|61651673 
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Spectrin alpha 2  H412R gi|115496850 
Spectrin beta 2 isoform 2  H412R gi|117938334 
Sperm antigen with calponin homology and coiled-coil domains 1 WT H412R gi|71979930 
Sperm antigen with calponin homology and coiled-coil domains 1  H412R gi|117949789 
Sphingomyelin phosphodiesterase 2, neutral WT  gi|6678031 
Sphingosine phosphate lyase 1 WT H412R gi|31543694 
Splicing factor 3a, subunit 1  H412R gi|165932270 
Splicing factor 3b, subunit 2 WT H412R gi|30794206 
Splicing factor 3b, subunit 4 WT H412R gi|23346437 
Staphylococcal nuclease domain containing 1  H412R gi|77404392 
Structural maintenance of chromosomes 2  H412R gi|62990166 
Structural maintenance of chromosomes 4  H412R gi|29789347 
Succinate-CoA ligase, GDP-forming, alpha subunit  H412R gi|9845299 
Superkiller viralicidic activity 2-like 2  H412R gi|21312352 
T-cell, immune regulator 1 WT  gi|209863008 
TAP binding protein isoform 1 WT H412R gi|70778974 
TAR DNA binding protein isoform 5  H412R gi|56682935 
TNF receptor-associated protein 1  H412R gi|13385998 
TRNA splicing endonuclease 34  H412R gi|13195596 
Tetratricopeptide repeat domain 27  H412R gi|164519039 
Thioredoxin 1 WT H412R gi|6755911 
Thioredoxin domain containing 10 WT H412R gi|117606385 
Thioredoxin domain containing 5  H412R gi|83921612 
Thioredoxin interacting protein isoform 1 WT H412R gi|60687518 
Thioredoxin-related transmembrane protein 2 WT H412R gi|21313210 
Three prime repair exonuclease 1 WT H412R gi|59624981 
Threonyl-tRNA synthetase 2, mitochondrial  H412R gi|21313644 
Thymopoietin isoform delta WT H412R gi|121949767 
Toll-like receptor 13 WT  gi|45429999 
Toll-like receptor 2 WT  gi|158749638 
Toll-like receptor 3 WT  gi|31543872 
Toll-like receptor 7 WT  gi|18875360 
Toll-like receptor 9 WT  gi|157057166 
Toll-like receptor 9 WT  gi|20140793 
Torsin A interacting protein 1 WT  gi|21450141 
Transferrin receptor  H412R gi|11596855 
Transforming growth factor beta regulated gene 4  H412R gi|194394227 
Transgelin 2  H412R gi|30519911 
Translation initiation factor eIF-2B subunit alpha/beta/delta-like protein WT H412R gi|31541890 
Translocase of inner mitochondrial membrane 50 homolog WT H412R gi|22094989 
Translocation protein 1 WT H412R gi|39930429 
Transmembrane emp24 domain-containing protein 10 WT H412R gi|21312062 
Transmembrane emp24 protein transport domain containing 9 WT H412R gi|145966911 
Transmembrane protein 109  H412R gi|19527378 
Transmembrane protein 214 WT  gi|31559970 
Transmembrane protein 33 isoform 1 WT H412R gi|22267448 
Transmembrane protein 43 WT H412R gi|21311891 
Transmembrane protein 55b WT  gi|84095197 
Transporter 1, ATP-binding cassette, sub-family B  H412R gi|7305539 
Tripartite motif protein 27 WT H412R gi|125347389 
Tripartite motif protein 28  H412R gi|170295840 
Tripartite motif-containing 32  H412R gi|27477053 
Tropomodulin 3  H412R gi|8394460 
Tropomyosin 1, alpha, isoform CRA_k  H412R gi|148694203 
Tropomyosin 4  H412R gi|47894398 
Tropomyosin alpha-3 chain  H412R gi|20178336 
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Ts translation elongation factor, mitochondrial  H412R gi|21313468 
Tu translation elongation factor, mitochondrial WT H412R gi|27370092 
Tubulin folding cofactor B  H412R gi|170650659 
Tubulin, beta 4 WT H412R gi|31981939 
Tubulin, beta 6  H412R gi|27754056 
Tubulin-specific chaperone d WT H412R gi|28077067 
Tubulin-specific chaperone e  H412R gi|31543843 
Tumor protein, translationally-controlled 1  H412R gi|6678437 
Tumor suppressor candidate 3 WT H412R gi|124248487 
Tyrosyl-tRNA synthetase WT H412R gi|165377181 
UBX domain containing 8 WT H412R gi|158533976 
UDP glucuronosyltransferase 1 family, polypeptide A7C WT H412R gi|47059123 
UDP-glucose ceramide glucosyltransferase-like 1 WT H412R gi|45387933 
UMP-CMP kinase WT H412R gi|165377065 
UPF0510 protein C19orf63 homolog WT  gi|166215193 
USO1 homolog, vesicle docking protein  H412R gi|23956096 
Ubiquilin 2  H412R gi|34328236 
Ubiquitin specific peptidase 7  H412R gi|154146209 
Ubiquitin-conjugating enzyme E2M WT H412R gi|21704162 
Ubiquitin-conjugating enzyme E2Q  H412R gi|170172548 
Ubiquitin-like modifier activating enzyme 6 WT H412R gi|27370032 
Ubiquitin-like with PHD and ring finger domains 1 isoform B  H412R gi|162287241 
Unnamed protein product  H412R gi|74214757 
Uridine monophosphate synthetase  H412R gi|33859498 
Vac14 homolog  H412R gi|31542488 
Vacuolar H+ATPase B2 WT H412R gi|19705578 
Vacuolar protein sorting 16  H412R gi|46852153 
Vacuolar protein sorting 35  H412R gi|13928670 
Valosin containing protein WT H412R gi|30023842 
Valyl-tRNA synthetase WT H412R gi|34328204 
Vav 1 oncogene  H412R gi|31981440 
Vesicle amine transport protein 1 homolog (T californica)  H412R gi|33859662 
Vesicle-associated membrane protein, associated protein A WT H412R gi|94721328 
Vimentin  H412R gi|31982755 
Voltage-dependent anion channel 1 WT H412R gi|6755963 
Voltage-dependent anion channel 2 WT H412R gi|6755965 
WD repeat domain 36 isoform 2  H412R gi|158517942 
WD repeat domain 6  H412R gi|13878227 
Werner helicase interacting protein 1  H412R gi|31981384 
Williams-Beuren syndrome chromosome region 16 homolog  H412R gi|15809010 
Wiskott-Aldrich syndrome homolog  H412R gi|6678581 
XTP3-transactivated protein B  H412R gi|114205437 
YME1-like 1  H412R gi|7305635 
Zinc metalloproteinase, STE24 homolog  H412R gi|27370012 
 
Table 15: List of potential Clptm interaction partners. 
Protein Description Protein 
Accession 
  
5'-methylthioadenosine phosphorylase gi|45544618 
7-dehydrocholesterol reductase gi|6681179 
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1 gi|6680748 
ATP-binding cassette, subfamily G, member 1 gi|6752940 
ATPase type 13A1 gi|18875382 
ATPase, Ca++ transporting, slow twitch 2 isoform a gi|158635979 
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ATPase, H+ transporting, V0 subunit D isoform 1 gi|31981304 
ATPase, H+ transporting, lysosomal accessory protein 1 gi|9055172 
Acetyl-Coenzyme A acyltransferase 1B gi|22122797 
Acyl-Coenzyme A dehydrogenase, medium chain gi|6680618 
Aldolase A, fructose-bisphosphate gi|6671539 
Alpha-1,3-mannosyltransferase ALG3 gi|22122365 
Annexin A5 gi|6753060 
Archain 1 gi|148747410 
Arylacetamide deacetylase-like 1 gi|30520239 
Asparaginase like 1 gi|31560239 
Atlastin GTPase 3 gi|31559920 
B-cell receptor-associated protein 31 gi|31981310 
Basic leucine zipper and W2 domains 1 gi|13385296 
Basigin isoform 2 gi|116014342 
Bri3 binding protein gi|58037467 
CD5 antigen-like precursor gi|160358823 
CLPTM1-like gi|22122537 
COX4 neighbor gi|6754870 
Calcium binding protein P22 gi|9790225 
Calnexin gi|160333216 
Casein alpha s1 gi|30794348 
Chaperonin subunit 8 (theta) gi|126723461 
Chemokine (C-X3-C) receptor 1 gi|87299632 
Chloride channel CLIC-like 1 gi|21704070 
Chromosome segregation 1-like gi|12963737 
Cleft lip and palate associated transmembrane protein 1 gi|103472025 
Coatomer protein complex subunit alpha gi|31981828 
Coatomer protein complex, subunit beta 1 gi|15426055 
Coatomer protein complex, subunit beta 2 (beta prime) gi|29789080 
Coatomer protein complex, subunit gamma isoform 1 gi|8567338 
Coiled-coil domain containing 115 gi|58037169 
Coiled-coil domain containing 47 gi|125628650 
Coronin, actin binding protein 1A gi|6753492 
Cytochrome P450 reductase gi|6679421 
Cytochrome P450, family 20, subfamily A, polypeptide 1 gi|74271886 
Cytochrome b-245, beta polypeptide gi|161333819 
Cytochrome b-5 gi|13385268 
Cytochrome b5 type B precursor gi|31542438 
Damage specific DNA binding protein 1 gi|7657011 
Dehydrogenase/reductase (SDR family) member 13 gi|117647267 
Der1-like domain family, member 2 gi|15808990 
Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex) gi|21313536 
DnaJ (Hsp40) homolog, subfamily B, member 11 gi|110625998 
DnaJ (Hsp40) homolog, subfamily B, member 12 gi|31982701 
Dolichyl-di-phosphooligosaccharide-protein glycotransferase gi|46195798 
ER lipid raft associated 1 gi|31981799 
ER lipid raft associated 2 gi|23956396 
Emerin gi|6679641 
Enolase 2, gamma neuronal gi|7305027 
Env polypeptide gi|200091 
Epsilon subunit of coatomer protein complex gi|10946972 
Equilibrative nucleoside transporter 1 gi|12584968 
Eukaryotic translation initiation factor 3, subunit 6 gi|45476573 
FK506 binding protein 52 gi|6753882 
Fibrinogen, alpha polypeptide isoform 1 gi|167555029 
Galactokinase 1 gi|93102413 
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Guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1 gi|6680047 
HCLS1 associated X-1 gi|6754160 
Heat shock protein 1 (chaperonin) gi|183396771 
Heme oxygenase (decycling) 2 gi|209862939 
Hemoglobin alpha 1 chain gi|145301578 
Histidine ammonia lyase gi|6754152 
Hydrogen/potassium-exchanging ATPase 4A gi|110225337 
Hypothetical protein 4732456N10 gi|29244176 
Hypothetical protein LOC215900 gi|31982193 
Hypothetical protein LOC230866 isoform 1 gi|31542273 
Implantation-associated protein gi|148747202 
Importin 5 gi|29789199 
Intergral membrane protein 1 gi|148747128 
Isoleucyl-tRNA synthetase gi|29789383 
L-arginine:glycine amidinotransferase gi|13385454 
LAG1 homolog, ceramide synthase 2 gi|22095015 
Lectin, mannose-binding 2 gi|34328278 
Leucine rich repeat containing 59 gi|19527026 
Low density lipoprotein receptor-related protein associated protein 1 gi|63999380 
Major facilitator superfamily domain containing 10 gi|13386144 
Malectin gi|188497650 
Membrane magnesium transporter 1 gi|22122803 
Na+/K+ -ATPase alpha 1 subunit gi|21450277 
Na+/K+ -ATPase alpha 2 subunit gi|30409956 
Neuroplastin gi|153945724 
Nucleolin gi|84875537 
PREDICTED: DnaJ (Hsp40) homolog, subfamily B, member 14 gi|149251954 
PREDICTED: hypothetical protein LOC72512 isoform 13 gi|94404729 
Paraoxonase 3 gi|27370510 
Peripheral myelin protein 2 gi|71892436 
Phosphatidylinositol glycan anchor biosynthesis, class S gi|41351529 
Phosphoglycerate dehydrogenase gi|52353955 
Phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide 
synthetase 
gi|13385434 
Presenilin 2 gi|190684663 
Presenilin-like protein 3 gi|23094389 
Progressive ankylosis gi|157951668 
Prolactin regulatory element binding protein gi|158749640 
Proliferating cell nuclear antigen gi|7242171 
Proteasome 26S  ATPase subunit 4 gi|124248577 
Proteasome 26S ATPase subunit 6 gi|27754103 
Proteasome 26S non-ATPase subunit 11 gi|134053905 
Protein disulfide-isomerase A3 gi|112293264 
Protein phosphatase 2a, catalytic subunit, alpha isoform gi|9506983 
Protein tyrosine phosphatase, non-receptor type 1 gi|133505845 
Pyrophosphatase gi|27754065 
RAB1, member RAS oncogene family gi|6679587 
RAB18, member RAS oncogene family gi|30841008 
RAB1B, member RAS oncogene family gi|21313162 
RAB7, member RAS oncogene family gi|148747526 
RIKEN cDNA 2310044H10 gi|37574074 
RIKEN cDNA 2900064A13 gi|19526956 
RNA polymerase II transcriptional coactivator gi|6755364 
Ribophorin I gi|31543605 
Ribophorin II gi|34996495 
Ribosomal protein S19 gi|12963511 
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RuvB-like protein 1 gi|9790083 
RuvB-like protein 2 gi|6755382 
SAC1 (supressor of actin mutations 1, homolog)-like gi|13507622 
SEC22 vesicle trafficking protein-like 1 gi|6755448 
Sec11-like 1 gi|9910550 
Serine (or cysteine) proteinase inhibitor, clade A, member 1a gi|6678079 
Signal peptidase complex subunit 2 homolog gi|13385134 
Signal recognition particle receptor, B subunit gi|6678137 
Signal sequence receptor, alpha gi|165377206 
Signal sequence receptor, delta gi|6678145 
Signal sequence receptor, gamma gi|21312968 
Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 gi|190877473 
Solute carrier family 16, member 1 gi|6677995 
Solute carrier family 16, member 3 gi|84697028 
Solute carrier family 16, member 6 isoform a gi|71067107 
Solute carrier family 19 (sodium/hydrogen exchanger), member 1 gi|13654260 
Solute carrier family 2 (facilitated glucose transporter), member 6 gi|153945872 
Solute carrier family 38, member 10 gi|31541852 
Solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12 gi|92110009 
Solute carrier organic anion transporter family, member 4a1 gi|22507335 
Splicing factor 3b, subunit 4 gi|23346437 
Squalene epoxidase gi|6678127 
Sterol O-acyltransferase 1 gi|84619697 
Succinate dehydrogenase Fp subunit gi|54607098 
Succinate dehydrogenase complex, subunit B, iron sulfur (Ip) gi|34328286 
Succinate-CoA ligase, GDP-forming, alpha subunit gi|9845299 
Succinate-Coenzyme A ligase, GDP-forming, beta subunit gi|165972309 
T-complex protein 1 gi|110625624 
Thioredoxin domain containing 1 gi|33859722 
Thioredoxin domain containing 10 gi|117606385 
Thioredoxin-related transmembrane protein 2 gi|21313210 
Three prime repair exonuclease 1 gi|59624981 
Thymopoietin isoform beta gi|121949769 
Thymopoietin isoform delta gi|121949767 
Thymopoietin isoform zeta gi|121949779 
Torsin A interacting protein 1 gi|21450141 
Transmembrane emp24 domain-containing protein 10 gi|21312062 
Transmembrane emp24 protein transport domain containing 5 gi|21746165 
Transmembrane protein 111 gi|28827824 
Transmembrane protein 120A gi|29789387 
Transmembrane protein 38B gi|21312532 
Transmembrane protein 85 gi|13386014 
Tropomyosin 1, alpha gi|31560030 
Tropomyosin 3, gamma gi|40254525 
Tumor differentially expressed protein 1 gi|213385301 
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide gi|6756041 
UBX domain containing 8 gi|158533976 
Ubiquinol-cytochrome c reductase core protein 1 gi|46593021 
Unc93 homolog B gi|23956094 
Unnamed protein product gi|74226916 
Vesicle-associated membrane protein, associated protein A gi|94721328 
Vesicle-associated membrane protein, associated protein B and C gi|31543940 
Zinc metalloproteinase, STE24 homolog gi|27370012 
 
 
V Appendix 157 
 
Peptides of selected proteins found by large scale immunoprecipitation and mass 
spectrometry analysis of wild type UNC93B: 
 
Clptm (peptide coverage 26.3%) 
MAAAQEADGAGSAVVAAGGGSSGQVTSNGSIGRDTPAETQPQNPPPQPAPNAWQVIKGVLFRIFIIWAIS 
SWFRRGPSPQDQSGPGGAPRVASRNLFPKDTLMNLHVYISEHEHFTDFNATSALFWEQHDLVYGDWTSGE 
NSDGCYEHFAELDIPQSVQQNGSIYIHVYFTKSGFHPDPRQKALYRRLATVHMSRMINKYKRRRFQKTKN 
LLTGETEADPEMIKRAEDYGPVEVISHWHPNITINIVDDHTPWVKGSVPPPLDQYVKFDAVSGDYYPIIY 
FNDYWNLQKDYYPINESLASLPLRVSFCPLSLWRWQLYAAQSTKSPWNFLGDELYEQSDEEQDSVKVALL 
ETSPYLLALTIIVSIVHSVFEFLAFKNDIQFWNSRQSLEGLSVRSVFFGVFQSFVVLLYILDNETNFVVQ 
VSVFIGVLIDLWKITKVMDVRLDREHRVAGIFPCPTFKDKSTYIESSTKVYDDMAFRYLSWILFPLLGCY 
AVYSLLYLEHKGWYSWVLSMLYGFLLTFGFITMTPQLFINYKLKSVAHLPWRMLTYKALNTFIDDLFAFV 
IKMPVMYRIGCLRDDVVFFIYLYQRWIYRVDPTRVNEFGMSGEDVSAAASRAQASTAAGALTPAPSTAVS 
GEDASTVPKATSGACTASQPQEAPPKPAEDKKKD 
 
PTP1B (peptide coverage 7.8%) 
MEMEKEFEEIDKAGNWAAIYQDIRHEASDFPCKVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINAS 
LIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRIMEKGSLKCAQYWPQQEEKEMVFDDTGL 
KLTLISEDVKSYYTVRQLELENLTTKETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSLEHGP 
IVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRRFRMGLIQTADQLRFSYLAVIEGAKF 
IMGDSSVQDQWKELSREDLDLPPEHVPPPPRPPKRTLEPHNGKCKELFSSHQWVSEETCGDEDSLAREEG 
RAQSSAMHSVSSMSPDTEVRRRMVGGGLQSAQASVPTEEELSSTEEEHKAHWPSHWKPFLVNVCMATLLA 
TGAYLCYRVCFH 
 
Trex1 (peptide coverage 10.2%) 
MGSQTLPHGHMQTLIFLDLEATGLPSSRPEVTELCLLAVHRRALENTSISQGHPPPVPRPPRVVDKLSLC
IAPGKACSPGASEITGLSKAELEVQGRQRFDDNLAILLRAFLQRQPQPCCLVAHNGDRYDFPLLQTELAR
LSTPSPLDGTFCVDSIAALKALEQASSPSGNGSRKSYSLGSIYTRLYWQAPTDSHTAEGDVLTLLSICQW
KPQALLQWVDEHARPFSTVKPMYGTPATTGTTNLRPHAATATTPLATANGSPSNGRSRRPKSPPPEKVPE
APSQEGLLAPLSLLTLLTLAIATLYGLFLASPGQ 
 
 
 
Peptides of selected proteins found by large scale immunoprecipitation and mass 
spectrometry analysis of mutant (H412R) UNC93B: 
 
Clptm (peptide coverage 27.7%) 
MAAAQEADGAGSAVVAAGGGSSGQVTSNGSIGRDTPAETQPQNPPPQPAPNAWQVIKGVLFRIFIIWAIS 
SWFRRGPSPQDQSGPGGAPRVASRNLFPKDTLMNLHVYISEHEHFTDFNATSALFWEQHDLVYGDWTSGE 
NSDGCYEHFAELDIPQSVQQNGSIYIHVYFTKSGFHPDPRQKALYRRLATVHMSRMINKYKRRRFQKTKN 
LLTGETEADPEMIKRAEDYGPVEVISHWHPNITINIVDDHTPWVKGSVPPPLDQYVKFDAVSGDYYPIIY 
FNDYWNLQKDYYPINESLASLPLRVSFCPLSLWRWQLYAAQSTKSPWNFLGDELYEQSDEEQDSVKVALL 
ETSPYLLALTIIVSIVHSVFEFLAFKNDIQFWNSRQSLEGLSVRSVFFGVFQSFVVLLYILDNETNFVVQ 
VSVFIGVLIDLWKITKVMDVRLDREHRVAGIFPCPTFKDKSTYIESSTKVYDDMAFRYLSWILFPLLGCY 
AVYSLLYLEHKGWYSWVLSMLYGFLLTFGFITMTPQLFINYKLKSVAHLPWRMLTYKALNTFIDDLFAFV 
IKMPVMYRIGCLRDDVVFFIYLYQRWIYRVDPTRVNEFGMSGEDVSAAASRAQASTAAGALTPAPSTAVS 
GEDASTVPKATSGACTASQPQEAPPKPAEDKKKD 
 
PTP1B (peptide coverage 30.6%) 
MEMEKEFEEIDKAGNWAAIYQDIRHEASDFPCKVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINAS 
LIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRIMEKGSLKCAQYWPQQEEKEMVFDDTGL 
KLTLISEDVKSYYTVRQLELENLTTKETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSLEHGP 
IVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRRFRMGLIQTADQLRFSYLAVIEGAKF 
IMGDSSVQDQWKELSREDLDLPPEHVPPPPRPPKRTLEPHNGKCKELFSSHQWVSEETCGDEDSLAREEG 
RAQSSAMHSVSSMSPDTEVRRRMVGGGLQSAQASVPTEEELSSTEEEHKAHWPSHWKPFLVNVCMATLLA 
TGAYLCYRVCFH 
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Trex1 (peptide coverage 16.6%) 
MGSQTLPHGHMQTLIFLDLEATGLPSSRPEVTELCLLAVHRRALENTSISQGHPPPVPRPPRVVDKLSLC
IAPGKACSPGASEITGLSKAELEVQGRQRFDDNLAILLRAFLQRQPQPCCLVAHNGDRYDFPLLQTELAR
LSTPSPLDGTFCVDSIAALKALEQASSPSGNGSRKSYSLGSIYTRLYWQAPTDSHTAEGDVLTLLSICQW
KPQALLQWVDEHARPFSTVKPMYGTPATTGTTNLRPHAATATTPLATANGSPSNGRSRRPKSPPPEKVPE
APSQEGLLAPLSLLTLLTLAIATLYGLFLASPGQ 
 
 
 
Peptides of selected proteins found by large scale immunoprecipitation and mass 
spectrometry analysis of Clptm: 
 
PTP1B (peptide coverage 24.7%) 
MEMEKEFEEIDKAGNWAAIYQDIRHEASDFPCKVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINAS 
LIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRIMEKGSLKCAQYWPQQEEKEMVFDDTGL 
KLTLISEDVKSYYTVRQLELENLTTKETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSLEHGP 
IVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRRFRMGLIQTADQLRFSYLAVIEGAKF 
IMGDSSVQDQWKELSREDLDLPPEHVPPPPRPPKRTLEPHNGKCKELFSSHQWVSEETCGDEDSLAREEG 
RAQSSAMHSVSSMSPDTEVRRRMVGGGLQSAQASVPTEEELSSTEEEHKAHWPSHWKPFLVNVCMATLLA 
TGAYLCYRVCFH 
 
Trex1 (peptide coverage 26.4%) 
MGSQTLPHGHMQTLIFLDLEATGLPSSRPEVTELCLLAVHRRALENTSISQGHPPPVPRPPRVVDKLSLC
IAPGKACSPGASEITGLSKAELEVQGRQRFDDNLAILLRAFLQRQPQPCCLVAHNGDRYDFPLLQTELAR
LSTPSPLDGTFCVDSIAALKALEQASSPSGNGSRKSYSLGSIYTRLYWQAPTDSHTAEGDVLTLLSICQW
KPQALLQWVDEHARPFSTVKPMYGTPATTGTTNLRPHAATATTPLATANGSPSNGRSRRPKSPPPEKVPE
APSQEGLLAPLSLLTLLTLAIATLYGLFLASPGQ 
 
STING (peptide coverage 10.8%) 
MPYSNLHPAIPRPRGHRSKYVALIFLVASLMILWVAKDPPNHTLKYLALHLASHELGLLLKNLCCLAEEL
CHVQSRYQGSYWKAVRACLGCPIHCMAMILLSSYFYFLQNTADIYLSWMFGLLVLYKSLSMLLGLQSLTP
AEVSAVCEEKKLNVAHGLAWSYYIGYLRLILPGLQARIRMFNQLHNNMLSGAGSRRLYILFPLDCGVPDN
LSVVDPNIRFRDMLPQQNIDRAGIKNRVYSNSVYEILENGQPAGVCILEYATPLQTLFAMSQDAKAGFSR
EDRLEQAKLFCRTLEEILEDVPESRNNCRLIVYQEPTDGNSFSLSQEVLRHIRQEEKEEVTMNAPMTSVA
PPPSVLSQEPRLLISGMDQPLPLRTDLI 
 
 Danksagung/Acknowledgment 
An dieser Stelle möchte ich mich bei allen bedanken, die mich bei der Anfertigung 
meiner Doktorarbeit unterstützt haben: 
 
Zuerst möchte ich mich bei Prof. Dr. Melanie M. Brinkmann bedanken, die mich 
während meiner Doktorarbeit hervorragend betreut hat. Besonders möchte ich mich 
dafür bedanken, dass sie jederzeit für mich ansprechbar war und mich stets gefördert, 
aber auch oft sehr gefordert und die Entstehung dieser Arbeit damit erst ermöglich hat. 
 
Ich möchte mich auch bei Prof. Dr. Ralf-Rainer Mendel für die Übernahme der 
Mentorenschaft für diese Arbeit sowie bei Prof. Dr. Martin Korte für die Übernahme des 
Prüfungsvorsitzes bedanken. 
Außerdem möchte ich mich bei Prof. Dr. Ingo Schmitz, Dr. Maximiliano Gutierrez und 
Prof. Dr. med. Mathias Hornef für die vielen Anregungen und hilfreichen Diskussionen 
im Rahmen meiner Thesis Committee Meetings bedanken. 
 
Ein besonderer Dank geht an unsere technischen Assistentinnen Christine Standfuß-
Gabisch und Brigitte Denker, die mir während meiner Arbeit bei der Durchführung 
unzähliger Versuche geholfen haben. Ich bedanke mich auch bei Matthias Ottinger, der 
mich bei der Planung und Durchführung der in vivo Versuche tatkräftig unterstützt hat. 
 
Außerdem möchte mich ganz herzlich bei der gesamten Arbeitsgruppe VIMM inklusive 
aller ehemaligen Gruppenmitglieder für die gute und produktive Zusammenarbeit 
bedanken. Christine, Brigitte, Ulrike, Vladimir, Sripriya, Helene, Kendra, Baca und 
Margit, es hat mir viel Freude gemacht mit euch zu arbeiten. Vor allem wird mir aber 
auch die Zeit, in der wir nicht unbedingt gearbeitet haben sehr positiv in Erinnerung 
bleiben. Ich möchte ich mich auch bei den drei Bachelor- und Masterstudenten Olga, 
Christoph und Ann-Kristin bedanken, die ich während der Zeit meiner Doktorarbeit 
betreut habe, und die alle einen kleinen Teil zu dieser Arbeit beigetragen haben. 
 
Ein besonderes Dankeschön geht auch an Stefan, dafür, dass er während der 
gesamten Zeit dieser Arbeit eine wichtige Stütze für mich war und mir immer mit sehr 
viel Geduld zugehört und mich weiter ermutigt hat. 
 
Nicht zuletzt danke ich auch meiner Familie, die mich nicht nur während der letzten 
dreieinhalb Jahre meiner Doktorarbeit immer unterstützt hat. 
